Document:

EX-10.10

 Exhibit 10.10 

Execution Version 

CONFIDENTIAL 
 Certain
identified information has been excluded from the exhibit because it is both (i) not 
 material and (ii) is the type of information
that the registrant treats as private or confidential. 
 Double asterisks denote omissions. 

COLLABORATION AND LICENSE AGREEMENT 

by and between 
 VERVE
THERAPEUTICS, INC. 
 and 

BEAM THERAPEUTICS INC. 

April 3, 2019 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 Article 1
	 	DEFINITIONS	  	 	1	 
			
	 Article 2
	 	LICENSES	  	 	18	 
			
	 2.1
	 	License Grants; Retained Rights	  	 	18	 
			
	 2.2
	 	Sublicenses	  	 	19	 
			
	 2.3
	 	Other IP	  	 	21	 
			
	 2.4
	 	Third Party Agreements	  	 	22	 
			
	 2.5
	 	Exchange of Information	  	 	23	 
			
	 2.7
	 	No Implied Licenses	  	 	25	 
			
	 Article 3
	 	MANAGEMENT; EXCHANGE OF INFORMATION	  	 	25	 
			
	 3.1
	 	Collaboration Overview	  	 	25	 
			
	 3.2
	 	Limits on Committee Authority	  	 	25	 
			
	 3.3
	 	Joint Steering Committee	  	 	25	 
			
	 3.4
	 	Joint Research Committee	  	 	28	 
			
	 3.5
	 	Joint Manufacturing Committee	  	 	28	 
			
	 3.6
	 	Joint Development Committee	  	 	30	 
			
	 3.7
	 	Joint Commercialization Committee	  	 	31	 
			
	 3.8
	 	Alliance Managers	  	 	32	 
			
	 3.9
	 	Committee Size and Composition; Observers	  	 	33	 
			
	 3.10
	 	Chairpersons	  	 	33	 
			
	 3.11
	 	Committee Meetings	  	 	34	 
			
	 3.12
	 	Safety Reporting	  	 	34	 
			
	 3.13
	 	Records and Reports	  	 	34	 
			
	 3.14
	 	Compliance with Law and Ethical Business Practices	  	 	35	 
			
	 Article 4
	 	RESEARCH AND DEVELOPMENT	  	 	35	 
			
	 4.1
	 	General Obligations	  	 	35	 
			
	 4.2
	 	Research Plan	  	 	36	 
			
	 4.3
	 	Development Plans	  	 	36	 
			
	 4.4
	 	Development Costs	  	 	38	 
			
	 Article 5
	 	BEAM OPT-IN OPTION	  	 	38	 
			
	 5.1
	 	Opportunity to Opt In	  	 	38	 
			
	 5.2
	 	Subsequent Development Plan; Election Not to Opt-In	  	 	38	 

  
 i 

							
	 5.3
	 	Beam Opt-Out Option	  	 	39	 
			
	 5.4
	 	Verve Opt-Out Option	  	 	39	 
			
	 5.5
	 	Discussion of Proposal	  	 	40	 
			
	 Article 6
	 	REGULATORY RESPONSIBILITY	  	 	40	 
			
	 6.1
	 	General	  	 	40	 
			
	 6.2
	 	Opt-In Products and Collaboration Products	  	 	40	 
			
	 6.3
	 	Clinical Trial Data License to Beam	  	 	41	 
			
	 Article 7
	 	COMMERCIALIZATION	  	 	41	 
			
	 7.1
	 	Commercialization Efforts	  	 	41	 
			
	 7.2
	 	Commercialization of Product(s)	  	 	41	 
			
	 7.3
	 	US Commercialization Plan	  	 	41	 
			
	 7.4
	 	Commercialization Reports	  	 	41	 
			
	 7.5
	 	Commercialization Costs	  	 	42	 
			
	 7.6
	 	Co-Promotion	  	 	42	 
			
	 Article 8
	 	MANUFACTURING	  	 	42	 
			
	 8.1
	 	Clinical Supply Plan	  	 	42	 
			
	 8.2
	 	Commercial Supply	  	 	43	 
			
	 8.3
	 	Manufacturing Intellectual Property	  	 	43	 
			
	 Article 9
	 	DELIVERY TECHNOLOGY	  	 	44	 
			
	 9.1
	 	General	  	 	44	 
			
	 9.2
	 	Third Party Agreements	  	 	44	 
			
	 Article 10
	 	PAYMENTS AND CONSIDERATION; EQUITY PURCHASE	  	 	44	 
			
	 10.1
	 	Initial Issuance	  	 	44	 
			
	 10.2
	 	Development Milestone Payments	  	 	45	 
			
	 10.3
	 	Net Sales Milestones	  	 	46	 
			
	 10.4
	 	Royalties	  	 	46	 
			
	 10.5
	 	Revenue and Cost Sharing in the Collaboration Territory; Reconciliation Payments	  	 	49	 
			
	 10.6
	 	Currency Exchange	  	 	52	 
			
	 10.7
	 	Record-Keeping and Audit	  	 	52	 
			
	 10.8
	 	Income Tax Withholding	  	 	53	 
			
	 Article 11
	 	CONFIDENTIALITY AND PUBLICATION	  	 	54	 
			
	 11.1
	 	Confidentiality; Exceptions	  	 	54	 
			
	 11.2
	 	Authorized Disclosure	  	 	55	 
			
	 11.3
	 	Publications	  	 	55	 

  
 ii 

							
	 11.4
	 	Press Releases; Disclosure of Agreement	  	 	56	 
			
	 11.5
	 	Use of Names	  	 	56	 
			
	 11.6
	 	Termination of Prior Agreement	  	 	56	 
			
	 11.7
	 	Remedies	  	 	57	 
			
	 Article 12
	 	REPRESENTATIONS, WARRANTIES AND COVENANTS	  	 	57	 
			
	 12.1
	 	Representations and Warranties of Each Party	  	 	57	 
			
	 12.2
	 	Verve Representations, Warranties and Covenants	  	 	57	 
			
	 12.3
	 	Beam Representations, Warranties and Covenants	  	 	59	 
			
	 12.4
	 	Disclaimer	  	 	60	 
			
	 Article 13
	 	INTELLECTUAL PROPERTY PROVISIONS	  	 	61	 
			
	 13.1
	 	Ownership of Intellectual Property	  	 	61	 
			
	 13.2
	 	Filing, Prosecution and Maintenance of Patent Rights	  	 	61	 
			
	 13.3
	 	Enforcement and Defense of Beam Patent Rights	  	 	63	 
			
	 13.4
	 	Enforcement and Defense of Verve Patent Rights, Product-Specific Patent Rights or Joint Collaboration Patent Rights	  	 	64	 
			
	 13.5
	 	Patent Term Restoration	  	 	65	 
			
	 13.6
	 	Trademarks and Corporate Logos	  	 	65	 
			
	 Article 14
	 	INDEMNIFICATION	  	 	66	 
			
	 14.1
	 	General Indemnification by Beam	  	 	66	 
			
	 14.2
	 	General Indemnification by Verve	  	 	67	 
			
	 14.3
	 	Products Liability Claims.	  	 	67	 
			
	 14.4
	 	Claims for Indemnification	  	 	67	 
			
	 14.5
	 	Disclaimer of Liability	  	 	68	 
			
	 Article 15
	 	TERM AND TERMINATION	  	 	68	 
			
	 15.1
	 	Term	  	 	68	 
			
	 15.2
	 	At-Will Termination by Verve	  	 	69	 
			
	 15.3
	 	Termination for Cause	  	 	69	 
			
	 15.4
	 	Termination for Patent Challenge	  	 	69	 
			
	 15.5
	 	Effects of Termination	  	 	70	 
			
	 15.6
	 	Effect of Termination; Survival	  	 	73	 
			
	 Article 16
	 	MISCELLANEOUS	  	 	74	 
			
	 16.1
	 	Use of Affiliates	  	 	74	 
			
	 16.2
	 	Interpretation	  	 	74	 
			
	 16.3
	 	Force Majeure	  	 	74	 
			
	 16.4
	 	Assignment	  	 	75	 

  
 iii 

							
	 16.5
	 	Severability	  	 	75	 
	 16.6
	 	Notices	  	 	75	 
	 16.7
	 	Dispute Resolution	  	 	76	 
	 16.8
	 	Governing Law and Arbitration	  	 	76	 
	 16.9
	 	Entire Agreement; Amendments	  	 	77	 
	 16.10
	 	Headings	  	 	77	 
	 16.11
	 	Independent Contractors	  	 	77	 
	 16.12
	 	Waiver	  	 	77	 
	 16.13
	 	Cumulative Remedies	  	 	77	 
	 16.14
	 	Waiver of Rule of Construction	  	 	78	 
	 16.15
	 	Business Day Requirements	  	 	78	 
	 16.16
	 	Counterparts	  	 	78	 

 SCHEDULES 

Schedule 1.14 – Beam Base Editor Patent Rights 

Schedule 1.17 – Beam C2C1 Patent Rights 

Schedule 1.57.1 – Beam Competitors 

Schedule 1.167 – Third Party Agreements 

Schedule 2.4.1 – Third Party Agreement Provisions 

Schedule 4.1.3 – Third Party Agreement Diligence Obligations 
  

  
 iv 

 COLLABORATION AND LICENSE AGREEMENT 

This Collaboration and License Agreement (this “Agreement”) is effective as of April 3, 2019 (the “Effective
Date”) and is entered into by and between Verve Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (“Verve”) and Beam Therapeutics Inc., a corporation organized and
existing under the laws of the State of Delaware (“Beam”, collectively with Verve, the “Parties” and each, a “Party”). 

RECITALS: 

WHEREAS, Verve or its Affiliates owns or controls certain technology related to gene editing and certain technology related to the
Licensed Targets (as hereinafter defined); 
 WHEREAS, Beam or its Affiliates owns or controls certain technology related to DNA base
editing and RNA base editing platforms, including technology with respect to guide RNAs; 
 WHEREAS, Verve and Beam desire to enter
into a collaboration to develop and commercialize Products (as hereinafter defined) upon the terms and conditions set forth herein; 

WHEREAS, for purposes of such collaboration, Verve desires to obtain a license under certain intellectual property, including the Beam
Base Editor Technology, upon the terms and conditions set forth herein, and Beam desires to grant such a license; and 
 WHEREAS,
each Party may desire to, pursuant to the terms of this Agreement, grant the other Party rights to certain delivery technology that comes under such grantor Party’s control during the Term (as hereinafter defined) for use in base editing or
gene editing products, as the case may be; 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants
herein contained, the receipt and sufficiency of which are hereby acknowledged, Verve and Beam hereby agree as follows: 
 Article 1 DEFINITIONS 

Unless specifically set forth to the contrary in this Agreement, the following terms, whether used in the singular or plural, shall have the respective
meanings set forth below or, if not listed below, the meaning designated in this Agreement. 
  

	1.1	 “AAA” shall have the meaning given to such term in
Section 16.8. 

  

	1.2	 [**]. 

  

	1.3	 “Act” shall mean, as applicable, the United States Federal Food, Drug and Cosmetic Act,
21 U.S.C. §§ 301 et seq., or the Public Health Research Act, 42 U.S.C. §§ 262 et seq., as such may be amended from time to time. 

	1.4	 “Action” shall mean (a) any claim, cause of action or suit (whether in contract or
tort or otherwise), litigation (whether at law or in equity, whether civil or criminal), or arbitration brought against a Party by any Third Party and (b) any claim, action, cause of action or suit (whether in contract or tort or otherwise),
litigation (whether at law or in equity, whether civil or criminal), controversy, assessment, arbitration, investigation, hearing, charge, complaint, demand, notice or proceeding of, to, from, by or before any Governmental Authority with respect to
a Party. 

  

	1.5	 “Affiliate” shall, with respect to a Person, mean any entity directly or indirectly
controlled by, controlling, or under common control with, such Person, but only for so long as such control shall continue. For purposes of this definition, “control” (including, with correlative meanings, “controlled by”,
“controlling” and “under common control with”) means (a) possession, direct or indirect, of the power to direct or cause direction of the management or policies of an entity (whether through ownership of securities or other
ownership interests, by contract or otherwise), or (b) beneficial ownership of at least fifty percent (50%) (or the maximum ownership interest permitted by Applicable Law) of the voting securities or other ownership or general partnership
interest (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests in an entity. Notwithstanding anything to the contrary in this Agreement, GV 2017, L.P. and any bona fide
investment fund or management company controlled by, controlling, or under common control with GV 2017, L.P. shall not be deemed an Affiliate of Verve for purposes of this Agreement. 

 

	1.6	 “Agreement” shall have the meaning given to such term in the preamble to this
agreement. 

  

	1.7	 “Alliance Manager” shall have the meaning given to such term in
Section 3.8.1. 

  

	1.8	 [**]. 

  

	1.9	 “Applicable Law” means the applicable laws, rules and regulations, including any
rules, regulations, guidelines or other requirements of the Regulatory Authorities, that may be in effect from time to time in the Territory. 

  

	1.10	 “Base Editor” shall mean [**]. 

 

	1.11	 “Base Editor Product” shall mean [**]. 

 

	1.12	 “Beam” shall have the meaning given to such term in the preamble to this Agreement.

  

	1.13	 “Beam Base Editor Know-How” shall mean, subject
to Section 2.4.3, all Know-How, patentable or otherwise, which (a) is Controlled by Beam or its Affiliates as of the Effective Date or during the Term, (b) [**] and (c) [**].

  

	1.14	 “Beam Base Editor Patent Rights” shall mean, subject to
Section 2.4.3, Patent Rights which (a) as of the Effective Date or during the Term are Controlled by Beam or its Affiliates and (b) claim Beam Base Editor Know-How. Beam
Base Editor Patent Rights includes those Patent Rights listed on Schedule 1.14. 

  

	1.15	 “Beam Base Editor Technology” shall mean Beam Base Editor Know-How and Beam Base Editor Patent Rights. 

  
 2 

	1.16	 “Beam C2C1 Know-How” shall mean, subject to
Section 2.4.3, all Know-How, patentable or otherwise, which (a) is Controlled by Beam or its Affiliates as of the Effective Date or during the Term, (b) [**] and (c) [**].

  

	1.17	 “Beam C2C1 Patent Rights” shall mean Patent Rights which, as of the Effective Date or
during the Term, are Controlled by Beam or its Affiliates and claim Beam C2C1 Know-How. Beam C2C1 Patent Rights includes those Patent Rights listed on Schedule 1.17. 

 

	1.18	 “Beam C2C1 Technology” shall mean the Beam C2C1
Know-How and Beam C2C1 Patent Rights. 

  

	1.19	 “Beam Collaboration Know-How” shall mean
(a) all Know-How, patentable or otherwise, conceived, developed, generated or reduced to practice during the Term solely by Beam or its Affiliates or other persons acting on behalf of Beam through the
Development, Commercialization or Manufacture of Licensed Products or otherwise arising out of Beam’s performance of its obligations under this Agreement and (b) all Know-How, patentable or
otherwise, that is [**] during the Term (i) solely by either Party, their respective Affiliates or other persons acting on behalf of a Party or (ii) jointly by, on one hand, Beam, its Affiliates or persons acting on behalf of Beam and, on
the other hand, Verve, its Affiliates or persons acting on behalf of Verve, in each case of clauses (b)(i) and (ii), through the Development, Commercialization or Manufacture of Products or otherwise arising out of a Party’s performance of its
obligations under this Agreement. 

  

	1.20	 “Beam Collaboration Patent Rights” shall mean Patent Rights which (a) as of the
Effective Date or during the Term are Controlled by Beam or its Affiliates and (b) claim Beam Collaboration Know-How. 

 

	1.21	 “Beam Collaboration Technology” shall mean Beam Collaboration Know-How and Beam Collaboration Patent Rights. 

  

	1.22	 “Beam Delivery Technology” shall mean, [**]. 

 

	1.23	 “Beam Delivery Technology Product” shall [**]. 

 

	1.24	 “Beam Indemnified Parties” shall have the meaning given to such term in
Section 14.2. 

  

	1.25	 “Beam IP Competitive Infringement” shall have the meaning given to such term in
Section 13.3.1. 

  

	1.26	 “Beam Manufacturing Know-How” shall have the
meaning given to such term in Section 8.3. 

  

	1.27	 “Beam Manufacturing Technology” shall have the meaning given to such term in
Section 8.3. 

  

	1.28	 “Beam Opt-In Option” shall have the
meaning given to such term in Section 5.1. 

  

	1.29	 “Beam Opt-Out Date” shall have the meaning
given to such term in Section 5.3. 

  
 3 

	1.30	 “Beam Opt-Out Option” shall have the
meaning given to such term in Section 5.3. 

  

	1.31	 “Beam Third Party Agreement” shall have the meaning given to such term in
Section 12.3.5. 

  

	1.32	 “Beam-[**] Agreement” shall mean the License Agreement by and between [**], a
wholly-owned subsidiary of Beam, dated as of [**], as such agreement may be amended from time to time in accordance with its terms. 

  

	1.33	 “Beam-[**] Agreement” shall mean the License Agreement by and between [**] and Beam
dated as of [**], as such agreement may be amended from time to time in accordance with its terms. 

  

	1.34	 “Beam-[**] Agreement” shall mean the License Agreement by and between [**] and
Beam, dated as of [**], as such agreement may be amended from time to time in accordance with its terms. 

  

	1.35	 “[**]” shall have the meaning given to such term in
Section 1.31. 

  

	1.36	 “Business Day” means a day other than a Saturday, Sunday, or a bank or other public
holiday in New York, New York, United States. 

  

	1.37	 “C2C1” shall mean [**]. 

 

	1.38	 “Calendar Quarter” shall mean the respective periods of three (3) consecutive
calendar months ending on March 31, June 30, September 30 and December 31; provided that the first Calendar Quarter of the Term shall begin on the Effective Date and end on the last day of the then current Calendar Quarter and
the last Calendar Quarter of the Term shall begin on the first day of such Calendar Quarter and end on the last day of the Term. 

  

	1.39	 “Calendar Year” shall mean each successive period of twelve (12) months commencing
on January 1 and ending on December 31; provided that the first Calendar Year of the Term shall begin on the Effective Date and end on December 31 of the then current Calendar Year and the last Calendar Year of the Term shall begin
on the first day of such Calendar Year and end on the last day of the Term. 

  

	1.40	 “Challenged Patent Right” shall have the meaning given to such term in
Section 1.128. 

  

	1.41	 “Change of Control” means, with respect to a Person, any of the following:
(a) the sale or disposition of all or substantially all of the assets of such Person to a non-Affiliate of such Person, (b) the acquisition by a non-Affiliate
of such Person, directly or indirectly, other than by an employee benefit plan (or related trust) sponsored or maintained by such Person or any of its Affiliates, of more than fifty percent (50%) of such Person’s outstanding shares of voting
capital stock or similar equity (e.g., capital stock entitled to vote generally for the election of directors), (c) the merger or consolidation of such Person with or into another corporation or entity, or (d) a liquidation or dissolution of
such Person or any direct or indirect parent of such Person, excluding, in the case of (b) or (c) above, an acquisition or a merger or consolidation of a Person in which holders of shares of such Person’s voting

  
 4 

	 	
capital stock or similar equity immediately prior to the acquisition, merger or consolidation have more than fifty percent (50%) of the ownership of voting capital stock or similar equity of the
acquiring non-Affiliate or the surviving corporation or entity in such merger or consolidation, as the case may be, immediately after the merger or consolidation. Notwithstanding the foregoing, a Change of
Control will not be deemed to occur on account of a sale of assets, merger or other transaction effected exclusively for the purpose of changing the corporate domicile or legal form of such Person. 

 

	1.42	 [**]. 

  

	1.43	 “Clinical Trial” shall mean a Phase I Clinical Trial, Phase II Clinical Trial, Phase
III Clinical Trial, or Phase IV Clinical Trial. 

  

	1.44	 “Clinical Trial Data” shall mean, with respect to a Product that is a Licensed Product
or Collaboration Product, (a) all pharmacokinetic, clinical, safety and other similar data that relate to the Development of such Product, including all data and information related to any Clinical Trials of such Product (including all final
reports and case report forms) and (b) all clinical test designs and operating records related to any Clinical Trial for such Product. 

  

	1.45	 “Code” shall have the meaning given to such term in
Section 15.5.3. 

  

	1.46	 “Collaboration Marks” shall have the meaning given to such term in
Section 13.6.1. 

  

	1.47	 “Collaboration Product” shall mean an
Opt-In Product for which (a) Beam has elected the Beam Opt-In Option in accordance with Section 5.1, (b) Beam has not elected the Beam Opt-Out Option and (c) Verve has not elected the Verve Opt-Out Option. 

  

	1.48	 “Collaboration Technology” shall mean the Beam Collaboration Technology, the Verve
Collaboration Technology and the Joint Collaboration Technology. 

  

	1.49	 “Collaboration Territory” shall mean the United States, its territories and
possessions. 

  

	1.50	 “Collaboration Territory Revenue” shall mean, for any given time period, [**].
Collaboration Territory Revenue in any given time period shall be determined on an accrual basis from the Parties’ books and records maintained in accordance with GAAP. 

 

	1.51	 “Commercial Operations” means, with respect to any Person and a country, the promotion,
marketing or selling of any pharmaceutical or biologic product in such country by such Person or its Affiliates, either itself or jointly with a Third Party. 

  

	1.52	 “Commercialization Budget” shall mean, with respect to a Collaboration Product
in the Collaboration Territory, the budget for Shared Commercialization Costs included in the US Commercialization Plan for such Collaboration Product. 

  

	1.53	 “Commercialization Senior Officer” shall mean, with respect to a Party, any officer
designated under Section 3.3.3 (or such officer’s designee) that has the requisite decision-making authority and expertise within such Party to make decisions related to Commercialization under this Agreement.

  
 5 

	1.54	 “Commercialize” shall mean to promote, market, distribute, sell and provide
product support for a Product, and “Commercializing” and “Commercialization” shall have correlative meanings. 

  

	1.55	 “Commercially Reasonable Efforts” shall mean, with respect to the efforts and
resources to be expended by a Party with respect to any objective, the efforts and resources [**]. It is anticipated that the level of effort to be expended in the use of Commercially Reasonable Efforts will change over time, including to reflect
changes in the status of the Product and the countries (or markets) involved. For the avoidance of doubt, where a Party has an obligation to use Commercially Reasonable Efforts, the efforts of such Party and its Affiliates and sublicensees shall be
considered in determining whether such Party has satisfied such obligation. 

  

	1.56	 “Committee” shall mean the JSC and any Subcommittee. 

 

	1.57	 “Competitor” means: 

 

	 	1.57.1	 with respect to Beam, [**]. An entity that is a Competitor under the foregoing clause (b) shall
only be deemed a Competitor for so long as such control exists. [**]. After Beam has added such [**] additional entities, Beam may propose that [**] or more additional entities that meet the requirements set forth in the foregoing
(i) and (ii) be added to Schedule 1.57.1, and such entity(ies) shall only be added to Schedule 1.57.1 by mutual written agreement of the Parties. 

 

	 	1.57.2	 and with respect to Verve, a Third Party that is, or has an Affiliate that is, (i) developing or
commercializing a Verve Competitive Product or (ii) engaged in a Verve Competitive Program. 

  

	1.58	 “Confidential Information” shall have the meaning given to such term in
Section 11.1. 

  

	1.59	 “Control”, “Controls” or “Controlled by” shall mean,
with respect to any product, Patent Right or other tangible or intangible intellectual property right, the possession (whether by ownership or license, other than licenses granted pursuant to this Agreement) by a Party or its Affiliate of the
ability to grant to the other Party access to, ownership of, or a license or sublicense under, such product, Patent Right, or other intellectual property without violating the terms of any agreement or other arrangement with any Third Party;
provided, however, that any product, Patent Right or other tangible or intangible intellectual property right Controlled by (a) a Future Acquirer of a Party or (b) a Third Party that becomes an Affiliate of a Party due to a
Change of Control of such Party following the Effective Date will not be treated as “Controlled” by such Party or its Affiliate for purposes of this Agreement. 

 

	1.60	 “Co-Promote” shall mean the joint
promotion of a Product by Verve and Beam through their respective sales forces under a single trademark in the Collaboration Territory, but shall not include any Manufacturing activities or Development activities or any other actions undertaken with
Regulatory Authorities in order to obtain or maintain Marketing Authorizations. “Co-Promotion” and “Co-Promoting” shall have a
correlative meaning. 

  
 6 

	1.61	 “Co-Promotion Agreement” shall have the
meaning given to such term in Section 7.6. 

  

	1.62	 “Cost of Goods Manufactured” shall mean, with respect to a Product, [**].

  

	1.63	 “Cost Report” shall have the meaning given to such term in
Section 10.5.2(a). 

  

	1.64	 “Covered” shall mean, with respect to a given product, process, method or service, that
a Valid Claim would (absent a license thereunder or ownership thereof) be infringed (whether directly infringed or indirectly by induced or contributory infringement) by the making, using, selling, offering for sale, importation or other
exploitation of such product, process, method or service. With respect to a claim of a pending patent application, “infringed” refers to activity that would infringe or be covered by such Valid Claim if it were contained in an issued
patent. Cognates of the word “Covered” shall have correlative meanings. 

  

	1.65	 “CPI” shall mean, with respect to personnel located in the U.S., the Consumer Price
Index – All Urban Consumers published by the United States Department of Labor, Bureau of Statistics (or its successor equivalent index), and with respect to personnel located outside the U.S., (a) an equivalent index in a foreign country
applicable to FTEs in such country, accounting if possible for the area in such country where the personnel are located, or (b) other inflation measure or rate agreed to by the Parties. 

 

	1.66	 [**]. 

  

	1.67	 “Delivery Technology” shall mean, (a) with respect to Beam, the Beam
Delivery Technology and (b) with respect to Verve, the Verve Delivery Technology. 

  

	1.68	 “Delivery Technology Product” shall mean, [**]. 

 

	1.69	 “Detail” means, with respect to a Collaboration Product in the Collaboration Territory,
a face-to-face contact between a sales representative and a physician or other medical professional licensed to prescribe drugs, during which a primary position detail
(as defined in the Co-Promotion Agreement) or a secondary position detail (as defined in the Co-Promotion Agreement) is made to such person, in each case as measured by
each Party’s internal recording of such activity in accordance with the Co-Promotion Agreement; provided that such meeting is consistent with and in accordance with the requirements of Applicable
Law and this Agreement. When used as a verb, “Detail” means to engage in a Detail. 

  

	1.70	 “Develop” shall mean to research, develop, analyze, test and conduct preclinical,
clinical and all other regulatory trials for a Product, as well as any and all activities pertaining to manufacturing development, formulation development and lifecycle management, including new formulations and all other activities related to
securing and maintaining Marketing Authorization for a Product. “Developing” and “Development” shall have correlative meanings. 

  
 7 

	1.71	 “Development Budget” shall mean, with respect to a Subsequent Development Plan
for a Collaboration Product, the budget for Development activities for such Collaboration Product in the Territory under such Development Plan in the Major Markets, as may be amended from time to time by the JSC. Each Development Budget shall be
itemized by general Development activity and the Party expected to incur such expense. 

  

	1.72	 “Development Cost Report” shall have the meaning given to such term in
Section 10.5.2(a). 

  

	1.73	 “Development Plan” shall mean, on a Product-by-Product basis, the Initial Development Plan and the Subsequent Development Plan for such Product. 

  

	1.74	 “Development Senior Officer” shall mean, with respect to a Party, any officer designated under
Section 3.3.3 (or such officer’s designee) that has the requisite decision-making authority and expertise within such Party to make decisions related to Development under this Agreement. 

 

	1.75	 “Disclosing Party” shall have the meaning given to such term in
Section 11.1. 

  

	1.76	 “Dispute” shall have the meaning given to such term in
Section 16.7. 

  

	1.77	 “EMA” shall mean the European Medicines Agency and any successor Regulatory Authority
having substantially the same function. 

  

	1.78	 “European Union” means the organization of member states of the European Union,
as it may be constituted from time to time during the Term. 

  

	1.79	 “Existing Confidentiality Agreement” shall have the meaning given to such term in
Section 11.6. 

  

	1.80	 “FDA” shall mean the United States Food and Drug Administration and any successor
Regulatory Authority having substantially the same function. 

  

	1.81	 “Field” shall mean the prevention or treatment of human diseases.

  

	1.82	 “First Commercial Sale” shall mean, with respect to a Product in a country, [**].

  

	1.83	 “FTE” shall mean [**] hours of work devoted to or in support of Development or
Commercialization activities under this Agreement that is carried out by one or more qualified employees, contract personnel or consultants of a Party, measured in accordance with such Party’s normal time allocation practices.

  

	1.84	 “FTE Cost” shall mean, for any period, the FTE Rate multiplied by the number of FTEs in
such period. 

  

	1.85	 “FTE Rate” shall mean, (a) for the period during the Term through the end of the
first full Calendar Year, a rate of [**] U.S. Dollars ($[**]) per FTE and [**]. 

  
 8 

	1.86	 “Fully Absorbed Standard Costs” shall mean, with respect to a Product, [**].

  

	1.87	 “Future Acquirer” shall mean, with respect to a Party, the non-Affiliate party to any Change of Control of such Party and such non-Affiliate Person’s Affiliates immediately prior to the Change of Control. 

 

	1.88	 “GAAP” shall mean United States generally accepted accounting principles, consistently
applied. 

  

	1.89	 “Governmental Authority” shall mean any United States federal, state or local,
or any foreign, government or political subdivision thereof, or any multinational organization or authority, or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or
taxing authority or power, any court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body. 

  

	1.90	 “[**]” has the meaning set forth in Section 1.34.

  

	1.91	 “IND” shall mean an investigational new drug application, clinical trial authorization,
or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority. 

 

	1.92	 “Indemnified Party” shall have the meaning given to such term in
Section 14.4.1. 

  

	1.93	 “Indemnifying Party” shall have the meaning given to such term in
Section 14.4.1. 

  

	1.94	 “Independent Product” means any Base Editor Product or Nuclease Product that is not a
Licensed Product or a Delivery Technology Product. 

  

	1.95	 “Indication” shall mean [**]. 

 

	1.96	 “Initial Development Plan” shall have the meaning given to such term in
Section 4.3.1. 

  

	1.97	 “Initiate” or “Initiation” shall mean, with respect to a Clinical
Trial, the administration of the first dose to a human subject in such Clinical Trial. 

  

	1.98	 “Institution” means each of [**]. 

 

	1.99	 [**]. 

  

	1.100	 “JMC” shall have the meaning given to such term in
Section 3.5.1. 

  

	1.101	 “Joint Collaboration Know-How” shall
mean all Know-How, patentable or otherwise, conceived, developed, generated or reduced to practice during the Term jointly by, on one hand, Beam, its Affiliates or persons acting on behalf of Beam and, on the
other hand, Verve, its Affiliates or persons acting on behalf of Verve, in each case through the Development, Commercialization or Manufacture of Products or otherwise arising out of a Party’s performance of its obligations under this
Agreement; provided that [**]. 

  
 9 

	1.102	 “Joint Collaboration Patent Rights” shall mean Patent Rights claiming any Joint
Collaboration Know-How. 

  

	1.103	 “Joint Collaboration Technology” shall mean the Joint Collaboration Know-How and Joint Collaboration Patent Rights. 

  

	1.104	 “JRC” shall have the meaning given to such term in
Section 3.4.1. 

  

	1.105	 “JSC” shall have the meaning given to such term in
Section 3.3. 

  

	1.106	 “Know-How” shall mean any invention,
discovery, development, data, information, process, method, technique, trade secret, composition of matter, formulation, article of manufacture or other know-how, and any physical embodiments of any of the
foregoing. 

  

	1.107	 [**]. 

  

	1.108	 “Licensed Base Editor Product” means, on a country-by-country basis, any Base Editor Product (a) the making, using, selling, offering for sale, importing or exporting of which in the country in question is Covered by at least one Valid Claim of
the Beam Base Editor Patent Rights or (b) was made, discovered, developed or determined to have utility through the use of any of the Beam Base Editor Technology. For clarity, a Licensed Base Editor Product can also be Covered by one or more
Valid Claims of the Beam C2C1 Patent Rights or have been made, discovered, developed or determined to have utility through the use of the Beam C2C1 Technology. 

 

	1.109	 “Licensed C2C1 Product” means, on a country-by-country basis, any Nuclease Product (a) the making, using, selling, offering for sale, importing or exporting of which in the country in question is Covered by at least one Valid Claim of the
Beam C2C1 Patent Rights or (b) was made, discovered, developed or determined to have utility through the use of any of the Beam C2C1 Technology. 

  

	1.110	 “Licensed Product” means Licensed Base Editor Products and Licensed C2C1 Products.

  

	1.111	 “Licensed Targets” shall mean ANGPTL3, PCSK9, [**]. 

 

	1.112	 “Licensee” shall have the meaning given to such term in
Section 1.127. 

  

	1.113	 “Licensor” shall have the meaning given to such term in
Section 1.127. 

  

	1.114	 “Losses” shall have the meaning given to such term in
Section 14.1. 

  

	1.115	 “Major Market” means each of [**]. 

  
 10 

	1.116	 “Manufacture” or “Manufacturing” shall mean, with respect to a
Product, including components thereof, the receipt, handling and storage of materials, the manufacturing, processing, packaging and labeling (excluding the development of packaging and labeling components for Marketing Authorization), holding
(including storage), quality assurance and quality control testing (including release) of such compound or product (other than quality assurance and quality control related to development of the manufacturing process, which activities shall be
considered Development activities) and shipping of such Product (or components thereof). 

  

	1.117	 “Marketing Authorization” shall mean all approvals from the relevant Regulatory
Authority necessary to market and sell a product in any country, including Pricing Approval if necessary. 

  

	1.118	 “Material Transfer Agreement” shall have the meaning given to such term in
Section 2.6.5. 

  

	1.119	 “[**]” shall mean [**]. 

 

	1.120	 “NDA” shall mean a New Drug Application, Biologics License Application, Worldwide
Marketing Application, Marketing Authorization Application, filing pursuant to Section 510(k) of the Act, or similar application or submission for Marketing Authorization of a Product filed with a Regulatory Authority to obtain Marketing
Authorization for a biological, pharmaceutical or diagnostic product in the applicable jurisdiction. 

  

	1.121	 “Net Sales” shall mean [**]. 

 

	1.122	 “Nuclease Product” shall mean [**]. 

 

	1.123	 “Opt-In Information Package” shall have the
meaning given to such term in Section 5.1. 

  

	1.124	 “Opt-In Product” shall mean [**] (a) Licensed
Product, (b) [**] other Nuclease Product or (c) [**] other Base Editor Product [**]. 

  

	1.125	 “Opt-Out Date” shall mean the Beam Opt-Out Date or the Verve Opt-Out Date, as applicable. 

  

	1.126	 “Party” or “Parties” shall have the meaning given to such term in the
preamble to this Agreement. 

  

	1.127	 “Party Materials” shall have the meaning given to such term in
Section 2.6.1. 

  

	1.128	 “Patent Challenge” means any direct or indirect dispute or challenge, or any
knowing, willful or reckless assistance in the dispute or challenge, of the validity, patentability, scope, priority, construction, non-infringement, inventorship, ownership or enforceability of any Patent
Right (a “Challenged Patent Right”) licensed by a Party (the “Licensor”) to the other Party (the “Licensee”) under this Agreement or any claim thereof, or opposition or assistance in the opposition
of the grant of any letters patent within the Challenged Patent Rights, in any legal or administrative proceedings, including in a court of law, before the United States Patent and Trademark Office or other agency or tribunal in any jurisdiction, or
in arbitration including by reexamination, inter partes review, 

  
 11 

	 	
opposition, interference, post-grant review, nullity proceeding, preissuance submission, third party submission, derivation proceeding or declaratory judgment action; provided,
however, that the term Patent Challenge shall not include (a) the Licensee or any of its Affiliates or sublicensees being an essential party in any patent interference proceeding before the United States Patent and Trademark Office,
which interference the Licensee or its applicable Affiliate or sublicensee acts in good faith to try to settle or (b) the Licensee or any of its Affiliates or sublicensees, due to its status as an exclusive licensee of patent rights other than
the Challenged Patent Rights, being named by the Licensor of such patent rights as a real party in interest in such an interference, so long as the Licensee or its applicable Affiliate or sublicensee either abstains from participation in, or acts in
good faith to settle, the interference. For clarity, a Patent Challenge shall not include arguments made by the Licensee that (x) distinguish the inventions claimed in Patent Rights owned or controlled by the Licensee from those claimed in the
Challenged Patent Rights but (y) do not disparage the Challenged Patent Rights or raise any issue of Challenged Patent Rights’ compliance with or sufficiency under applicable patent laws, regulations or administrative rules, in each case
(i) in the ordinary course of ex parte prosecution of the Patent Rights owned or controlled by the Licensee or (ii) in inter partes proceedings before the United States Patent and Trademark Office or other agency or tribunal in any
jurisdiction (excluding interferences or derivation proceedings), or in arbitration, wherein the Patent Rights owned or controlled by the Licensee have been challenged. For further clarity, unless in conflict with the definition of a “Patent
Challenge” that exists as of the Effective Date under a Third Party Agreement applicable to the Challenged Patent Rights, a Patent Challenge shall not include any counterclaim made, filed or maintained by the Licensee or its applicable
Affiliate or sublicensee as a defendant in any claim, demand, lawsuit, cause of action or other action made, filed or maintained by the Licensor or its Affiliate or designee asserting infringement of any Patent Right. 

 

	1.129	 “Patent Rights” shall mean (a) all patents and patent applications in any
country or supranational jurisdiction in the Territory, (b) any substitutions, divisionals, continuations, continuations-in-part, provisional applications,
reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates and the like of any such patents or patent applications, (c) foreign counterparts of
any of the foregoing, (d) all applications claiming priority to any of the foregoing, (e) any patents issuing on any patent application identified in clauses (a) through (d), (f) any application to which any of the foregoing claim
priority and (g) any application that claims common priority with any of the foregoing. 

  

	1.130	 “Permitted Uses” shall have the meaning given to such term in
Section 2.6.2. 

  

	1.131	 “Person” shall mean an individual, Governmental Authority, government official,
corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, or any other form of entity not specifically listed
herein. 

  

	1.132	 “Pharmacovigilance Agreement” shall have the meaning given to such term in
Section 3.12. 

  
 12 

	1.133	 “Phase I Clinical Trial” shall mean a human clinical trial in any country that would
satisfy the requirements of 21 CFR 312.21(a). 

  

	1.134	 “Phase II Clinical Trial” shall mean a human clinical trial in any country that would
satisfy the requirements of 21 CFR 312.21(b). 

  

	1.135	 “Phase III Clinical Trial” shall mean a human clinical trial in any country that would
satisfy the requirements of 21 CFR 312.21(c). 

  

	1.136	 “Phase IV Clinical Trial” shall mean (i) any human clinical trial (other
than a Phase I Clinical Trial, Phase II Clinical Trial or Phase III Clinical Trial) in any country which is conducted on a Product for an Indication in the Field after Marketing Authorization of such Product has been obtained from an appropriate
Regulatory Authority in such country for such Indication, and includes (a) clinical trials conducted voluntarily after Marketing Authorization for enhancing marketing or scientific knowledge of an approved Indication in the Field or
(b) trials conducted after Marketing Authorization due to request or requirement of a Regulatory Authority or as a condition of a previously granted Marketing Authorization or (ii) any REMS/RMP related study of a Product for an Indication
in the Field after Marketing Authorization of such Product has been obtained from an appropriate Regulatory Authority in such country for such Indication. 

  

	1.137	 “Post-Approval Shared Development Costs” shall mean, on a Collaboration Product-by-Collaboration Product basis, the sum of [**]. 

  

	1.138	 “Post-Approval Shared Regulatory Costs” shall mean, on an Collaboration Product-by-Collaboration Product basis, the sum of [**]. 

  

	1.139	 “Post-Termination Licensed Technology” shall have the meaning given to such term in
Section 15.5.2(b). 

  

	1.140	 “Pricing Approval” means, with respect to a product in any country where a Governmental
Authority authorizes reimbursement for, or approves or determines pricing for, pharmaceutical products, (a) receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement
authorization or pricing approval or determination (as the case may be) for such product in such country and (b) the earlier to occur of (i) Verve, its Affiliate or sublicensee indicating agreement with such price(s) in such country or
(ii) Verve, its Affiliate or sublicensee commencing Commercialization activities for such Product in such country after Marketing Authorization (other than Pricing Approval). 

 

	1.141	 “Product(s)” shall mean any Base Editor Product, Nuclease Product or Delivery
Technology Product, as applicable. 

  

	1.142	 “Product-Specific Know-How” means any
Beam Base Editor Know-How, Beam C2C1 Know-How or Beam Collaboration Know-How that [**]. 

  
 13 

	1.143	 “Product-Specific Patent Right” means any Beam Base Editor Patent Right, Beam C2C1
Patent Right or Beam Collaboration Patent Right that solely claims or discloses any Product-Specific Know-How. 

  

	1.144	 “Receiving Party” shall have the meaning given to such term in
Section 11.1. 

  

	1.145	 “Reconciliation Report” shall have the meaning given to such term in
Section 10.5.2(d). 

  

	1.146	 “Regulatory Authority” shall mean any applicable Governmental Authority involved in
granting approvals for the manufacturing or marketing of a Product (including Marketing Authorizations therefor) in the Territory, including in the United States, the FDA, and in the European Union, the EMA. 

 

	1.147	 “Regulatory Documentation” shall have the meaning given to such term in
Section 6.2. 

  

	1.148	 “Research Plan” shall have the meaning given to such term in
Section 4.2. 

  

	1.149	 “Royalty Term” shall mean: 

 

	 	1.149.1	 on a country-by-country
and Licensed Product-by-Licensed Product basis, the period during which royalties shall be paid on the sum of Net Sales of such Licensed Product in such country, from
the First Commercial Sale of such Licensed Product until the latest of: (a) the expiration date of the last to expire Valid Claim within the Beam Base Editor Patent Rights, Beam C2C1 Patent Rights, Beam Collaboration Patent Rights, Patent
Rights within Beam Delivery Technology or Joint Collaboration Patent Rights Covering the applicable Licensed Product (or if the last such Valid Claim with respect to such Licensed Product in such country is a pending Valid Claim, the date such
pending Valid Claim ceases to be a Valid Claim; provided, however, that subsequent issuance of such Valid Claim shall again extend the Royalty Term from the date of such issuance to the expiration date of such Valid Claim); (b) the
period of regulatory exclusivity associated with such Licensed Product in such country; or (c) ten (10) years after the First Commercial Sale of such Licensed Product in such country; 

 

	 	1.149.2	 on a country-by-country
and Beam Delivery Technology Product-by-Beam Delivery Technology Product basis, the period during which royalties shall be paid on the sum of Net Sales of such Beam Delivery Technology Product in such country,
from the First Commercial Sale of such Beam Delivery Technology Product until the latest of: (a) the expiration date of the last to expire Valid Claim within the Patent Rights within Verve Delivery Technology Covering the applicable Beam
Delivery Technology Product (or if the last such Valid Claim with respect to such Beam Delivery Technology Product in such country is a pending Valid Claim, the date such pending Valid Claim ceases to be a Valid Claim; provided,
however, that subsequent issuance of such Valid Claim shall again extend the Royalty Term from the date of such issuance to the expiration date of such Valid Claim); (b) the period of regulatory exclusivity associated with such Beam Delivery
Technology Product in such country; or (c) ten (10) years after the First Commercial Sale of such Beam Delivery Technology Product in such country; 

  
 14 

	 	1.149.3	 on a country-by-country
and Verve Delivery Technology Product-by-Verve Delivery Technology Product basis, the period during which royalties shall be paid on the sum of Net Sales of such Verve Delivery Technology Product in such
country, from the First Commercial Sale of such Verve Delivery Technology Product until the latest of: (a) the expiration date of the last to expire Valid Claim within the Patent Rights within Beam Delivery Technology Covering the applicable
Verve Delivery Technology Product (or if the last such Valid Claim with respect to such Verve Delivery Technology Product in such country is a pending Valid Claim, the date such pending Valid Claim ceases to be a Valid Claim; provided,
however, that subsequent issuance of such Valid Claim shall again extend the Royalty Term from the date of such issuance to the expiration date of such Valid Claim); (b) the period of regulatory exclusivity associated with such Verve Delivery
Technology Product in such country; or (c) ten (10) years after the First Commercial Sale of such Verve Delivery Technology Product in such country; or 

  

	 	1.149.4	 on a country-by-country
and Terminated Reversion Product-by-Terminated Reversion Product basis, the period during which royalties shall be paid on the sum of Net Sales of such Terminated
Reversion Product in such country, from the First Commercial Sale of such Terminated Reversion Product until the latest of: (a) the expiration date of the last to expire Valid Claim within the Patent Rights within the Post-Termination Licensed
Technology Covering the applicable Terminated Reversion Product (or if the last such Valid Claim with respect to such Terminated Reversion Product in such country is a pending Valid Claim, the date such pending Valid Claim ceases to be a Valid
Claim; provided, however, that subsequent issuance of such Valid Claim shall again extend the Royalty Term from the date of such issuance to the expiration date of such Valid Claim); (b) the period of regulatory exclusivity associated
with such Terminated Reversion Product in such country; or (c) ten (10) years after the First Commercial Sale of such Terminated Reversion Product in such country. 

 

	1.150	 “Safety Issue” shall mean, with respect to a Product, [**].

  

	1.151	 “Sales and Marketing Expenses” shall mean the sum of [**].

  

	1.152	 “Senior Officers” shall have the meaning given to such term in
Section 3.3.3. 

  

	1.153	 “Shared Commercialization Costs” shall mean, with respect to a Collaboration
Product, the sum of the following: [**]. 

  

	1.154	 “Shared Costs” shall mean any Shared Commercialization Costs or Shared
Development Costs. 

  

	1.155	 “Shared Development Costs” shall mean, with respect to a Collaboration Product, the sum
of [**]. 

  
 15 

	1.156	 “Shared Distribution Costs” shall mean the sum of [**]. 

 

	1.157	 “Subcommittees” shall mean the JRC, JDC, JMC, JCC or any other committee or
subcommittee (other than the JSC) formed in accordance with this Agreement. 

  

	1.158	 “Subsequent Development Plan” shall have the meaning given to such term in
Section 4.3.2(a). 

  

	1.159	 “Supply Agreement(s)” shall mean any and all supply agreements entered into by the
Parties (or their respective Affiliates) with respect to Products as of the Effective Date or thereafter. 

  

	1.160	 “Surviving Sublicensee” shall have the meaning given to such term in
Section 2.2.4. 

  

	1.161	 “Technology Transfer Plan” shall have the meaning given to such term in
Section 2.5. 

  

	1.162	 “Term” shall have the meaning given to such term in
Section 15.1. 

  

	1.163	 “Terminated Product” shall have the meaning given to such term in
Section 15.5.1. 

  

	1.164	 “Terminated Reversion Product” shall have the meaning given to such term in
Section 15.5.2(a). 

  

	1.165	 “Territory” shall mean all of the countries in the world, and their territories and
possessions. 

  

	1.166	 “Third Party” shall mean a Person other than Verve, Beam or their respective
Affiliates. 

  

	1.167	 “Third Party Agreements” shall mean (a) subject to Section
3.3.3(b)(viii), any agreement entered into after the Effective Date between a Third Party and Verve or its Affiliate pursuant to which Verve or its Affiliate gains rights to use such Third Party’s intellectual property in the
Development, Manufacture or Commercialization of a Licensed Product or Collaboration Product under this Agreement, (b) with respect to Beam, any agreement set forth on Schedule 1.167(a) and, with respect to
Verve, any agreement set forth on Schedule 1.167(b) or (c) any agreement between a Third Party and a Party or its Affiliate that is deemed a “Third Party Agreement” under
Section 2.4.3 or 9.2. 

  

	1.168	 “Third Party Payments” shall mean compensation paid to any Third Party by a
Party or by both Parties (or their respective Affiliates) under any Third Party Agreement. 

  

	1.169	 “US Commercialization Plan” shall have the meaning given to such term in
Section 7.3.1. 

  

	1.170	 “Valid Claim” means, with respect to any Patent Rights, (a) a claim of an
issued and unexpired patent within such Patent Rights that has not been (i) held permanently revoked, unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, unappealable or unappealed
within the time allowed for appeal, (ii) rendered unenforceable through disclaimer, or (iii) permanently lost through an interference or opposition proceeding without any right of appeal or review, or not

  
 16 

	 	
appealed or put in for review within the applicable statutory or regulatory period; or (b) a pending claim of a pending patent application within such Patent Rights that has not been
(i) abandoned or finally rejected without the possibility of appeal or refiling or (ii) pending more than [**] from the date of the first substantive office action on such pending patent application, provided such patent application is not
pending more than [**] from its earliest priority date. A pending claim that ceases to be a Valid Claim due to the foregoing time limit shall, if it later issues, qualify again as a Valid Claim, provided that it meets the requirements of clauses
(a)(i)-(iii) of the foregoing definition. 

  

	1.171	 “Verve” shall have the meaning given to such term in the preamble to this Agreement.

  

	1.172	 “Verve Collaboration Know-How” shall mean all Know-How, patentable or otherwise, conceived, developed, generated or reduced to practice during the Term solely by Verve or its Affiliates or other persons acting on behalf of Verve through the Development,
Commercialization or Manufacture of Products or otherwise arising out of Verve’s performance of its obligations under this Agreement; provided that Verve Collaboration Know-How shall not include
any Beam Collaboration Know-How. 

  

	1.173	 “Verve Collaboration Patent Rights” shall mean Patent Rights which (a) as of the
Effective Date or during the Term are Controlled by Verve or its Affiliates and (b) claim Verve Collaboration Know-How. 

 

	1.174	 “Verve Collaboration Technology” shall mean Verve Collaboration Know-How and Verve Collaboration Patent Rights. 

  

	1.175	 “Verve Competitive Product” shall have the meaning given to such term in
Section 1.176. 

  

	1.176	 “Verve Competitive Program” shall mean any research or development program for which
[**], with the goal of discovering or developing (a) a Base Editor Product or (b) a Nuclease Product (such product ((a) or (b)), an “Verve Competitive Product”); provided that, the determination as to whether a
Third Party is engaged in a Verve Competitive Program shall be conclusively determined based on [**]. 

  

	1.177	 “Verve Delivery Technology” shall mean, [**]. 

 

	1.178	 “Verve Delivery Technology Product” shall have the meaning given to such term in
Section 1.68. 

  

	1.179	 “Verve Indemnified Parties” shall have the meaning given to such term in
Section 14.1. 

  

	1.180	 “Verve IP Competitive Infringement” shall have the meaning given to such term in
Section 13.4.1. 

  

	1.181	 “Verve Opt-Out Date” shall have the meaning
given to such term in Section 5.4. 

  

	1.182	 “Verve Opt-Out Option” shall have the meaning
given to such term in Section 5.4. 

  
 17 

	1.183	 “Verve Third Party Agreement” shall have the meaning given to such term in
Section 12.2.7. 

  

	1.184	 “Verve-[**] Agreement” shall mean the [**] License Agreement by and between [**] and
Verve, dated as of [**], as such agreement may be amended from time to time in accordance with its terms. 

  

	1.185	 “Verve-[**] Agreement” shall mean the [**] License Agreement by and between [**] and
Verve, dated as of [**], as such agreement may be amended from time to time in accordance with its terms. 

 Article 2 LICENSES

  

	2.1	 License Grants; Retained Rights. 

 

	 	2.1.1	 Subject to the terms and conditions of this Agreement (including
Section 2.4.1), Beam hereby grants, and shall cause its Affiliates to grant, to Verve an exclusive (even as to Beam and its Affiliates, except as set forth in Section 2.1.6) license under the Beam
Base Editor Technology, Beam C2C1 Technology and Beam’s interest in the Joint Collaboration Technology, with a right to grant and authorize the further grant through multiple tiers of sublicenses in accordance with this Agreement (including
Section 2.2), solely to Develop, make, have made, use, offer for sale, sell, have sold, and import Licensed Products in the Field in the Territory. 

 

	 	2.1.2	 Subject to the terms and conditions of this Agreement, Verve hereby grants, and Verve shall cause its
Affiliates to grant, to Beam a non-exclusive license under the Know-How (patentable or otherwise) and Patent Rights Controlled by Verve or its Affiliates as of the
Effective Date or during the Term, and Verve’s interest in the Joint Collaboration Technology, with a right to grant and authorize the further grant through multiple tiers of sublicenses in accordance with this Agreement (including
Section 2.2), solely to conduct the activities allocated to Beam under a Research Plan or Development Plan (if any). 

  

	 	2.1.3	 Subject to the terms and conditions of this Agreement, Verve hereby grants, and shall cause its
Affiliates to grant, to Beam an exclusive license (except with respect to Verve, its Affiliates, licensees and sublicensees) under Verve Delivery Technology, with a right to grant and authorize the further grant of sublicenses in accordance with
this Agreement (including Section 2.2), solely to Develop, make, have made, use, offer for sale, sell, have sold, and import product candidates and products (except for Base Editor Products) including a [**] in the
Territory. 

  

	 	2.1.4	 Subject to the terms and conditions of this Agreement (including
Section 2.4.1), Beam hereby grants, and shall cause its Affiliates to grant, to Verve an exclusive license (with Beam and its Affiliates) under Beam Delivery Technology, with a right to grant and authorize the further grant
of sublicenses in accordance with this Agreement (including Section 2.2), solely to Develop, make, have made, use, offer for sale, sell, have sold, and import Base Editor Products and Nuclease Products in the Field in the
Territory. 

  
 18 

	 	2.1.5	 Subject to the terms and conditions of this Agreement, on a Collaboration
Product-by-Collaboration Product basis, effective upon Beam’s exercise of the Beam Opt-In Option with respect to a
Collaboration Product, Verve hereby grants, and shall cause its Affiliates to grant, to Beam a non-exclusive license under the Know-How (patentable or otherwise) and
Patent Rights Controlled by Verve or its Affiliates as of the date of Beam’s exercise of the Beam Opt-In Option or thereafter during the Term, and Verve’s interest in the Joint Collaboration
Technology, with a right to grant and authorize the further grant of sublicenses as permitted under this Agreement (including the US Commercialization Plan) or the Co-Promotion Agreement, to offer for sale,
sell, have sold, and import (including Commercialize and Co-Promote) such Collaboration Product in the Field in the Collaboration Territory. 

 

	 	2.1.6	 Notwithstanding anything to the contrary in this Agreement, including without limitation the license
grant to Verve set forth in Section 2.1.1, Beam and its Affiliates shall retain the right under Beam Base Editor Technology, Beam C2C1 Technology and Beam’s interest in the Joint Collaboration Technology to
(a) Manufacture Base Editor Products in accordance with Article 8 or any Supply Agreement and (b) otherwise exercise their respective rights and perform their respective obligations under the this Agreement,
including without limitation the Development of Collaboration Products in the Territory as set forth in this Agreement (including any Development Plan) and the Commercialization of Collaboration Products in the Collaboration Territory as set forth
in this Agreement (including the US Commercialization Plan) or a Co-Promotion Agreement. 

  

	2.2	 Sublicenses. 

 

	 	2.2.1	 In no event shall any sublicense granted pursuant to Section 2.1 diminish,
reduce or eliminate any of the obligations of the sublicensing Party under this Agreement. Any sublicense granted pursuant to Section 2.1 shall be subject and subordinate to, and consistent with, the terms and conditions of
this Agreement and shall require each such sublicensee to comply with all applicable terms of this Agreement, including the prohibition of further sublicensing by the sublicensee except where such sublicense is in compliance with the provisions of
this Agreement. 

  

	 	2.2.2	 [**]. The sublicensing Party shall provide the other Party with a fully-executed copy of any agreement
(which the sublicensing Party may redact as necessary to protect confidential or commercially sensitive information) reflecting any such sublicense promptly after the execution thereof. If a Party grants a sublicense, the terms and conditions of
this Agreement and the Third Party Agreements that are applicable to sublicensees shall apply to such sublicensee to the same extent as they apply to such Party. Further, the sublicensing Party assumes full

  
 19 

	 	
responsibility, and shall remain primarily liable, for causing the performance of all obligations of each Affiliate and sublicensee of such sublicensing Party to which it grants a sublicense, and
will itself pay and account to the other Party for all payments due under this Agreement by reason of operation of any such sublicense. 

  

	 	2.2.3	 [**]. 

  

	 	2.2.4	 Any sublicensed rights granted by Verve pursuant to Section 2.2.2 with respect
to a Terminated Product shall terminate effective upon the termination of this Agreement with respect to such Terminated Product, provided that, subject to and to the extent permitted under the Third Party Agreements, the terms of such
sublicensed rights shall not terminate if, as of the effective date of such termination, the relevant sublicensee for such sublicense is not in material breach of its obligations to Verve under its sublicense agreement, and within [**] of such
termination, such sublicensee agrees in writing to be bound directly to Beam under a license agreement substantially similar to this Agreement with respect to the rights sublicensed and granted hereunder, substituting such sublicensee (a
“Surviving Sublicensee”) for Verve, and provided further that (a) the scope of the rights granted to the Surviving Sublicensee under such license agreement (with respect to such Terminated Product) shall be equal
to (or, upon mutual agreement of the Parties, less than) the scope of the rights that had been sublicensed and granted by Verve to the Surviving Sublicensee pursuant to such sublicense agreement; (b) such license agreement shall obligate the
Surviving Sublicensee to pay directly to Beam amounts corresponding to those set forth in Article 10 which are payable based on the activities of such Surviving Sublicensee, its Affiliates and its sublicensees from and
after the effective date of such termination; (c) Beam will not be required to undertake obligations in addition to those required by this Agreement; (d) that Beam’s rights under such direct license will be consistent with its rights
under this Agreement, taking into account the scope of the license granted under such direct license; and (e) such license agreement shall not modify the rights and obligations of the Parties following any termination of this Agreement in whole
or in part. 

  

	 	2.2.5	 The Parties acknowledge and agree that: 

 

	 	(a)	 [**] is an intended third party beneficiary of the rights granted to Verve by Beam pursuant to
Section 2.1.1 and 2.1.4 under the Beam Base Editor Technology and Beam C2C1 Technology licensed to Beam by [**] under the Beam-[**] Agreement, solely for the purpose of enforcing all patent challenge, intellectual
property ownership, indemnification and insurance and compliance with law provisions applicable to such Beam Base Editor Technology and Beam C2C1 Technology licensed to Verve under this Agreement and, with respect to such insurance and
indemnification provisions, each applicable Product, and enforcing the right to terminate this Agreement for breach of such patent challenge, indemnification (solely with respect to Verve’s obligation to indemnify [**] as set forth in
Schedule 2.4.1(a)) and insurance provisions; 

  
 20 

	 	(b)	 Each other Institution is an intended third party beneficiary of the rights granted to Verve by Beam pursuant
to Section 2.1.1 and 2.1.4 under the Beam Base Editor Technology and Beam C2C1 Technology licensed to Beam by such other Institution under the applicable Third Party Agreement for the purpose of enforcing such
Institution’s rights, including indemnification and insurance provisions that relate to such Beam Base Editor Technology and Beam C2C1 Technology licensed to Verve under this Agreement, and each Product relating to such grant of rights;

  

	 	(c)	 The rights of [**] or any other Institution may be enforced by any Institution in any court of competent
jurisdiction and, without limiting the generality of the foregoing, Verve consents to jurisdiction in Massachusetts courts with respect to any such Institution’s enforcement of its rights under this Agreement; and 

 

	 	(d)	 Notwithstanding the governing law selected under this Agreement, Verve agrees that, in the event of any
difference in interpretation or result as between the laws of the jurisdiction of this Agreement and the laws of Massachusetts, the laws of Massachusetts shall control in any action in which [**] or any other Institution is enforcing its rights
under this Agreement. 

  

	2.3	 Other IP. 

 

	 	2.3.1	 Subject to the terms and conditions of this Agreement, Beam hereby grants to Verve the non-exclusive right, free of charge, to use the Beam name and logo solely for the purpose of Co-Promoting the Collaboration Products in accordance with the terms of this
Agreement and the Co-Promotion Agreement, and Verve hereby grants to Beam the non-exclusive right, free of charge, to use the Verve name and logo in the Collaboration
Territory solely for the purpose of Co-Promoting the Collaboration Products in accordance with the terms of this Agreement and the Co-Promotion Agreement,
provided that such rights shall be exercised, and all Collaboration Products bearing such names or logos shall be manufactured, in accordance with the quality standards established by the JSC. Beam or its Affiliate shall remain the owner of
the Beam name and logo and the trademarks and the goodwill pertaining thereto. Verve or its Affiliate shall remain the owner of the Verve name and logo and the trademarks and the goodwill pertaining thereto. Notwithstanding any provision of this
Agreement or any Co-Promotion Agreement to the contrary, the quality standards established by the JSC may not conflict with or otherwise contravene any quality standards or restrictions on use set forth in the
Co-Promotion Agreement. 

  
 21 

	 	2.3.2	 Subject to the terms and conditions of this Agreement, Verve hereby grants to Beam an exclusive (except
as to Verve and its Affiliates) license, free of charge, to use the Collaboration Marks solely in connection with Co-Promoting the Collaboration Products in the Collaboration Territory in accordance with the
terms of this Agreement and the Co-Promotion Agreement. 

  

	 	2.3.3	 Subject to the terms and conditions of this Agreement, each Party hereby grants to the other Party an
exclusive (except as to such Party and its Affiliates) license, free of charge, to use the copyrighted material created for use in connection with the marketing of the Collaboration Products in the Collaboration Territory solely for use in
connection with Co-Promoting the Collaboration Products in the Collaboration Territory in accordance with the terms of this Agreement and the Co-Promotion Agreement.

  

	2.4	 Third Party Agreements. 

 

	 	2.4.1	 Notwithstanding anything to the contrary in this Agreement, each Party acknowledges and agrees that the
rights, licenses, and sublicenses granted by the other Party to such Party in this Agreement (including any right to sublicense) are subject to the terms of the Third Party Agreements set forth on Schedule 1.167(a) (with respect
to rights granted by Beam) and Schedule 1.167(b) (with respect to rights granted by Verve) and the rights granted to Third Parties thereunder, the scope of the licenses granted to such other Party thereunder and the rights
retained by such Third Parties and any other Third Parties (including Governmental Authorities) set forth therein, including, with respect to Beam Third Party Agreements, (a) Sections [**] of the Beam-[**] Agreement,
(b) Sections [**] of the Beam-[**] Agreement and (c) Sections [**] of the Beam-[**] Agreement; and with respect to Verve Third Party Agreements, (x) [**] of the Verve-[**] Agreement and (y) [**] of the Verve-[**] Agreement.
Without limiting the above in any way, at the granting Party’s request, the receiving Party shall use Commercially Reasonable Efforts to, and cause its Affiliates and all sublicensees to use Commercially Reasonable Efforts to, take such
reasonable actions, as may be required to assist the granting Party in complying with its obligations under Third Party Agreements, solely to the extent applicable to such receiving Party’s rights or obligations under this Agreement. Without
limiting any of the foregoing, (a) Verve agrees to be bound by the terms and conditions of the provisions set forth in Schedule 2.4.1(a), as applicable, with respect to sublicenses granted by Beam to Verve under
Section 2.1 under Third Party Agreements, and (b) Beam agrees to be bound by the terms and conditions of the provisions set forth in Schedule 2.4.1(b), as applicable, with respect to
sublicenses granted by Verve to Beam under Section 2.1 under Third Party Agreements. 

  

	 	2.4.2	 Verve acknowledges and agrees that, if any of the licenses granted to Beam under the Beam Third Party
Agreements are terminated, in whole or in part, then, to the extent that any Patent Rights or Know-How licensed under such terminated license is part of Beam Base Editor Technology or Beam Delivery Technology

  
 22 

	 	
hereunder, then Verve’s license under such terminated licenses(s) shall automatically terminate, subject to any right of Verve to receive a direct license from the relevant Third Party,
including from [**] under Section [**] of the Beam-[**] Agreement, Section [**] of the Beam-[**] Agreement and Section [**] of the Beam-[**] Agreement. Beam acknowledges and agrees that, if any of the licenses granted to Verve under
the Verve Third Party Agreements are terminated, in whole or in part, then, to the extent that any Patent Rights or Know-How licensed under such terminated license is part of Verve Delivery Technology
hereunder, then Beam’s license under such terminated licenses(s) shall automatically terminate, subject to any right of Beam to receive a direct license from the relevant Third Party. 

 

	 	2.4.3	 Notwithstanding anything to the contrary in this Agreement, in the event that Beam enters into an
agreement or arrangement following the Effective Date under which Beam or its Affiliate is granted rights to any Patent Right or Know-How that would be Beam Base Editor Technology or Beam C2C1 Technology
hereunder, such Patent Right or Know-How is hereby [**] a Beam Base Editor Patent Right, Beam Base Editor Know-How, Beam C2C1 Patent Right or Beam C2C1 Know-How hereunder, as applicable, [**], in each case to the extent permitted under any confidentiality obligations related to such arrangement or agreement, (a) [**]. Beam will use commercially reasonable efforts
to secure the right to disclose to Verve the information described in the foregoing clauses (i) through (iii). Beam shall be required to provide the notice described in clause (a) of this Section 2.4.3 within [**]
of the effective date of an agreement or arrangement under which Beam or its Affiliate is granted rights to any Patent Right or Know-How that would be a Beam Base Editor Patent Right, Beam Base Editor Know-How, Beam C2C1 Patent Right or Beam C2C1 Know-How hereunder if accepted by Verve. If Verve does not provide the notice described in clause (b) of this
Section 2.4.3 or indicates in such written notice that it does not wish to obtain a sublicense under the relevant Patent Right or Know-How, such Patent Right or Know-How is hereby deemed not to be a Beam Base Editor Patent Right, Beam Base Editor Know-How, Beam C2C1 Patent Right or Beam C2C1
Know-How hereunder. 

  

	 	2.4.4	 Verve shall be responsible for [**]. Any undisputed payment owed by Verve under this
Section 2.4.4 shall be made by Verve to Beam within [**] after receipt of invoice from Beam. 

  

	 	2.4.5	 Beam shall be responsible for [**]. Any undisputed payment owed by Beam under this
Section 2.4.5 shall be made by Beam to Verve within [**] after receipt of invoice from Verve. 

  

	2.5	 Exchange of Information. Promptly after the Effective Date, the Parties shall agree to a
plan (including a timeline) in which each Party shall disclose to the other Party on an ongoing basis during the Term in English and in writing or in an electronic format all Beam Base Editor Technology and all Collaboration Technology respectively,
to the extent not previously disclosed (as may be amended from time to time in accordance with this Agreement, the “Technology Transfer Plan”). The Technology Transfer Plan can be amended from time to time by mutual written
agreement by the Parties. 

  
 23 

	2.6	 Transfer of Materials. 

 

	 	2.6.1	 Transfer. A Party may agree under this Agreement (including the applicable Research Plan
or Development Plan) to provide the other Party certain Know-How that are tangible biological materials (the “Party Materials”). Except as expressly set forth in this Agreement, the Party
Materials are provided by the providing Party on an “as-is” basis without any representation or warranty of any type, express or implied, including any representation or warranty of merchantability, non-infringement, title or fitness for a particular purpose, each of which is hereby expressly disclaimed by the providing Party. 

 

	 	2.6.2	 Permitted Use of Party Materials. The Party receiving Party Materials from the other Party
will use such Party Materials solely as contemplated in a Research Plan, Development Plan, or otherwise within the scope of the licenses granted to such receiving Party under this Agreement (collectively, “Permitted Uses”). Without
limiting the generality of the foregoing, except for Permitted Uses, the receiving Party of any Party Materials will not (a) make or attempt to make any analogues, progeny or derivatives of, or modifications to, such Party Materials or attempt
to reverse engineer, characterize or in any way try to ascertain the identity, chemical structure, sequence, mechanism of action or composition of such Party Materials, or (b) use such Party Materials for such receiving Party’s own benefit
or for the benefit of any of its Affiliates or any Third Party. Further, the Party receiving Party Materials will not administer any such Party Materials to any human and will comply with all Applicable Laws applicable to the handling and use of
such Party Materials. 

  

	 	2.6.3	 Unauthorized Use of Party Materials. If any Party receives Party Material from the other
Party and uses such Party Material in any manner other than Permitted Uses, then any and all results of such unauthorized use, whether patentable or not, will belong solely and exclusively to the providing Party. Without limiting any other remedy
that the providing Party of Party Materials may have under this Agreement or Applicable Law, the receiving Party of such Party Materials, on behalf of itself and its Affiliates, hereby assigns and agrees to assign to the providing Party all of the
receiving Party’s and its Affiliates’ right, title and interest in and to all such discoveries and inventions arising from any such unauthorized uses of such Party Materials. 

 

	 	2.6.4	 Title to Party Materials; Return. All right, title and interest in and to the Party
Materials provided by a Party under this Agreement will remain the sole and exclusive property of such providing Party notwithstanding the transfer to and use by the other Party of the same. At the end of the activities under this Agreement that
relate to any Party Materials (including any termination of this Agreement in whole or in part), any Party who has received relevant Party Materials will either destroy or return to the providing Party, at such providing Party’s sole
discretion, all of such Party Materials that are unused. 

  
 24 

	 	2.6.5	 Material Transfer Agreement. This Agreement supersedes and replaces that certain
Material Transfer Agreement by and between the Parties dated as of [**], as amended (the “Material Transfer Agreement”). All Materials (as such term is defined in the Material Transfer Agreement) delivered to a Party by the other
Party under the Material Transfer Agreement shall be deemed Party Materials of the respective providing Party hereunder and shall be so subject to the terms of this Agreement. 

 

	2.7	 No Implied Licenses. Except as expressly set forth in this Agreement, neither Party shall,
by virtue of this Agreement, acquire any license or other intellectual property interest, by implication or otherwise, in (a) any information disclosed to it under this Agreement, (b) any patents or patent applications Controlled or owned
by the other Party or its Affiliates, (c) any trademarks (whether registered or protected by common law), trademark applications, or any goodwill associated with the foregoing Controlled or owned by the other Party or its Affiliates, or
(d) any other intellectual property rights, however denominated, throughout the world, Controlled or owned by the other Party or its Affiliates. 

Article 3 MANAGEMENT; EXCHANGE OF INFORMATION 
  

	3.1	 Collaboration Overview. The Parties desire and intend to collaborate with respect to the
Development and Commercialization of Products in the Field in the Territory, as and to the extent set forth in this Agreement. 

  

	3.2	 Limits on Committee Authority. Each Party shall retain the rights, powers and discretion granted
to it under this Agreement and no such rights, powers, or discretion shall be delegated to or vested in the JSC or any Subcommittee unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so
agree in writing. Notwithstanding anything to the contrary in this Agreement, in no circumstances shall the JSC or any Subcommittee have any power to amend, modify or waive compliance with this Agreement. 

 

	3.3	 Joint Steering Committee. Within [**] after the Effective Date (or later if mutually
agreed by the Parties), the Parties shall establish a joint steering committee (the “JSC”) to facilitate communications between the Parties and oversee, review and manage the Development and Commercialization of Opt-In Products and Collaboration Products as set forth herein. 

  

	 	3.3.1	 Composition of the JSC. The JSC shall be comprised of [**] of Verve and [**] of Beam. Each
Party may change one or more of its representatives to the JSC from time to time in its sole discretion, effective upon notice to the other Party of such change. Within [**] after the Effective Date, the Parties shall each appoint their initial
representative to the JSC unless otherwise agreed by the Parties. These representatives shall have appropriate technical credentials, experience and knowledge, and ongoing familiarity with the Products and shall be duly authorized under their
respective company’s internal governance procedures to make the decisions or carry out the activities given to them under this Agreement. 

  
 25 

	 	3.3.2	 Specific Responsibilities. In addition to its overall responsibility for monitoring and
providing a forum to discuss and coordinate the Parties’ activities under this Agreement, the JSC shall, subject to the terms of this Agreement, in particular: 

 

	 	(a)	 oversee the collaborative activities of the Parties under this Agreement; 

 

	 	(b)	 oversee the activities of Verve and Beam with respect to each Development Plan for Opt-In Products and Collaboration Products (including the Development Budget in any Development Plan for a Collaboration Product) and the Commercialization of Collaboration Product(s); 

 

	 	(c)	 review and decide whether to approve any proposed Development Plan for
Opt-In Products and Collaboration Products (including the Development Budget in any Development Plan for a Collaboration Product) and any proposed amendments thereto; 

 

	 	(d)	 oversee activities under the Technology Transfer Plan; 

 

	 	(e)	 review and decide whether to approve any amendments to the Research Plan submitted by the JRC;

  

	 	(f)	 review and decide whether to approve each proposed US Commercialization Plan (including the Commercialization
Budget in any US Commercialization Plan) and any proposed amendments thereto; 

  

	 	(g)	 with respect to Collaboration Products, approve pricing of such Products and supply thereof within the
Collaboration Territory; 

  

	 	(h)	 approve clinical supply plans for Opt-In Products and Collaboration
Products and commercial supply plans for Collaboration Products; 

  

	 	(i)	 review and decide whether to approve the designation of any costs or expenses as Post-Approval Shared
Development Costs or Post-Approval Shared Regulatory Costs; 

  

	 	(j)	 receive and discuss reports from Subcommittees and provide guidance thereto; 

 

	 	(k)	 attempt to resolve issues presented to it by, and disputes within, any Subcommittee; 

  
 26 

	 	(l)	 approve strategies for obtaining, maintaining, defending and enforcing trademark protection for Collaboration
Products within the Collaboration Territory in accordance with the terms and conditions of Section 13.6.1(a); 

  

	 	(m)	 approve all trademarks selected to be used to identify Collaboration Products and all trademarks, logos,
taglines, trade dress, packaging configuration, domain names or indicia of origin for use in connection with the sale or marketing of Collaboration Products, in each case in the Collaboration Territory in accordance with the terms and conditions of
Section 13.6.1(a); 

  

	 	(n)	 review and decide whether to approve any other recommendations and submissions from the JRC, JMC, JDC and JCC;

  

	 	(o)	 establish such additional Subcommittees as it deems necessary to achieve the objectives and intent of this
Agreement; and 

  

	 	(p)	 have any other responsibility expressly designated for the JSC under this Agreement. 

 

	 	3.3.3	 Decision-Making. Decisions of the JSC shall be made [**] by the representatives. In
the event that the JSC cannot or does not, after good faith efforts, reach agreement on any issue, such issue shall be referred to the Alliance Managers. The Alliance Managers shall work with the JSC and use good faith commercially reasonable
efforts to reach mutually acceptable resolutions on all such disputed matters. If the Alliance Managers are unable to assist the JSC in resolving such dispute within [**] after the dispute is first referred to the Alliance Managers, either Party may
elect to submit such issue to the Parties’ executive officers as follows: (i) for a Development-related issue, the issue shall be referred for resolution to the Development Senior Officers, or (ii) for a Commercialization-related
issue, the issue shall be referred for resolution to the Commercialization Senior Officers. These executives are referred to collectively as the “Senior Officers”. [**] and [**] shall be designated by each Party by written notice to
the other Party within [**] after the Effective Date, and each Senior Officer of a Party may be changed by advance written notice by such Party to the other Party. In the event that the Senior Officers cannot resolve the issue, [**], with the
following exceptions, all of which shall require agreement of the representatives of both Parties or the JSC or the agreement of both Senior Officers: 

  

	 	(a)	 For Opt-In Products: 

[**]. 
  

	 	(b)	 For Collaboration Products: 

[**]. 

  
 27 

	3.4	 Joint Research Committee. 

 

	 	3.4.1	 Composition of the Joint Research Committee. Within [**] after the Effective Date (or
later if by mutually agreed by the Parties), the Parties shall establish a joint research committee to oversee early stage research of Opt-In Products and to coordinate the conduct of the Research Plan with
respect to such Opt-In Products (such committee, the “JRC”). Unless otherwise expressly provided in this Agreement or agreed by the Parties in writing, the JRC shall serve solely in an
advisory capacity and have no independent decision-making authority. Each Party shall initially appoint [**] to the JRC, with each representative having knowledge and expertise in the research of Base Editor products and having sufficient seniority
within the applicable Party to make decisions arising within the scope of the JRC’s responsibilities and being duly authorized under their respective company’s internal governance procedures to make the decisions or carry out the
activities given to them under this Agreement. The Parties may agree to increase the number of representatives from each Party on the JRC; provided, however, that the JRC shall at all times be comprised of an equal number of
representatives from each Party. 

  

	 	3.4.2	 Specific Responsibilities of the JRC. In addition to its general responsibilities, the JRC
shall, subject to the terms of this Agreement, in particular: 

  

	 	(a)	 review and discuss the progress of the Research Plan; and discuss, prepare and approve for submission to the
JSC any proposed amendments to the Research Plan; 

  

	 	(b)	 discuss the use of Delivery Technology with respect to Opt-In Products
and Collaboration Products under this Agreement; 

  

	 	(c)	 discuss when the formation of a JDC would be appropriate given the stage of research for the Opt-In Products; and 

  

	 	(d)	 perform such other functions as may be appropriate to further the purposes of this Agreement, as directed by
the JSC or as set forth under this Agreement. 

  

	 	3.4.3	 Decision-Making. The JRC shall act by [**] consent. The representatives from each Party
will have, collectively, [**] on behalf of that Party. If the JRC cannot reach [**] consent on an issue that comes before the JRC and over which the JRC has oversight, then such matter shall be raised to the JSC for resolution in accordance with
Section 3.3.3. 

  

	3.5	 Joint Manufacturing Committee. 

 

	 	3.5.1	 Composition. Within [**] after JSC approval of an Initial Development Plan for the first
Licensed Product (or at such other time as mutually agreed by the Parties), the Parties shall establish a committee to oversee CMC Development activities and manufacturing of supplies of such Licensed Products for research,

  
 28 

	 	
preclinical, clinical and commercial use (the “JMC”) under this Agreement. Unless otherwise expressly provided in this Agreement or agreed by the Parties in writing, the JMC
shall serve solely in an advisory capacity and have no independent decision-making authority. Each Party shall initially appoint [**] to the JMC, with each representative having knowledge and expertise in the manufacturing of products similar to the
Products, having sufficient seniority within the applicable Party to make decisions arising within the scope of the JMC’s responsibilities and being duly authorized under their respective company’s internal governance procedures to make
the decisions or carry out the activities given to them under this Agreement. The Parties may agree to increase the number of representatives from each Party on the JMC; provided, however, that the JMC shall at all times be comprised
of an equal number of representatives from each Party. 

  

	 	3.5.2	 Specific Responsibilities of the JMC. In addition to its general responsibilities, the JMC
shall, subject to the terms of this Agreement, in particular: 

  

	 	(a)	 coordinate the manufacturing activities of Beam and Verve under any Supply Agreement with respect to applicable
Products in the Territory; 

  

	 	(b)	 for Collaboration Products, coordinate with the JDC to allocate appropriate amounts from the Development Budget
to Manufacturing activities; 

  

	 	(c)	 facilitate the flow of information between the Parties with respect to the Manufacture of Collaboration
Products and Opt-In Products; 

  

	 	(d)	 discuss, coordinate with the JDC and refer to the JSC for approval a clinical supply plan for Opt-In Products and Collaboration Products under Section 8.1; 

  

	 	(e)	 discuss, coordinate with the JDC and refer to the JSC for approval a commercial supply plan for Collaboration
Products under Section 8.2; 

  

	 	(f)	 discuss and plan for manufacturing technology transfers as may be contemplated by this Agreement or a Supply
Agreement, including on termination pursuant to Section 15.5.2(g); and 

  

	 	(g)	 perform such other functions as appropriate to further the purposes of this Agreement, as directed by the JSC
or as specified in this Agreement. 

  

	 	3.5.3	 Decision-Making. The JMC shall act by [**] consent. The representatives from each Party
will have, collectively, [**] on behalf of that Party. If the JMC cannot reach [**] consent on an issue that comes before the JMC and over which the JMC has oversight, then such matter shall be raised to the JSC for resolution in accordance with
Section 3.3.3. 

  
 29 

	3.6	 Joint Development Committee. 

 

	 	3.6.1	 Composition of the Joint Development Committee. Prior to the earlier of: (a) [**]
following a decision by the JSC that a joint development committee would be appropriate given the stage of Development of one or more Licensed Products and (b) [**] after the Parties agree on an Initial Development Plan for the first Licensed
Product, the Parties shall establish a committee to oversee Development of Products and to coordinate the Development and regulatory activities of the Parties with respect to such Products (the “JDC”). Unless otherwise expressly
provided in this Agreement or agreed by the Parties in writing, the JDC shall serve solely in an advisory capacity and have no independent decision-making authority. Each Party shall initially appoint [**] to the JDC, with each representative having
knowledge and expertise in the development of products or in obtaining and maintaining Marketing Authorizations of products, having sufficient seniority within the applicable Party to make decisions arising within the scope of the JDC’s
responsibilities and being duly authorized under their respective company’s internal governance procedures to make the decisions or carry out the activities given to them under this Agreement. The Parties may agree to increase the number of
representatives from each Party on the JDC; provided, however, that the JDC shall at all times be comprised of an equal number of representatives from each Party. 

 

	 	3.6.2	 Specific Responsibilities of the JDC. In addition to its general responsibilities, the JDC
shall, subject to the terms of this Agreement, in particular: 

  

	 	(a)	 discuss, prepare and approve for submission to the JSC any Development Plan, and any amendments to a
Development Plan (including, for Collaboration Products, the Development Budget under a Subsequent Development Plan); 

  

	 	(b)	 with respect to Collaboration Products, if any, review and update [**] financial forecasts for Development,
including regulatory activities, to ensure actual and anticipated expenditure is within the approved Development Budget for the relevant Calendar Year, and make recommendations to the JSC for approval regarding any variances before such additional
expenditure is incurred; 

  

	 	(c)	 create, approve for submission to the JSC, and implement the overall strategy for Development and the design
and objectives of all Clinical Trials and non-clinical studies conducted under each Development Plan; 

  

	 	(d)	 advise the JSC on whether and when to Initiate or discontinue, and the conduct of, any Clinical Trial and any non-clinical study under each Development Plan; 

  

	 	(e)	 facilitate the flow of information between the Parties with respect to Development and Marketing Authorizations
of the Collaboration Products in the Territory; 

  
 30 

	 	(f)	 discuss and approve for submission to the JSC the overall regulatory and filing strategy for obtaining
Marketing Authorization for Collaboration Products in the Territory and for maintaining such Marketing Authorization including post-approval commitments and life cycle management; 

 

	 	(g)	 advise the JSC on the submission of the NDAs for the Collaboration Products; 

 

	 	(h)	 review, coordinate and approve for submission to the JSC the scientific presentation and publication strategy
relating to the Collaboration Products in the Territory; and 

  

	 	(i)	 perform such other functions as may be appropriate to further the purposes of this Agreement, as directed by
the JSC or as specified in this Agreement. 

  

	 	3.6.3	 Decision-Making. The JDC shall act by [**] consent. The representatives from each Party
will have, collectively, [**] on behalf of that Party. If the JDC cannot reach [**] consent on an issue that comes before the JDC and over which the JDC has oversight, then such matter shall be raised to the JSC for resolution in accordance with
Section 3.3.3. 

  

	3.7	 Joint Commercialization Committee. 

 

	 	3.7.1	 Composition. The Parties shall establish a committee to oversee Commercialization of
Collaboration Products (other than commercial manufacture and Product distribution) in the Collaboration Territory (the “JCC”) at such time as may be determined by the JSC, but in no event later than [**] after the Initiation of the
first Phase III Clinical Trial of a Collaboration Product. Unless otherwise expressly provided in this Agreement or agreed by the Parties in writing, the JCC shall serve solely in an advisory capacity and have no independent decision-making
authority. Each Party shall initially appoint [**] representatives to the JCC, with each representative having knowledge and expertise in the commercialization of products similar to the Collaboration Products, having sufficient seniority within the
applicable Party to make decisions arising within the scope of the JCC’s responsibilities and being duly authorized under their respective company’s internal governance procedures to make the decisions or carry out the activities given to
them under this Agreement. The Parties may agree to change the number of representatives from each Party on the JCC; provided, however, that the JCC shall at all times be comprised of an equal number of representatives from each Party.

  
 31 

	 	3.7.2	 Specific Responsibilities of the JCC. In addition to its general responsibilities, the JCC
shall in particular: 

  

	 	(a)	 discuss, prepare and approve for submission to the JSC all US Commercialization Plans (including the
Commercialization Budget), including any amendments thereto; 

  

	 	(b)	 review and update revenue forecasts and review the Commercialization Budget for Collaboration Products in the
Collaboration Territory at least on a [**] basis to ensure actual and anticipated expenditure is within the approved Commercialization Budget for the relevant Calendar Year, and make recommendations to the JCC for approval regarding any variances
before such additional expenditure is incurred; 

  

	 	(c)	 review and discuss the Commercialization activities (including
Co-Promotion) of Beam and Verve with respect to Collaboration Products in the Collaboration Territory; 

  

	 	(d)	 prepare forecasts of relevant Collaboration Products to be shared with the JMC for planning of inventory levels
of such Products; 

  

	 	(e)	 subject to the terms and conditions of Section 13.6.1, discuss and approve for
submission to the JSC the appropriate timing for selection of trademarks, and discuss, review and approve for submission to the JSC all proposed trademarks cleared by the Parties selected to be used to identify Collaboration Products in the
Collaboration Territory and all proposed trademarks, logos, taglines, trade dress, packaging configuration, domain names or indicia of origin, in each case, cleared by the Parties for use in connection with the sale or marketing of Collaboration
Products in the Collaboration Territory; 

  

	 	(f)	 review, discuss, coordinate and approve for submission to the JSC, in the Collaboration Territory, the
Parties’ medical affairs activities with respect to the Collaboration Products; and 

  

	 	(g)	 perform such other functions as appropriate to further the purposes of this Agreement, as directed by the JSC
or as specified in this Agreement. 

  

	 	3.7.3	 Decision-Making. The JCC shall act by [**] consent. The representatives from each Party
will have, collectively, [**] on behalf of that Party. If the JCC cannot reach [**] consent on an issue that comes before the JCC and over which the JCC has oversight, then such matter shall be raised to the JSC for resolution in accordance with
Section 3.3.3. 

  

	3.8	 Alliance Managers. 

 

	 	3.8.1	 Appointment. Each Party shall have the right to appoint an employee who shall oversee
interactions between the Parties for all matters related to this Agreement and any related agreements between the Parties or their Affiliates (each an “Alliance Manager”). Such persons shall endeavor to assure clear and responsive
communication between the Parties and the effective exchange of 

  
 32 

	 	
information, and may serve as a single point of contact for any matters arising under this Agreement. The Alliance Managers shall have the right to attend all JSC and Subcommittee meetings as non-voting participants and may bring to the attention to the JSC or any Subcommittee any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as the
Parties may mutually agree in writing. Each Party may designate different Alliance Managers by notice in writing to the other Party. 

  

	 	3.8.2	 Responsibilities of the Alliance Managers. Without limiting the generality of the
foregoing, each Alliance Manager shall: 

  

	 	(a)	 identify and bring disputes and issues that may result in disputes (including without limitation any asserted
occurrence of a material breach by a Party) to the attention of the JSC in a timely manner, and function as the point of first referral in all matters of conflict resolution; 

 

	 	(b)	 provide a single point of communication for seeking consensus both internally within the Parties’
respective organizations and between the Parties; 

  

	 	(c)	 plan and coordinate cooperative efforts, internal communications and external communications between the
Parties with respect to this Agreement; and 

  

	 	(d)	 take responsibility for ensuring that meetings and the production of meeting agendas and minutes occur as set
forth in this Agreement, and that relevant action items resulting from such meetings are appropriately carried out or otherwise addressed. 

  

	3.9	 Committee Size and Composition; Observers. The JSC and any Subcommittee may change its
size from time to time by mutual, [**] consent of its members, provided that the JSC and each Subcommittee shall consist at all times of an equal number of representatives of each of Verve and Beam. Each Party may replace one or more of its
JSC or Subcommittee representatives at any time upon written notice to the other Party. The JSC or any Subcommittee may invite non-members (including consultants and advisors of a Party who are under an
obligation of confidentiality consistent with this Agreement) to participate in the discussions and meetings of such Committee, provided that such participants are involved in activities related to the business of such Committee and shall
have no voting authority at such Committee. 

  

	3.10	 Chairpersons. Each Committee shall be chaired by a representative of [**]. The role of the
chairperson shall be to convene and preside at meetings of the Committee, as applicable, to prepare and circulate agendas and to ensure the preparation of minutes, but the chairperson shall have no additional powers or rights beyond those held by
the other representatives of the Committee, as applicable. 

  
 33 

	3.11	 Committee Meetings. Each Committee shall meet at least [**] at a time mutually agreed by the
Parties, spaced at regular intervals unless the Parties mutually agree to a different frequency. Each Committee may meet in person, or at the request of either Party, by videoconference, teleconference or other similar communications equipment. In-person Committee meetings will be held at locations alternately selected (as within a Committee) by Verve and by Beam. Either Party may also call a special meeting of a Committee (by videoconference or
teleconference) by at least [**] prior written notice to the other Party in the event such requesting Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting, and such requesting Party shall provide
such Committee no later than [**] prior to the special meeting with materials reasonably adequate to enable an informed decision on the relevant matter; provided that for time sensitive matters, a Party may call a special meeting of such
Committee and provide relevant materials with less than [**] notice if the Parties agree that an issue warrants an expedited meeting. No later than [**] prior to any meeting of a Committee (other than a special meeting as described above), the
Alliance Managers shall prepare and circulate an agenda for such meeting to all members of such Committee; provided, however, that either Party shall be free to propose additional topics to be included on such agenda, either prior to
or, if representatives of each Party are present at a meeting, during the course of such meeting. Each Party will bear the expense of its respective Committee members’ participation in Committee meetings. The Alliance Managers shall be
responsible for keeping reasonably detailed written minutes of such Committee’s meetings that reflect all decisions made at such meetings. The Alliance Managers shall send meeting minutes to each member of such Committee for review and approval
within [**] after each meeting of such Committee. Minutes will be deemed approved unless [**] members of the relevant Committee objects to the accuracy of such minutes within [**] of receipt. 

 

	3.12	 Safety Reporting. The Parties shall agree upon a pharmacovigilance agreement (the
“Pharmacovigilance Agreement”) for exchanging adverse event and other safety information relating to a Licensed Product prior to either Party’s initiation of any clinical activities implicating pharmacovigilance
obligations for such Licensed Product in the Territory. The Pharmacovigilance Agreement shall ensure that adverse event and other safety information is exchanged according to a schedule that will permit each Party to comply with Applicable
Laws, including any local regulatory requirements. 

  

	3.13	 Records and Reports. 

 

	 	3.13.1	 Records. Each Party shall maintain records, in sufficient detail and in good scientific
manner appropriate for patent and regulatory purposes under Applicable Law, which shall fully and properly reflect all work done and results achieved by such Party under this Agreement. 

 

	 	3.13.2	 Copies and Inspection of Records. Each Party shall have the right, during normal business
hours and upon reasonable notice, to inspect and copy all records of the other Party referred to in Section 3.13.1. The reviewing Party shall maintain such records and the information disclosed therein in confidence in
accordance with Section 11.1. Upon request, the non-reviewing Party shall provide copies of the records described in this Section 3.13.2.

  
 34 

	3.14	 Compliance with Law and Ethical Business Practices. 

 

	 	3.14.1	 In conducting its activities under this Agreement, each Party shall comply in all material respects with
Applicable Law and accepted pharmaceutical industry business practices, including, without limitation, the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301, et seq.), the Anti-Kickback Statute (42 U.S.C. § 1320a-7b), Civil Monetary Penalty Statute (42 U.S.C. § 1320a-7a), the False Claims Act (31 U.S.C. § 3729 et seq.), comparable state statutes, the regulations
promulgated under all such statutes, and the regulations issued by the FDA. Each Party shall promptly notify the other Party in writing of any material deviations from Applicable Law with respect to activities under this Agreement of which it
becomes aware. 

  

	 	3.14.2	 Each Party hereby certifies that it has not and will not employ or otherwise use in any capacity the
services of any person or entity debarred under Section 21 U.S.C. § 335a in performing any activities under this Agreement. Each Party shall notify the other Party, in writing, immediately if any such debarment occurs or comes to its
attention, and shall, with respect to any person or entity so debarred, promptly remove such person or entity from performing any further activities under this Agreement. 

 

	 	3.14.3	 No Party shall, or shall be required to, undertake any activity under or in connection with this
Agreement which violates any Applicable Law. 

 Article 4 RESEARCH AND DEVELOPMENT 

 

	4.1	 General Obligations. 

 

	 	4.1.1	 Each Party shall use Commercially Reasonable Efforts to conduct the activities for which it is
responsible under the Research Plan and any Development Plan. All Development activities of the Parties relating to the Development of Licensed Product(s) in the Territory will be performed in accordance with this Agreement, the Research Plan and
the applicable Development Plan. Subject to Section 4.3.2(b) and Section 4.1.2, during the Term, neither Party shall undertake any Development activities with respect to Licensed Products in the
Field in the Territory that are not contemplated by the Research Plan or a Development Plan. Verve shall initiate discovery efforts as contemplated under the Research Plan for a Base Editor Product directed towards [**]. In addition, following
initiation of activity under the Research Plan, Verve shall use Commercially Reasonable Efforts to Develop and seek Marketing Authorization for [**]. 

  

	 	4.1.2	 With respect to any Licensed Product for which Beam does not, and can no longer under the terms of this
Agreement, exercise the Beam Opt-In Option, Section 4.1.1 shall not apply, except that Verve shall still be subject to the last sentence of Section 4.1.1
which sets forth certain diligence obligations and shall perform, and cause to be performed, all Development activities related to such Licensed Product in the Territory in accordance with this Agreement. 

  
 35 

	 	4.1.3	 Without limiting any other provision of this Agreement, Verve agrees that, to the extent applicable to
its contemplated activities under this Agreement, it shall satisfy the diligence obligations set forth in Schedule 4.1.3 related to Development applicable to sublicensees of Beam Base Editor Technology or Beam Delivery Technology under Third
Party Agreements to which Beam or its Affiliate is a party. Schedule 4.1.3 may be amended from time to time by Beam upon written notice to Verve in the event Beam reasonably determines that additional diligence obligations
under Third Party Agreements to which Beam or its Affiliate is a party relate to the Development activities of Verve hereunder as a sublicensee of Beam Base Editor Technology and Beam Delivery Technology, subject to compliance with
Sections 2.4.3 and 9.2 with respect to any such Third Party Agreements entered into after the Effective Date and provided that any such additional diligence obligations shall only apply following the date of such
amendment. Either Party may perform its obligations under this Agreement through Third Party subcontractors; provided that, [**]. Any efforts of Verve or its Affiliates and sublicensees shall be deemed to be the efforts of Verve for purposes
of satisfying the diligence requirements of this Agreement. 

  

	4.2	 Research Plan. Within [**] following the Effective Date, the Parties shall agree in
writing upon an initial research plan for Licensed Products (as amended from time to time under this Agreement, the “Research Plan”). The Research Plan shall include, and each amendment to the Research Plan shall include, [**]. The
Research Plan may only be amended as recommended by the JRC and approved by the JSC in accordance with this Agreement. The Research Plan shall be effective from the date in which the Parties first agree upon the initial Research Plan in writing in
accordance with this Section 4.2 and shall terminate when all activities under such Research Plan have been completed. 

  

	4.3	 Development Plans. 

 

	 	4.3.1	 Initial Development Plan. Within [**] prior to the anticipated commencement of IND-enabling studies for a Licensed Product, Verve shall submit to the JDC a proposed initial development plan for [**] (such development plan once recommended for approval by the JDC and approved by the JSC, the
“Initial Development Plan”). An Initial Development Plan may only be amended as recommended by the JDC and approved by the JSC in accordance with this Agreement, and each such amendment shall [**]. An Initial Development Plan shall
be effective from the date on which it is approved by the JSC and shall terminate when all activities under such Initial Development Plan have been completed or, if earlier, as of the date upon which Beam exercises the Beam Opt-In Option with respect to the applicable Opt-In Product pursuant to Section 5.1. For the avoidance of doubt, subject to the exceptions set forth
in clauses (a) and (b) of Section 3.3.3, [**]. 

  
 36 

	 	4.3.2	 Subsequent Development Plan; Subsequent Development Updates. 

 

	 	(a)	 Subject to Section 4.3.2(b), with respect to any Collaboration Product, there shall
be a “Subsequent Development Plan” for such Collaboration Product that includes [**]. Notwithstanding any provision in this Agreement to the contrary, in the event Beam exercises a Beam Opt-In
Option upon receipt of an [**] for a Collaboration Product, the Subsequent Development Plan for such Collaboration Product will additionally include [**], such additional activities to be conducted at Verve’s sole cost and expense, in
accordance with Section 5.1. 

  

	 	(b)	 For any Opt-In Product for which Beam does not exercise the Beam Opt-In Option, or commencing as of the applicable Opt-Out Date for any Collaboration Product, there shall be no Subsequent Development Plan but Verve shall update Beam every
[**] (beginning [**] after Beam’s failure to exercise the Beam Opt-In Option for any such Opt-In Product that is a Licensed Product or, with respect to any
Collaboration Product for which Beam exercises the Beam Opt-Out Option, [**] after the applicable Beam Opt-Out Date, as the case may be) on the Development of such
Licensed Product until the First Commercial Sale of such Licensed Product or until Development activities for such Licensed Product have ended, whichever occurs earlier. Such update shall consist of [**]. Upon request by Beam, the Parties shall
meet, either in-person or via videoconference or teleconference, to discuss such status update and Verve shall consider in good faith the implementation of any reasonable comment by Beam with respect to the
Development of such Licensed Product. 

  

	 	(c)	 Notwithstanding anything to the contrary in this Agreement, Verve may not conduct any Development activity with
respect to a Licensed Product that is not a Collaboration Product that, [**]. 

  

	 	4.3.3	 Amendments to the Development Plan. On [**] basis, the JDC shall evaluate whether any
amendment to the then-current Development Plans, and, subject to this Agreement, the corresponding Development Budget if applicable, are appropriate to reflect [**]. In the event that such amendment is deemed necessary, the JDC shall submit such
amendment for approval of the JSC no later than [**] of the preceding Calendar Year. Each such amended Development Plan shall contain [**]. In addition, the JDC may prepare amendments to the Development Plan and any Development Budget (if
applicable) for the JSC’s approval from time to time during a Calendar Year in order to reflect changes in such plan and budget allocations for such Calendar Year, in each case, in accordance with the foregoing. Once approved by the JSC, the
amended [**] Development Plan (including the Development Budget, if any) shall become effective for the applicable period on the date approved by the JSC (or such other date as the JSC shall specify). Any
JSC-approved amended Development Plan (including, as applicable, any amended Development Budget) for a Product shall supersede the previous Development Plan and Development Budget for such Product.

  
 37 

	 	4.3.4	 Discontinued Development; Inconsistency. If the JSC determines to discontinue Developing a
Licensed Product or Collaboration Product upon recommendation by the JDC and otherwise in accordance with this Agreement, then any Development Plan (and the associated Development Budget, if applicable) solely related to such Licensed Product or
Collaboration Product, as the case may be, shall terminate upon such decision. In the event of any inconsistency between the applicable Development Plan and this Agreement, the terms of this Agreement shall prevail. 

 

	4.4	 Development Costs. Except with respect to Shared Costs for Collaboration Products as
described in Section 10.5.1, as between the Parties, [**]. 

 Article 5 BEAM
OPT-IN OPTION 
  

	5.1	 Opportunity to Opt In. For any Opt-In Product,
Beam will have the option with respect to such Opt-In Product to opt-in to share expenses of the Development of such Opt-In
Product in the Territory, jointly Commercialize such Opt-In Product in the Collaboration Territory and share the profits and expenses of Commercializing the Opt-In
Product in the Collaboration Territory, in each case on the terms set forth in this Agreement (such option with respect to an Opt-In Product, the “Beam Opt-In
Option” for such Opt-In Product). On an Opt-In
Product-by-Opt-In Product basis, within [**] of the final dosing of the final patient in a Phase I Clinical Trial of such Opt-In Product, Verve will deliver to Beam an information package for such Opt-In Product, such information package to include the following information: [**] (such
information package for an Opt-In Product, an “Opt-In Information Package”). [**]. During the [**] period following delivery of an Opt-In Information Package for an Opt-In Product, at Beam’s request, the Parties will work together in good faith in an effort to reach written agreement on a Subsequent
Development Plan for such Opt-In Product, including the related Development Budget. Beam will have [**] from receipt of the complete Opt-In Information Package to
determine whether it is interested in participating in future Development and Commercialization of such Opt-In Product on the terms and conditions set forth in this Agreement for Collaboration Products. Beam
may exercise the Beam Opt-In Option with respect to an Opt-In Product at any time during such [**] period by written notice to Verve. [**]. 

 

	5.2	 Subsequent Development Plan; Election Not to Opt-In.

  

	 	5.2.1	 With respect to any Opt-In Product, in the event that Beam
exercises the Beam Opt-In Option for such Opt-In Product pursuant to Section 5.1, (a) the agreed-upon Subsequent Development Plan shall become
the Subsequent Development Plan for such Opt-In Product and (b) such Opt-In Product shall become a Collaboration Product under this Agreement.

  

	 	5.2.2	 With respect to any Opt-In Product, in the event that Beam does
not exercise the Beam Opt-In Option for such Opt-In Product in the applicable [**] window pursuant to Section 5.1, such Opt-In Product shall not become a Collaboration Product under this Agreement and the Beam Opt-In Option for such Opt-In Product shall
thereupon terminate, [**]. 

  
 38 

	5.3	 Beam Opt-Out Option. With respect to each
Collaboration Product, Beam may opt out of payment of Shared Development Costs, Shared Commercialization Costs, sharing of Collaboration Territory Revenue and participation in Commercialization of such Collaboration Product under this Agreement
(“Beam Opt-Out Option”), upon written notice to Verve. In the event Beam elects the Beam Opt-Out Option for a Collaboration Product, effective as of
[**] following the delivery of such written election to Verve (the “Beam Opt-Out Date”), (a) such Collaboration Product will no longer be a Collaboration Product under this Agreement,
(b) royalties and milestones for such former Collaboration Product under this Agreement, if applicable, including under Sections 10.2 through 10.4, shall become effective and payable by Verve going forward as if Beam had never
exercised the Beam Opt-In Option for such Product, (c) Verve shall pay Beam a milestone payment equal [**] times the Shared Costs for such former Collaboration Product that Beam has paid under this
Agreement, such milestone payment to be made within [**] after aggregate Net Sales of such former Collaboration Product in a Calendar Year in the Territory first reach [**] Dollars ($[**]), (d) subject to this Section 5.3,
Beam shall no longer have any obligation to pay any portion of Shared Costs incurred following the Beam Opt-Out Date for such former Collaboration Product and (e) Beam shall no longer have the right to
Commercialize, including Co-Promote, such former Collaboration Product. Notwithstanding anything to the contrary in this Section 5.3, if Beam elects the Beam Opt-Out Option for a Collaboration Product during the conduct of a Clinical Trial for such Collaboration Product, it shall remain responsible for the Shared Costs reasonably incurred in the conduct of such Clinical
Trial under this Agreement as if such Collaboration Product remained a Collaboration Product for the duration of such Clinical Trial. 

  

	5.4	 Verve Opt-Out Option. With respect to each
Collaboration Product, Verve may opt out of payment of Shared Development Costs, Shared Commercialization Costs, sharing of Collaboration Territory Revenue and participation in Commercialization of such Collaboration Product under this Agreement
(“Verve Opt-Out Option”), upon written notice to Beam. In the event Verve elects the Verve Opt-Out Option for a Collaboration Product, effective as of
[**] following the delivery of such written election to Verve (the “Verve Opt-Out Date”), (a) such Collaboration Product will no longer be a Collaboration Product under this Agreement,
(b) such former Collaboration Product shall be deemed to be a Terminated Reversion Product (including, for clarity, any such former Collaboration Product that is not a Licensed Product) for purposes of Section 15.5 as
if Verve had terminated such Product under clause (b) of Section 15.2; provided, however, that any license granted by Verve pursuant to Section 15.5.2(b) with respect to such
Product shall be royalty-free and fully paid up, except with respect to payment of any amounts owed to a Third Party pursuant to an applicable license or other agreement as set forth in Section 15.5.2(b), (c) Beam shall pay
Verve a milestone payment equal to the sum of (i) the FTE Costs and out-of-pocket costs (including Third Party Payments) incurred by Verve for the conduct of the
Phase I Clinical Trial in accordance with the Initial Development Plan for such Collaboration Product and (ii) [**] times the Shared Costs for such former Collaboration Product that Verve has paid under this Agreement, such milestone payment to be
made within [**] after aggregate Net Sales of such former Collaboration Product in a Calendar Year in the Territory first reach [**] Dollars ($[**]), (d) subject to this Section 5.4, Verve shall no longer have any
obligation to pay any portion of Shared Costs incurred following the Verve Opt-Out Date for such former Collaboration Product and (e) 

  
 39 

	 	
Verve shall no longer have the right to Commercialize, including Co-Promote, such former Collaboration Product. Notwithstanding anything to the contrary in
this Section 5.4, if Verve elects the Verve Opt-Out Option for a Collaboration Product during the conduct of a Clinical Trial for such Collaboration Product, it shall remain
responsible for the Shared Costs reasonably incurred in the conduct of such Clinical Trial under this Agreement as if such Collaboration Product remained a Collaboration Product for the duration of such Clinical Trial. 

 

	5.5	 Discussion of Proposal. [**]. 

Article 6 REGULATORY RESPONSIBILITY 
  

	6.1	 General. Verve or its designee shall have sole responsibility and discretion in
formulating the regulatory strategy for any Nuclease Product or Base Editor Product that, in each case, is not either a Collaboration Product or Opt-In Product. Verve shall keep Beam informed as to material
developments related to interactions by it, its Affiliates or sublicensees with Regulatory Authorities with respect to Collaboration Products and Opt-In Products under this Agreement. Verve shall promptly
notify (but in any event within [**]) Beam upon becoming aware of any actual or potential Safety Issue or serious adverse event with respect to one or more Collaboration Products, Opt-In Products, Licensed
Products or Verve Delivery Technology Products. 

  

	6.2	 Opt-In Products and Collaboration Products. The
regulatory strategy for each Collaboration Product and Opt-In Product shall be formulated by the JSC. In any exercise of its final decision-making authority at the JSC under this Agreement, Verve shall
consider and determine whether to incorporate in good faith Beam’s reasonable comments to such regulatory strategy for an Opt-In Product or Collaboration Product. Verve shall be responsible for taking the
lead with the request and conduct of all interactions with Regulatory Authorities (meetings, telephone calls, etc.) in the Territory. Beam shall be entitled to have a non-participating representative present
at such scheduled interactions, with respect to all Opt-In Products and Collaboration Products, with Regulatory Authorities in the Territory. As between the Parties, Verve shall be responsible for preparing
all submissions, documents or other correspondence submitted to applicable Regulatory Authorities for such Products in the Territory (collectively, the “Regulatory Documentation”), and Verve or its designee(s) shall own all
Regulatory Documentation, INDs, NDAs and Marketing Authorizations with respect to Products. Beam shall have the right to review and comment on all Regulatory Documentation for Collaboration Products, and Verve shall reasonably consider and [**]
implement any comments provided by Beam with respect to such Regulatory Documentation. Verve or its designee(s) shall also be responsible for all maintenance of all INDs and all NDAs related to Products, provided that, with respect to Collaboration
Products, the FTE Costs and out-of-pocket costs that are incurred by Verve or its Affiliates in connection with such maintenance in the Major Markets shall be Shared
Development Costs. 

  
 40 

	6.3	 Clinical Trial Data License to Beam. Notwithstanding any other provision of this Agreement, Verve
hereby grants to, and shall cause its Affiliates to grant to, Beam the right to use, and shall have the right to sublicense to its Affiliates and Third Party collaborators, the right to use, all Clinical Trial Data generated by Verve or a Third
Party performing services on behalf of Verve, solely for internal research purposes; provided that Beam shall have the right to disclose such Clinical Trial Data that has been anonymized for the purposes of concealing any personally
identifiable information to potential and actual partners, collaborators, investors and acquirers under customary obligations of confidentiality and restricted use. 

Article 7 COMMERCIALIZATION 
  

	7.1	 Commercialization Efforts. Each Party shall conduct the activities for which it is responsible
under the applicable US Commercialization Plan. Verve shall use Commercially Reasonable Efforts to Commercialize Licensed Products, and Verve and Beam shall use Commercially Reasonable Efforts to Commercialize Collaboration Products, in each case in
the Field in the Major Markets in which Marketing Authorization has been obtained, as further described in this Article 7. 

  

	7.2	 Commercialization of Product(s). All Commercialization activities of the Parties with respect to
Collaboration Products in the Collaboration Territory will be performed under the direction of the JCC and the JSC in accordance with the then-current applicable US Commercialization Plan. In the event of any inconsistency between a US
Commercialization Plan or a Commercialization Budget and this Agreement, the terms of this Agreement shall prevail unless otherwise expressly set forth in the relevant US Commercialization Plan or Commercialization Budget. Verve will keep the JCC
informed of Commercialization activities of Verve with respect to Licensed Products and Collaboration Products outside the Collaboration Territory, and Verve will deliver to Beam on a [**] basis a written report summarizing its material
Commercialization activities with respect to Licensed Products that are not Collaboration Products and with respect to Collaboration Products outside the Collaboration Territory, such reports to be sufficient in content to allow Beam to evaluate
whether Verve has satisfied its diligence obligations with respect to such Collaboration Products in accordance with Section 7.1. Verve shall ensure that any Third Party, including a sublicensee, that undertakes
Commercialization activities with respect to a Licensed Product or Collaboration Product permits disclosure of all relevant information to Beam in the reports described in this Section 7.2. 

 

	7.3	 US Commercialization Plan. 

 

	 	7.3.1	 Within [**] after the Initiation of a Phase III Clinical Trial of a Collaboration Product in the Field
in the Territory, the JCC shall develop an initial high-level Commercialization plan for the Collaboration Products in the Field in the Collaboration Territory (such plan, if and when approved by the JSC and as may be amended from time to time in
accordance with this Agreement, the “US Commercialization Plan”). 

  

	 	7.3.2	 Each US Commercialization Plan shall contain, as applicable: [**]. 

 

	7.4	 Commercialization Reports. Each Party shall keep the JCC fully informed regarding the
progress and results of Commercialization activities for Collaboration Products in the Collaboration Territory conducted by such Party, including a [**] review of activities undertaken versus the US Commercialization Plan for such Collaboration
Products. 

  
 41 

	7.5	 Commercialization Costs. Subject to Section 10.5.1(b), as between the
Parties, Verve shall be solely responsible for all costs and expenses incurred (including both internal FTE-based costs and payments owed to Third Parties) in the conduct of activities under any US
Commercialization Plan. 

  

	7.6	 Co-Promotion. With respect to each Collaboration
Product, the Parties shall enter into an agreement that sets forth the terms of the Parties’ Co-Promotion of such Collaboration Products in the Collaboration Territory no later than [**] prior to the
anticipated First Commercial Sale of such Collaboration Product in the Collaboration Territory, such terms to be consistent with the high-level terms and principles set forth in this Section 7.6 (each such agreement, a
“Co-Promotion Agreement”). The Parties shall Co-Promote the Collaboration Products in the Collaboration Territory pursuant to the terms and
conditions of this Agreement and the applicable Co-Promotion Agreement, provided that Verve shall book all sales of Collaboration Products in the Collaboration Territory. Any
Co-Promotion Agreement entered into by the Parties pursuant to this Section 7.6 will set forth the terms under which Beam will engage in the
Co-Promotion of such Collaboration Product with Verve to primary care physicians, specialists, and other agreed target customers or stakeholders in the Collaboration Territory. Each Party will provide fifty
percent (50%) of the promotional effort required to promote the Collaboration Product in the Collaboration Territory at launch and throughout Commercialization in this Agreement and the allocation of the promotional effort between the Parties will
be made on an equitable basis as to both the quality and quantity of the activities to be undertaken, including the identity of target prescribers and the nature of the Details. Costs incurred by the Parties for
Co-Promotion activities under the Co-Promotion Agreement shall be Shared Commercialization Costs unless otherwise mutually agreed by the Parties and expressly set forth
in the Co-Promotion Agreement. For clarity, the applicable Co-Promotion Agreement shall automatically be terminated on the applicable
Opt-Out Date in the event Beam exercises a Beam Opt-Out Option or Verve exercises a Verve Opt-Out Option with respect to a
particular Collaboration Product. 

 Article 8 MANUFACTURING 

 

	8.1	 Clinical Supply Plan. The Parties, via the JMC, will discuss and formulate a clinical supply plan
for the Manufacture of each Opt-In Product and Collaboration Product required for the conduct of Development activities under this Agreement and shall submit such plan to the JSC for approval. In formulating
such clinical supply plan, the Parties will discuss, in good faith, [**]. To the extent that Beam is not Manufacturing a Licensed Base Editor Product, the Parties shall meet and decide upon a technology transfer plan regarding the transfer of
technology related to the Manufacture of such Licensed Base Editor Product (to the extent otherwise contemplated by this Agreement) by Beam to Verve or its designee, and each Party shall perform its obligations under such technology transfer plan
without additional consideration. 

  
 42 

	8.2	 Commercial Supply. The Parties, via the JMC, will discuss and formulate a commercial supply plan
for each Collaboration Product required for the conduct of Commercialization activities under this Agreement and shall submit such plan to the JSC for approval. If Beam has Manufactured clinical supplies of a Licensed Base Editor Product, the
Parties will discuss, [**]. To the extent that Beam is not Manufacturing commercial supply of a Licensed Base Editor Product and Manufacturing technology transfer from Beam to Verve for such Licensed Base Editor Product has not already occurred
pursuant to Section 8.1, the Parties shall meet and decide upon a technology transfer plan regarding the transfer of technology related to the Manufacture of such Licensed Base Editor Product (to the extent otherwise
contemplated by this Agreement) by Beam to Verve or its designee, and each Party shall perform its obligations under such technology transfer plan without additional consideration. 

 

	8.3	 Manufacturing Intellectual Property. Beam shall own all right, title and interest in any Know-How conceived, developed, generated or reduced to practice during the Term by Verve, its Affiliates, its sublicensees or other persons acting on behalf of Verve, its Affiliates or its sublicensees (including
any contract manufacturer) to the extent specifically directed to methods of manufacturing (a) Licensed Base Editor Products to the extent such Know-How relates to Base Editors or C2C1 or
(b) Licensed C2C1 Products to the extent such Know-How relates to C2C1 (such Know-How collectively, the “Beam Manufacturing
Know-How”) and any Patent Rights to the extent such Patent Rights claim Beam Manufacturing Know-How (such Patent Rights, collectively with the Beam
Manufacturing Know-How, the “Beam Manufacturing Technology”). Verve shall, and hereby does (and shall cause its Affiliates, its sublicensees or other persons acting on behalf of Verve, its
Affiliates or its sublicensees to) sell, assign, transfer, convey and deliver to Beam, all of its right, title and interest in, to and under any Beam Manufacturing Technology; provided that any contractual obligation put in place by Verve, its
Affiliate or its sublicensee that requires another Person (e.g. a contract manufacturer) to assign Beam Manufacturing Technology to Verve, its Affiliate or its sublicensee so that it can directly assign such Beam Manufacturing Technology to Beam in
accordance with this Section 8.3 will satisfy this obligation as long as such assignment by such other Person is required to be immediate upon such Person’s ownership of Beam Manufacturing Technology. Verve will and
shall cause its Affiliates, its sublicensees (or other persons acting on behalf of Verve, its Affiliates or its sublicensees to) promptly execute an assignment of Beam Manufacturing Technology, including assignments of Patent Rights in forms
registrable or recordable in the United States Patent and Trademark Office or applicable foreign offices in the Territory to the extent necessary to assign the Beam Manufacturing Technology, all in forms reasonably acceptable to Beam. Beam
Manufacturing Technology assigned under this Section 8.3 shall be deemed Beam Collaboration Technology under this Agreement. 

  

	8.4	 General. Except as expressly provided in Section 8.1 and
Section 8.2 with respect to Collaboration Products, Verve shall have sole authority over and control of the manufacture of Products, itself or through one or more Affiliates or Third Parties selected by Verve.

  
 43 

 Article 9 DELIVERY TECHNOLOGY 

 

	9.1	 General. From time to time during the Term, either Party or any of its Affiliates may
obtain rights to Know-How or Patent Rights that claim, embody or incorporate [**]. Each Party shall use reasonable efforts, in securing such rights, to Control such rights so that Know-How or Patent Rights, subject to Section 9.2, are Delivery Technology under this Agreement for the purposes of Section 2.1.3 or 2.1.4, as applicable;
provided that, for clarity, neither Party shall have the obligation to secure such rights (other than the obligation to use reasonable efforts as described in this sentence) or to pay any additional consideration or payment in order to
Control such Know-How or Patent Rights. 

  

	9.2	 Third Party Agreements. Notwithstanding anything to the contrary in this Agreement, in the event
that a Party enters into an agreement or arrangement with a Third Party under which such Party or its Affiliate is granted rights to any Patent Right or Know-How that would be Delivery Technology of such
grantee Party or its Affiliate hereunder, such Patent Right or Know-How is hereby deemed not to be Delivery Technology of such grantee Party or its Affiliate unless and until, in each case to the extent
permitted under any confidentiality obligations related to such arrangement or agreement, (a) such grantee Party provides the other Party with a written notice of such agreement or arrangement and [**], and (b) such other Party, within
[**] after receipt of such notice, [**]. Each Party will use commercially reasonable efforts to secure the right to disclose to the other Party the information described in the foregoing clauses (i) through (iii). The grantee Party shall be
required to provide the notice described in clause (a) of this Section 9.2 within [**] of the effective date of an agreement or arrangement under which the grantee Party or its Affiliate is granted rights to any Patent
Right or Know-How that would be Delivery Technology hereunder if accepted by the other Party. If the other Party provides notice to have such Patent Right or Know-How
deemed Delivery Technology hereunder, such other Party shall reimburse the grantee Party for all amounts that are owed to such Third Party solely as a result of the exercise of rights as a sublicensee under such Third Party Agreement within [**] of
receipt of an invoice from the grantee Party. If the other Party does not provide the notice described in clause (b) of this Section 9.2 or indicates in such written notice that it does not wish to obtain a sublicense
under the relevant Patent Right or Know-How, such Patent Right or Know-How is hereby deemed not to be Delivery Technology hereunder. 

Article 10 PAYMENTS AND CONSIDERATION; EQUITY PURCHASE 
  

	10.1	 Initial Issuance. In accordance with the terms of the Subscription Agreement entered into
by the Parties on the date hereof, Verve shall, on the Effective Date and concurrently with the execution of this Agreement, as partial consideration for the licenses granted hereunder, issue to Beam or designees identified to Verve in writing prior
to the Effective Date, an aggregate of 2,556,322 shares of Verve’s common stock. 

  
 44 

	10.2	 Development Milestone Payments. 

 

	 	10.2.1	 In further consideration for the licenses granted herein by Beam to Verve, upon the terms and conditions
contained herein, Verve shall pay to Beam the milestone payment set forth in the table below for each Licensed Product that achieves the corresponding milestone event: 

 

					
	 Milestone Event
	 	 For any Licensed Product that is not a
Collaboration
Product, in the Territory
	 	 For any Licensed Product that is a Collaboration
Product,
outside the Collaboration Territory

	[**]	 	[**] U.S. Dollars ($[**])	 	[**] U.S. Dollars ($[**])
	[**]	 	[**] U.S. Dollars ($[**])	 	[**] Dollars ($[**])
	[**]	 	[**] U.S. Dollars ($[**])	 	[**] U.S. Dollars ($[**])

 Verve shall notify Beam in writing within [**] following the achievement of each milestone, and shall make the
appropriate milestone payment within [**] after the achievement of such milestone. All milestone payments are payable only once under this Agreement for each Licensed Product to achieve such milestone. If a milestone set forth in the table in this
Section 10.2.1 is skipped (e.g. [**]), the payment associated with such skipped milestone shall be paid when the subsequent milestone is achieved in addition to the payment that would otherwise be due upon achievement of
such subsequent milestone. 
  

	 	10.2.2	 In further consideration for the licenses granted by each Party under Sections 2.1.3 and
2.1.4, respectively, upon the terms and conditions contained herein, each Party shall pay the other Party the milestone payment for each Delivery Technology Product of such paying Party to achieve the corresponding milestone event as set
forth in the table below: 

  

			
	 Milestone Event
	 	 For each Delivery Technology Product

	[**]	 	[**] Dollars ($[**])
	[**]	 	[**] Dollars ($[**])
	[**]	 	[**] Dollars ($[**])

 The owing Party shall notify the other Party in writing within [**] following the achievement of each
milestone, and shall make the appropriate milestone payment within [**] after the achievement of such milestone. All milestone payments are payable only once under this Agreement for each Delivery Technology Product to achieve such milestone. If the
[**] milestone set forth in the table in this Section 10.2.2 is skipped (e.g., [**]), the payment associated with such skipped milestone shall be paid upon [**] for such Delivery Technology Product. For purposes of this
Section 10.2, one (1) Licensed Product or Delivery Technology Product, as the case may be, that [**] for multiple Indications, multiple patient populations or multiple dosage forms shall be deemed to be a single
Licensed Product or Delivery Technology Product, as the case may be. 

  
 45 

	10.3	 Net Sales Milestones. 

 

	 	10.3.1	 Subject to Section 10.3.2, on a Licensed Product-by-Licensed Product basis, Verve will pay Beam the following one-time payments when aggregate Net Sales of a Licensed Product that is not a Collaboration
Product in a Calendar Year in the Territory first reach the respective thresholds indicated below: 

  

			
	 Calendar Year Territory-Wide Net Sales for a Licensed
Product that is not a
Collaboration Product
	 	 Net Sales Milestone

	Over [**] U.S. Dollars ($[**])	 	[**] U.S. Dollars ($[**])
	Over [**] U.S. Dollars ($[**])	 	[**] U.S. Dollars ($[**])

  

	 	10.3.2	 Notwithstanding Section 10.3.1, on a Licensed
Product-by-Licensed Product basis, with respect to any Licensed Product that is a Collaboration Product, Verve will pay Beam the following
one-time payments when aggregate Net Sales of such Licensed Product outside the Collaboration Territory first reach the respective thresholds indicated below:  

 

			
	 Calendar Year Net Sales for a Licensed Product that is a
Collaboration
Product Outside the Collaboration Territory
	 	 Net Sales Milestone

	Over [**] U.S. Dollars ($[**])	 	[**] U.S. Dollars ($[**])
	Over [**] U.S. Dollars ($[**])	 	[**] U.S. Dollars ($[**])

  

	 	10.3.3	 Verve will make any Net Sales threshold milestone payment payable with respect to a Calendar Year within
[**] after the end of the applicable Calendar Year. The Net Sales threshold milestone payments set forth above are payable only once on the first achievement by each Licensed Product of the relevant threshold. No amounts shall be due under this
Agreement for subsequent or repeated achievements of any milestone by the same Licensed Product. If more than one Net Sales threshold milestone is achieved in the same Calendar Year, Verve will pay to Beam all Net Sales threshold milestone payments
achieved in such Calendar Year in accordance with this Section 10.3.3. 

  

	10.4	 Royalties. 

 

	 	10.4.1	 Royalties to Beam for Licensed Products. 

 

	 	(a)	 Subject to the provisions of Sections 10.4.1(c) and 10.4.1(d), Verve will pay Beam royalties on a
tiered marginal royalty rate basis as set forth below based on the annual aggregate Territory-wide Net Sales resulting from the sale of each Licensed Product that is not a Collaboration Product, on a Licensed Product-by-Licensed Product basis, during each Calendar Year of the applicable Royalty Term for each such Licensed Product. 

  
 46 

			
	 Net Sales of a Licensed Product that is not a

Collaboration Product
	 	 Marginal Royalty Rate

(% of Calendar Year Net Sales for

such Licensed Product in the Territory)

	Annual Net Sales up to [**] Dollars ($[**])	 	[**]%
	Annual Net Sales including and above [**] Dollars ($[**]), up to [**] Dollars ($[**])	 	[**]%
	Annual Net Sales including and above [**] Dollars ($[**])	 	[**]%

 Each marginal royalty rate set forth in the table above will apply only to that portion of the Net Sales of a
given Licensed Product in the Territory during a given Calendar Year that falls within the indicated range. 
  

	 	(b)	 Subject to the provisions of Sections 10.4.1(c) and 10.4.1(d), Verve will pay Beam royalties on a
tiered marginal royalty rate basis as set forth below based on the annual aggregate Net Sales outside of the Collaboration Territory resulting from the sale of each Licensed Product that is a Collaboration Product, on a Licensed Product-by-Licensed Product basis, during each Calendar Year of the applicable Royalty Term for each such Licensed Product. 

 

			
	 Net Sales of a Licensed Product that is a

Collaboration Product Outside of the Collaboration Territory
	 	 Marginal Royalty Rate

(% of Calendar Year Net Sales for

such Licensed Product outside the Collaboration Territory)

	Annual Net Sales up to [**] Dollars ($[**]).	 	[**]%
	Annual Net Sales including and above [**] Dollars ($[**]), up to [**] Dollars ($[**])	 	[**]%
	Annual Net Sales including and above [**] Dollars ($[**])	 	[**]%

 Each marginal royalty rate set forth in the table above will apply only to that portion of the Net Sales of a
given Licensed Product in the applicable countries outside the Collaboration Territory during a given Calendar Year that falls within the indicated range. 
  

	 	(c)	 During time periods when the Royalty Term is only in effect in a given country for a given Licensed Product due
to clause (c) of Section 1.149.1, then the royalty rate provided for such Licensed Product in such country shall be reduced by [**] percent ([**]%) from that set forth in Section 10.4.1(a) or
10.4.1(b), as applicable, above for such portions of the Royalty Term for such Licensed Product in such country. 

  

	 	(d)	 On a Licensed
Product-by-Licensed Product basis, if Verve is legally required by a future court order, settlement agreement, contract, or other legally binding written commitment to
make payments to a Third Party for a license under or the use of Patent Rights held by such Third Party 

  
 47 

	 	
that [**], then Verve may offset [**] percent ([**]%) of any running royalty payments on net sales actually paid by Verve to such Third Party under such Third Party license with respect to such
patent application(s) or patent(s) with respect to sales of such Licensed Product against the running royalty payments that are due to Beam with respect to Net Sales of such Licensed Product in such country under
Section 10.4.1(a) or 10.4.1(b), as applicable; provided that, in no event, shall (a) the running royalty payments to Beam with respect to such any Licensed Products be reduced, after the application of
any reduction in Section 10.4.1(c) and this Section 10.4.1(d), by more than [**] percent ([**]%) of the amount otherwise due under Section 10.4.1(a) or 10.4.1(b),
as applicable, and (b) with respect to royalties paid to the Third Party solely on the basis of claims of pending patent applications of the Third Party (and no issued patent claim of the Third Party Covers the applicable Licensed Product),
such amounts shall only be offsettable in accordance with this Section 10.4.1(d) if the Covering pending claim of the Third Party’s pending application would meet the definition of Valid Claim set forth in this
Agreement were such pending claim within the Patent Rights as of the Effective Date. 

  

	 	10.4.2	 Royalties related to Delivery Technology. 

 

	 	(a)	 Subject to the provisions of Section 10.4.2(b) and 10.4.2(c), each Party will
pay the other Party royalties on a tiered marginal royalty rate basis as set forth below based on the annual aggregate Territory-wide Net Sales resulting from the sale of each Delivery Technology Product of such paying Party, on a Delivery
Technology Product-by-Delivery Technology Product basis, during each Calendar Year of the applicable Royalty Term for each such Delivery Technology Product.

  

			
	 Territory-Wide Net Sales of a Delivery Technology
Product
	 	 Marginal Royalty Rate

(% of Calendar Year Net Sales for

such Delivery Technology Product in the Territory)

	Annual Net Sales up to [**] Dollars ($[**]).	 	[**]%
	Annual Net Sales including and above [**] Dollars ($[**]), up to [**] Dollars ($[**])	 	[**]%
	Annual Net Sales including and above [**] Dollars ($[**])	 	[**]%

 Each marginal royalty rate set forth in the table above will apply only to that portion of the Net Sales of a
given Delivery Technology Product in the Territory during a given Calendar Year that falls within the indicated range. 
  

	 	(b)	 During time periods when the Royalty Term is only in effect in a given country for a given Delivery Technology
Product due to clause (c) of Section 1.149.2 or 1.149.3, as applicable, then the royalty rate provided for such Delivery Technology Product in such country shall be reduced by [**] percent ([**]%) from that set
forth in Section 10.4.2(a), as applicable, above for such portions of the Royalty Term for such Delivery Technology Product in such country. 

  
 48 

	 	(c)	 On a Delivery Technology
Product-by-Delivery Technology Product basis, if the licensee Party with respect to the Delivery Technology Product under Section 2.1.3 or
2.1.4, as applicable, is legally required by a future court order, settlement agreement, contract, or other legally binding written commitment to make payments to a Third Party for a license under or the use of Patent Rights held by such
Third Party that [**], then the licensee Party may offset [**] percent ([**]%) of any running royalty payments on net sales actually paid by such licensee Party to such Third Party under such Third Party license with respect to such patent
application(s) or patent(s) with respect to sales of such Delivery Technology Product against the running royalty payments that are due to the other Party with respect to Net Sales of such Delivery Technology Product in such country under
Section 10.4.2(a); provided that in no event shall (a) the running royalty payments to the other Party with respect to such Delivery Technology Products be reduced, after the application of any reduction in
Section 10.4.2(b) and this Section 10.4.2(c), by more than [**] percent ([**]%) of the amount otherwise due under Section 10.4.2(a) and (b) with respect to royalties
paid to the Third Party solely on the basis of claims of pending patent applications of the Third Party (and no issued patent claim of the Third Party Covers the applicable Delivery Technology Product), such amounts shall only be offsettable in
accordance with this Section 10.4.1(c) if the Covering pending claim of the Third Party’s pending application would meet the definition of Valid Claim set forth in this Agreement were such pending claim within the
Patent Rights as of the Effective Date. 

  

	10.5	 Revenue and Cost Sharing in the Collaboration Territory; Reconciliation Payments.

  

	 	10.5.1	 General. The terms and conditions of this Section 10.5 shall
govern each Party’s rights and obligations with respect to Shared Development Costs, Shared Commercialization Costs and Collaboration Territory Revenue, in each case relating to Collaboration Products. In the event of a conflict between
Section 10.5.1(a) or 10.5.1(b), on one hand, and, on the other hand, any Schedules to this Agreement, the terms of Section 10.5.1(a) or 10.5.1(b) shall take precedence, govern and
control. 

  

	 	(a)	 The Parties shall share all Shared Development Costs for each Collaboration Product incurred pursuant to this
Agreement on the basis of [**] percent ([**]%) by Verve and [**] percent ([**]%) by Beam; provided, however, that in the event Beam exercises a Beam Opt-In Option upon receipt of an [**] for a
Collaboration Product, Verve will be solely responsible for all of its own costs and all FTE Costs and out-of-pocket costs that are incurred as an expense in accordance
with GAAP (including Third Party Payments) by Beam or any of its Affiliates in connection with all Development activities through the end of the Phase I Clinical Trial for such Collaboration Product, in accordance with
Section 5.1 and the applicable Subsequent Development Plan. 

  
 49 

	 	(i)	 Development Budget for Collaboration Products. Notwithstanding the foregoing, expenses charged by either
Party as Shared Development Costs for an activity under a Subsequent Development Plan shall not exceed [**] percent ([**]%) of the amount included for the total itemized expenditure in the relevant then-current Development Budget for such
activity, and any expenses in excess of such [**]% threshold shall be borne by the incurring Party except if the cause of the excess expenditures is outside the incurring Party’s reasonable control, in which case the incurring Party
shall, upon learning of the likelihood of the excess expenditure, promptly revise the Development Budget and submit it in writing, with an explanation of the variance and the reasons therefor, to the JDC. If the JDC recommends approval of the
revised budget (the consent of each Party’s representatives on the JDC not to be unreasonably withheld, delayed or conditioned) then such revised Development Budget shall be incorporated into the respective Subsequent Development Plan.

  

	 	(b)	 The Parties shall share all Shared Commercialization Costs for such Collaboration Product incurred pursuant to
this Agreement, and Collaboration Territory Revenue for each Collaboration Product in the Collaboration Territory on the basis of fifty percent (50%) by Verve and fifty percent (50%) by Beam. Notwithstanding the provisions of
Section 10.5.1(a), Verve shall bear [**] percent ([**]%) of all Development costs and Commercialization costs for Products for which Beam has elected to exercise the Beam Opt-Out
Option pursuant to Section 5.3, which costs are incurred by Verve following the applicable Opt-Out Date, subject to the last sentence of Section 5.3, and
Beam shall bear [**] percent ([**]%) of all Development costs and Commercialization costs for Products for which Verve has elected to exercise the Verve Opt-Out Option pursuant to
Section 5.4, which costs are incurred by Beam following the applicable Opt-Out Date, subject to the last sentence of Section 5.4. Expenses charged by either
Party as Shared Commercialization Costs for an activity under a US Commercialization Plan shall not exceed [**] percent ([**]%) of the amount included for the total itemized expenditure in the relevant then-current Commercialization Budget for such
activity and any expenses in excess of such [**]% threshold shall be borne by the incurring Party except if the cause of the excess expenditures is outside the incurring Party’s reasonable control, in which case the incurring Party
shall, upon learning of the likelihood of the excess expenditure, promptly revise the Commercialization Budget and submit it in writing, with an explanation 

  
 50 

	 	
of the variance and the reasons therefor, to the JCC. If the JCC recommends approval of the revised budget (the consent of each Party’s representatives on the JCC not to be unreasonably
withheld, delayed or conditioned) then such revised Commercialization Budget shall be incorporated into the respective US Commercialization Plan. 

  

	 	10.5.2	 Calculation and Payment. 

 

	 	(a)	 Following any exercise by Beam of the Beam Opt-In Option, within [**]
after the end of each Calendar Quarter, each Party shall provide the other Party and the JCC and JDC, as applicable, with (i) a detailed, activity-based statement of its Shared Development Costs incurred in such Calendar Quarter, including,
without limitation, an itemized breakdown of the calculation of FTE Costs included in the Shared Development Costs (each, a “Development Cost Report”), (ii) a detailed, activity-based statement of its Shared Commercialization Costs
(each statement, together with the corresponding Development Cost Report, the “Cost Reports”), in each case to the extent incurred in such Calendar Quarter (or a good faith estimate of any portions thereof where actuals are not
known as of such time), as well as details of any adjustments to be made to the amounts submitted in the previous Calendar Quarter in previous Cost Reports, in a format to be agreed upon by the JCC and JDC, as applicable. 

 

	 	(b)	 Along with the Cost Reports, Verve shall provide Beam and the JCC with a report setting forth Verve’s
itemized Net Sales of each Collaboration Product in the Collaboration Territory during such Calendar Quarter. 

  

	 	(c)	 Within [**] after the end of each Calendar Quarter, each Party will provide the other Party and the JSC with a
written, non-binding, preliminary report that will set forth, in a format to be mutually agreed by the Parties promptly after the Effective Date, such Party’s good faith estimate of: (i) the amounts
and information that will be set forward in such Party’s Cost Reports for such Calendar Quarter; and (ii) in the case of Verve, the aggregate Net Sales of Collaboration Products in the Collaboration Territory and Collaboration Territory
Revenue for such Calendar Quarter. 

  

	 	(d)	 In addition to the preliminary reports to be provided by each Party in accordance with
Section 10.5.2(c) above, within [**] after the end of each Calendar Quarter, Verve shall provide Beam and the JSC with a written report (the “Reconciliation Report”) setting forth, in a format to be
mutually agreed by the Parties promptly after the Effective Date, the calculations of [**]. Any net payment owed from one Party to the other Party shall be paid within [**] following receipt of such reconciliation (i.e. within [**] after the end of
the Calendar Quarter); provided that if a Party disputes an amount provided in such Reconciliation Report then 

  
 51 

	 	
such disputed amount shall be reviewed by the JDC (with respect to Shared Development Costs) or JCC (with respect to Shared Commercialization Costs or Net Sales), as applicable, and any net
payment owed with respect to the undisputed amounts shall be paid within such [**] period (and the disputed amount, if determined to be owed, shall be paid within [**] of resolution of the dispute). If requested by Verve or Beam, any invoices or
other supporting documentation for any payments to a Third Party that individually exceed [**] Dollars ($[**]) shall be promptly provided. 

  

	10.6	 Currency Exchange. All payments to be made by a Party under this Agreement shall be made in US
dollars, by wire transfer, pursuant to the instructions of the Party receiving payment, as designated from time to time. To the extent Shared Development Costs or Shared Commercialization Costs are incurred in a currency other than US dollars, the
applicable expense shall be converted into US dollars on a monthly basis using as a rate of exchange the average actual foreign currency exchange rate for the month in which the expense is incurred. Likewise, to the extent Licensed Products or
Collaboration Products are sold in a currency other than US dollars, the amount received shall be converted into US dollars on a monthly basis using as a rate of exchange the average actual foreign currency exchange rate for the month in which the
expense is incurred. All currency conversions shall be according to the exchange rates utilized by each Party in its own internal accounting system, consistently applied. 

 

	10.7	 Record-Keeping and Audit. 

 

	 	10.7.1	 Each Party and its Affiliates shall maintain complete and accurate books and records of account, in
accordance with GAAP, of all transactions and other business activities under this Agreement, sufficient to confirm the accuracy of all reports furnished by a Party to the other Party under this Agreement, and all payments by a Party to the other
Party under this Agreement. During the Term and for [**] after final payment has been made under this Agreement, upon reasonable written notice to a Party, but no more often than [**], such Party shall permit an independent certified public
accountant of national standing designated by the other Party to audit such books and records of account of such Party in order to confirm the accuracy and completeness of all such reports and all such payments. The accounting firm shall disclose to
the Party requesting the audit only whether the audited reports are correct or incorrect and the specific details concerning any discrepancies. No other information shall be provided to the Party requesting the audit. 

 

	 	10.7.2	 The Party requesting an audit shall bear all costs and expenses incurred in connection with any such
audit; provided, however, that if any such audit correctly identifies any underpayments by the audited Party hereunder or overpayments by the auditing Party that are the fault of the audited Party hereunder in excess of [**] percent
([**]%) of the amount actually payable by such Party to the Party requesting the audit hereunder, or $[**] US dollars, whichever is greater, then, in addition to paying the full amount of such underpayment or overpayment, the audited Party shall
reimburse the other Party for all reasonable out-of-pocket costs and expenses incurred by such Party in connection with that audit. 

  
 52 

	 	10.7.3	 Neither Party shall be required to maintain books and records for more than [**] following the end of
the Calendar Year in which they were generated. 

  

	 	10.7.4	 The Party requesting an audit shall treat all financial information subject to review under this
Section 10.7 in accordance with the confidentiality and non-use provisions of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement
with the audited Party obligating it to retain all such information in confidence pursuant to such confidentiality agreement. 

  

	10.8	 Income Tax Withholding. 

 

	 	10.8.1	 VAT. It is understood and agreed between the Parties that any payments made under this
Agreement are exclusive of any value added or similar tax (VAT), which shall be added thereon as applicable. Where value added tax or similar tax is properly added to a payment made under this Agreement, the Party making the payment will pay the
amount of value added tax or similar tax only on receipt of a valid tax invoice issued in accordance with the Applicable Laws of the country in which the value added tax or similar tax is chargeable. 

 

	 	10.8.2	 Withholding Taxes. In the event any payments made pursuant to this Agreement become
subject to withholding taxes under the laws or regulation of any jurisdiction, the Party making such payment shall deduct and withhold the amount of such taxes for the account of the payee to the extent required by Applicable Laws or regulations and
such amounts payable to the payee shall be reduced by the amount of taxes deducted and withheld. Any such withholding taxes required under Applicable Laws or regulations to be paid or withheld shall be an expense of, and borne solely by, the payee.

  

	 	10.8.3	 Tax Cooperation. To the extent that the Party making a payment is required to deduct and
withhold taxes on any payments under this Agreement, the Party making such payment shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to the payee an official tax certificate or other
evidence of such withholding sufficient to enable the payee to claim such payments of taxes. The payee shall provide any tax forms to the Party making such payment that may be reasonably necessary in order for such Party not to withhold tax or to
withhold tax at a reduced rate under an applicable bilateral income tax treaty. The payee shall use reasonable efforts to provide any such tax forms to the Party making the payment at least [**] prior to the due date for any payments for which the
payee desires that the Party making the payment apply a reduced withholding rate. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by Applicable Law, of withholding taxes, VAT, or similar obligations
resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or VAT. 

  
 53 

	 	10.8.4	 Notwithstanding anything in this Agreement to the contrary, if an action (including but not limited to
any assignment or sublicense of its rights or obligations under this Agreement, or any failure to comply with Applicable Laws or filing or record retention requirements) by a Party leads to the imposition of withholding tax liability or VAT on the
other Party that would not have been imposed in the absence of such action or in an increase in such liability above the liability that would have been imposed in the absence of such action, such Party shall indemnify and hold harmless the other
Party from any such additional or increased withholding tax liability or VAT (except to the extent that the other Party can reclaim it, provided that such other Party will be reimbursed for any reasonable out of pocket costs incurred in the
reclaim). 

  

	10.9	 Late Payments. Any payments by a Party that are not being disputed in good faith by such Party
and not paid on or before the date such payments are due under this Agreement will bear interest at the lower of (a) [**] percent ([**]%) [**] and (b) the maximum rate allowed by law. Interest will accrue beginning on the [**] day following the
due date for payment and will be compounded [**]. Payment of such interest by the relevant Party shall not limit, in any way, the other Party’s right to exercise any other remedies it may have as a consequence of any payment due but unpaid
hereunder. 

 Article 11 CONFIDENTIALITY AND PUBLICATION 
  

	11.1	 Confidentiality; Exceptions. Except to the extent expressly authorized by this Agreement
or otherwise agreed in writing by the Parties, the Parties agree that the receiving Party (the “Receiving Party”) shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for
in this Agreement any confidential and proprietary information and materials, patentable or otherwise, in any form (written, oral, photographic, electronic, magnetic, or otherwise) which is disclosed to it by the other Party (the “Disclosing
Party”) or otherwise received or accessed by a Receiving Party in the course of performing its obligations or exercising its rights under this Agreement, including trade secrets, Know-How, inventions
or discoveries, proprietary information, formulae, processes, techniques and information relating to a Party’s past, present and future Commercialization, financial, and Development activities of any product or potential product or useful
technology of the Disclosing Party and the pricing thereof (collectively, “Confidential Information”), except to the extent that it can be established by the Receiving Party that such Confidential Information: 

 

	 	11.1.1	 was in the lawful knowledge and possession of the Receiving Party prior to the time it was disclosed to,
or learned by, the Receiving Party, or was otherwise developed independently by the Receiving Party, as evidenced by written records kept in the ordinary course of business, or other documentary proof of actual use by the Receiving Party;

  
 54 

	 	11.1.2	 was generally available to the public or otherwise part of the public domain at the time of its
disclosure to the Receiving Party; 

  

	 	11.1.3	 became generally available to the public or otherwise part of the public domain after its disclosure and
other than through any act or omission of the Receiving Party in breach of this Agreement; or 

  

	 	11.1.4	 was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third
Party who had no obligation to the Disclosing Party not to disclose such information to others. 

  

	11.2	 Authorized Disclosure. Except as expressly provided otherwise in this Agreement, a
Receiving Party may use and disclose Confidential Information of the Disclosing Party as follows: (a) under appropriate confidentiality provisions similar to those in this Agreement, in connection with the performance of its obligations or
exercise of rights granted or reserved in this Agreement (including the rights to Develop, Manufacture and Commercialize Products and to grant sublicenses as permitted hereunder); or (b) to the extent such disclosure is reasonably necessary in
filing or prosecuting patent, copyright and trademark applications in accordance with this Agreement, prosecuting or defending litigation, complying with applicable governmental regulations, seeking and obtaining regulatory approval, conducting non-clinical activities or clinical trials, preparing and submitting INDs to Regulatory Authorities, or is otherwise required by Applicable Law or the rules of a recognized stock exchange or automated quotation
system applicable to such Party; provided, however, that if a Receiving Party is required by Applicable Law to make any such disclosure of a Disclosing Party’s Confidential Information it will, except where impracticable, give
reasonable advance notice to the Disclosing Party of such disclosure requirement and, if requested by the Disclosing Party, cooperate with the Disclosing Party to secure confidential treatment of such Confidential Information required to be
disclosed; or (c) in communication with existing or prospective investors, consultants, advisors, licensees or collaborators or others on a need to know basis, in each case that are not Competitors of the Disclosing Party and under appropriate
confidentiality provisions substantially equivalent to those of this Agreement (except for the term of such obligations, which shall be customary for the particular disclosure) or (d) to the extent mutually agreed to in writing by the Parties.

  

	11.3	 Publications. Verve and Beam each acknowledge the other Party’s interest in
publishing the results of its research in order to obtain recognition within the scientific community and to advance the state of scientific knowledge. Each Party also recognizes the mutual interest in obtaining valid patent protection and in
protecting business interests and trade secret information. Consequently, except for disclosures permitted pursuant to Section 11.2, if either Party, its Affiliates, or their respective employee(s) wishes to make a
publication or public presentation related to a Collaboration Product or Licensed Product or which otherwise may reasonably contain Confidential Information, or intellectual property, of the other Party, such Party must first obtain approval by the
JSC of the general subject matter of such proposed publication or presentation and thereafter shall deliver to such other Party a copy of the proposed written publication or an outline of any proposed oral disclosure at least [**] prior to
submission for publication or presentation. The 

  
 55 

	 	
reviewing Party shall have the right (a) to require removal from the publication or presentation of such reviewing Party’s Confidential Information or (b) to request a reasonable
delay in publication or presentation in order to protect patentable information. If the reviewing Party requests a delay, the publishing Party shall delay submission or presentation for a period of [**] to enable patent applications protecting each
Party’s rights in such information to be filed in accordance with Section 13.2. Upon expiration of such [**], the publishing Party shall be free to proceed with the publication or presentation. If the reviewing Party
requests modifications to the publication or presentation, the publishing or presenting Party shall edit such publication or presentation to prevent disclosure of Confidential Information, trade secret and proprietary business information of the
reviewing Party prior to submission of the publication or presentation. Notwithstanding the foregoing, the Parties agree that (i) study information and results must be posted to clinicaltrials.gov in accordance with statutory deadlines and
(ii) such study results required to be posted pursuant to clause (i) of this Section 11.3 will, following such posting, no longer constitute Confidential Information of either Party. 

 

	11.4	 Press Releases; Disclosure of Agreement. The Parties shall reasonably cooperate and
mutually agree on an initial press release to be made by each Party regarding the execution of this Agreement. Neither Party shall issue or cause the publication of any other press release or public announcement regarding the terms of this Agreement
without the express prior approval of the other Party other than as required by Applicable Law or the rules of any stock exchange, provided that if any such publication, press release or public announcement is required by Applicable Law, the
Party obligated to make such publication, press release or public announcement shall, if practicable, notify the other Party in advance thereof and reasonably consider any timely comments from such other Party, including any reasonable request to
limit such publication, press release or public announcement. Notwithstanding anything to the contrary in this Agreement, each Party may disclose this Agreement, as well as redacted versions of any Third Party Agreements provided to such Party, on a
reasonable need-to-know basis to actual and potential investors, acquirers, sublicensees and collaborators under reasonable conditions of confidentiality, including, in
the case of the applicable Third Party Agreements, confidentiality obligations imposed under such Third Party Agreements. 

  

	11.5	 Use of Names. Neither Party shall use the name, symbol, trademark, trade name or logo of
the other Party or its Affiliates in any press release, publication or other form of public disclosure without the prior written consent of the other Party in each, except for those disclosures for which consent has already been obtained, including
as authorized in Section 2.3. 

  

	11.6	 Termination of Prior Agreement. This Agreement supersedes and replaces the Mutual
Confidential Disclosure Agreement by and between the Parties dated as of [**] (the “Existing Confidentiality Agreement”). All information exchanged between the Parties under the Existing Confidentiality Agreement shall be deemed
Confidential Information of the respective Disclosing Party hereunder and shall be so subject to the terms of this Agreement. 

  
 56 

	11.7	 Remedies. Each Party shall be entitled to seek, in addition to any other right or remedy
it may have, at Applicable Law or in equity, a temporary injunction, without the posting of any bond or other security, enjoining or restraining the other Party from any violation or threatened violation of this Article 11.

 Article 12 REPRESENTATIONS, WARRANTIES AND COVENANTS 
  

	12.1	 Representations and Warranties of Each Party. Each Party represents and warrants to the other
Party that as of the Effective Date: 

  

	 	12.1.1	 it has the full right, power and authority to enter into this Agreement and to perform its obligations
hereunder; 

  

	 	12.1.2	 this Agreement has been duly executed by it and is legally binding upon it, enforceable in accordance
with its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material Applicable Law or regulation of any court, governmental body or
administrative or other agency having jurisdiction over it; and 

  

	 	12.1.3	 it is licensed, registered, or qualified under Applicable Law, regulations, policies, and administrative
requirements to do business. 

  

	12.2	 Verve Representations, Warranties and Covenants. Verve represents and warrants to Beam as of the
Effective Date that and, with respect to Sections 12.2.5, 12.2.9, 12.2.10 and 12.2.11, covenants during the Term: 

  

	 	12.2.1	 to Verve’s knowledge, the Patent Rights to be licensed to Beam under Sections 2.1.2 and
2.1.3 have been properly maintained and are not invalid or unenforceable, in whole or in part; 

  

	 	12.2.2	 Verve is the sole and exclusive owner of, or has Control via a license to, the Patent Rights licensed to
Beam as of the Effective Date under Sections 2.1.2 and 2.1.3; 

  

	 	12.2.3	 Verve has not granted any right or license to any Third Party relating to any of the Patent Rights that
Verve Controls that conflicts or interferes with any of the rights or licenses granted hereunder by Verve to Beam; 

  

	 	12.2.4	 there are no claims, judgments or settlements against or owed by Verve and, to the knowledge of Verve,
no pending or threatened claims or litigation relating to the Patent Rights Controlled by Verve to be licensed to Beam under Sections 2.1.2 and 2.1.3; 

 

	 	12.2.5	 Verve will not, and will cause its Affiliates not to incur or permit to exist, with respect to any Know-How or Patent Rights Controlled by Verve or its Affiliates (including the Verve Delivery Technology and Joint Collaboration Technology) any lien, encumbrance, charge, security interest, mortgage, liability,
assignment, grant of license or other binding obligation that is or would be inconsistent with or would diminish, derogate from or otherwise conflict with the licenses and other rights granted to Beam under this Agreement; 

  
 57 

	 	12.2.6	 the Third Party Agreements set forth on Schedule 1.167(b) are all of the agreements or
arrangements between Third Parties and Verve or its Affiliates under which Verve or its Affiliates are granted rights to any Verve Delivery Technology or any other intellectual property rights related to or useful for the Development,
Commercialization, Manufacture or use of any Product or pursuant to which Beam would be subject to any obligations (including payment obligations) based upon the rights granted by Verve to Beam under this Agreement or the Development or
Commercialization of a Product under this Agreement; 

  

	 	12.2.7	 Verve has provided to Beam true and correct partially-redacted copies of all Third Party Agreements to
which Verve or its Affiliate is a party in their current form (including any amendments thereto) (each, a “Verve Third Party Agreement”), which Verve Third Party Agreements are in full force and effect, and the redacted provisions
do not materially relate to Beam’s rights or obligations under this Agreement, including provisions related to the scope of the licenses granted to Beam under Section 2.1.2, 2.1.3 or 2.1.5 or the
ownership of any Patent Rights invented or Know-How conceived, developed, generated or reduced to practice arising out of a Party’s performance of its obligations under this Agreement during the Term;

  

	 	12.2.8	 Verve is not in material breach and, to its knowledge, none of the Third Parties who are party to a
Verve Third Party Agreement are in material breach of the relevant Verve Third Party Agreement, Verve has not waived or allowed to lapse or terminate any of its rights under any Verve Third Party Agreements that would adversely affect the rights
granted to Beam under this Agreement, and Verve has not received any notice of breach of such Verve Third Party Agreements; 

  

	 	12.2.9	 Verve shall not amend any Third Party Agreement to which Verve or any of its Affiliates is a party in a
manner that would adversely affect the rights or obligations of Beam under this Agreement without Beam’s prior written consent; 

  

	 	12.2.10	 Verve shall furnish Beam with copies of all notices received by Verve relating to any alleged breach or
default by Verve under any Verve Third Party Agreement within [**] after Verve’s receipt thereof. In the event that Verve does not resolve any such breach that is an undisputed breach to make one or more payments when due under the Verve Third
Party Agreement, Verve shall notify Beam within a sufficient period of time before the expiration of the cure period for such breach under such Verve Third Party Agreement such that Beam, in its sole discretion, is able to cure or otherwise resolve
such payment breach. If Beam makes any payments to a Third Party in connection with the cure or other resolution of such payment breach of Verve, then Beam may credit the amount of such payments against any amounts payable to Verve pursuant to this
Agreement; and 

  
 58 

	 	12.2.11	 Verve shall promptly (and in any event within [**] following receipt) furnish Beam with copies of all
amendments of the Verve Third Party Agreements solely to the extent material to Beam or its rights granted under this Agreement. 

  

	12.3	 Beam Representations, Warranties and Covenants. Beam represents and warrants to Verve as of the
Effective Date and, with respect to Sections 12.3.7, 12.3.8, 12.3.9 and 12.3.11, covenants during the Term that: 

  

	 	12.3.1	 to Beam’s knowledge, the Beam Base Editor Patent Rights, Beam C2C1 Patent Rights and any Patent
Rights within the Beam Delivery Technology have been properly maintained and are not invalid or unenforceable, in whole or in part; 

  

	 	12.3.2	 Beam is the sole and exclusive owner of, or has Control via a license to, the Beam Base Editor Patent
Rights, Beam C2C1 Patent Rights and any Patent Rights within the Beam Delivery Technology; 

  

	 	12.3.3	 Beam has not granted any right or license to any Third Party relating to any of the Beam Base Editor
Patent Rights, Beam C2C1 Patent Rights or any Patent Rights within the Beam Delivery Technology that conflicts or interferes with any of the rights or licenses granted hereunder with respect to the Beam Base Editor Patent Rights, Beam C2C1 Patent
Rights and any Patent Rights within the Beam Delivery Technology; 

  

	 	12.3.4	 the Third Party Agreements set forth on Schedule 1.167(a) are all of the agreements or
arrangements between Third Parties and Beam or its Affiliates under which Beam or its Affiliates are granted rights to any Beam Base Editor Technology, Beam C2C1 Technology or Beam Delivery Technology or pursuant to which Verve would be subject to
any obligations (including payment obligations) based upon the rights granted by Beam to Verve under this Agreement or the Development or Commercialization of a Product under this Agreement; 

 

	 	12.3.5	 Beam has provided to Verve true and correct partially-redacted copies of all Third Party Agreements to
which Beam or its Affiliate is a party in their current form (including any amendments thereto) (each, a “Beam Third Party Agreement”), which Beam Third Party Agreements are in full force and effect, and the redacted provisions do
not materially relate to Verve’s rights or obligations under this Agreement, including provisions related to the scope of the licenses granted to Beam under the Beam Base Editor Patent Rights or Beam C2C1 Patent Rights or the ownership of any
Patent Rights invented or Know-How conceived, developed, generated or reduced to practice arising out of a Party’s performance of its obligations under this Agreement during the Term;

  

	 	12.3.6	 Beam is not in material breach and, to its knowledge, none of the Third Parties who are party to a Beam
Third Party Agreement are in material breach of the relevant Beam Third Party Agreement, Beam has not waived or allowed to lapse or terminate any of its rights under any Beam Third Party Agreements that would adversely affect the rights granted to
Verve under this Agreement, and Beam has not received any notice of breach of such Beam Third Party Agreements; 

  
 59 

	 	12.3.7	 Beam shall not amend any Beam Third Party Agreement in a manner that would adversely affect the rights
or obligations of Verve under this Agreement without Verve’s prior written consent; 

  

	 	12.3.8	 Beam shall furnish Verve with copies of all notices received by Beam relating to any alleged breach or
default by Beam under any Beam Third Party Agreement within [**] after Beam’s receipt thereof. In the event that Beam does not resolve any such breach that is an undisputed breach of Beam’s obligation to make one or more payments when due
under the Beam Third Party Agreement, Beam shall notify Verve within a sufficient period of time before the expiration of the cure period for such breach under such Beam Third Party Agreement such that Verve, in its sole discretion, is able to cure
or otherwise resolve such payment breach. If Verve makes any payments to a Third Party in connection with the cure or other resolution of such payment breach of Beam, then Verve may credit the amount of such payments against any royalties or other
amounts payable to Beam pursuant to this Agreement; 

  

	 	12.3.9	 Beam shall promptly (and in any event within [**] following receipt) furnish Verve with copies of all
amendments of the Beam Third Party Agreements, solely to the extent material to Verve or its rights granted under this Agreement; 

  

	 	12.3.10	 there are no claims, judgments or settlements against or owed by Beam and, to the knowledge of Beam, no
pending or threatened claims or litigation relating to the Beam Base Editor Technology, Beam C2C1 Technology or Beam Delivery Technology; and 

  

	 	12.3.11	 Beam will not, and will cause its Affiliates not to incur or permit to exist, with respect to any Beam
Base Editor Technology, Beam C2C1 Technology, Joint Collaboration Technology or Beam Delivery Technology, any lien, encumbrance, charge, security interest, mortgage, liability, assignment, grant of license or other binding obligation that is or
would be inconsistent with or would diminish, derogate from or otherwise conflict with the licenses and other rights granted to Verve under this Agreement. 

  

	12.4	 Disclaimer. THE FOREGOING REPRESENTATIONS AND WARRANTIES OF EACH PARTY ARE IN LIEU OF ANY
OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE HEREBY SPECIFICALLY EXCLUDED AND DISCLAIMED.

  
 60 

 Article 13 INTELLECTUAL PROPERTY PROVISIONS 

 

	13.1	 Ownership of Intellectual Property. 

 

	 	13.1.1	 General. Inventorship shall be determined in accordance with United States patent laws.

  

	 	13.1.2	 Beam Owned Intellectual Property. Subject to the licenses granted to Verve under
Section 2.1.1 and 2.1.4 and the rights retained by Beam under Section 2.1.6, the entire right, title and interest in and to the Beam Base Editor Technology, Beam Collaboration Technology and
Beam Delivery Technology shall be owned solely by Beam. Verve shall, and hereby does (and shall cause its Affiliates to) sell, assign, transfer, convey and deliver to Beam, all of its right, title and interest in, to and under any Beam Collaboration
Technology. Verve will promptly execute an assignment of Beam Collaboration Technology, including assignments of Patent Rights in forms registrable or recordable in the United States Patent and Trademark Office or applicable foreign offices in the
Territory to the extent necessary to assign the Beam Collaboration Technology, all in forms reasonably acceptable to Beam. 

  

	 	13.1.3	 Verve Owned Intellectual Property. Subject to the license granted to Beam under
Sections 2.1.2, 2.1.3 and 6.3, the entire right, title and interest in and to the Verve Collaboration Technology, Verve Delivery Technology and the Clinical Trial Data shall be owned solely by Verve. 

 

	 	13.1.4	 Other Solely Invented Intellectual Property. Subject to the licenses granted to each Party
and the rights retained by each Party under Section 2.1 and except as set forth in Section 8.3, Section 13.1.2 or Section 13.1.3, all Know-How, patentable or otherwise, conceived, developed, generated or reduced to practice during the Term solely by a Party or its Affiliates or other persons acting on behalf of such Party shall be owned by such
Party. 

  

	 	13.1.5	 Jointly Owned Intellectual Property. Subject to the licenses granted to each Party and the
rights retained by each Party under Section 2.1, (a) Joint Collaboration Technology shall be owned jointly by Verve and Beam and (b) each Party shall have the non-exclusive right
to use Joint Collaboration Know-How, practice the inventions claimed by the Joint Collaboration Patent Rights, and grant licenses under its interest in Joint Collaboration Technology, as it deems appropriate
without the consent of or any obligation to the other Party, including any duty to account. 

  

	13.2	 Filing, Prosecution and Maintenance of Patent Rights. 

 

	 	13.2.1	 As between the Parties, subject to Section 13.3.2, Beam shall have the
exclusive right to file, prosecute and maintain the Beam Base Editor Patent Rights, Beam Collaboration Patent Rights, Beam C2C1 Patent Rights and Patent Rights within the Beam Manufacturing Technology and Beam Delivery Technology. Subject to
Beam’s obligations under Third Party Agreements, Beam shall give Verve the 

  
 61 

	 	
opportunity to provide comments on and make requests of Beam concerning the prosecution and maintenance of the Beam Base Editor Patent Rights, Beam C2C1 Patent Rights, Beam Collaboration Patent
Rights and Patent Rights within the Beam Delivery Technology and Beam shall consider such comments and requests in good faith; however, final decision-making authority with respect to the prosecution and maintenance of such Patent Rights shall vest
in Beam. 

  

	 	13.2.2	 If and to the extent permitted by the Third Party Agreements to which Beam is a Party, Verve shall have
the first right to file, prosecute and maintain Product-Specific Patent Rights. Verve will keep Beam advised on the status of the preparation, filing, prosecution, and maintenance of all patent applications included within such Product-Specific
Patent Rights and the maintenance of any issued patents included within such Product-Specific Patent Rights. Further, Verve will consult and reasonably cooperate with Beam with respect to the preparation, filing, prosecution and maintenance of
Product-Specific Patent Rights, including: (i) allowing Beam a reasonable opportunity and reasonable time to review and comment regarding relevant communications to Verve and drafts of any responses or other proposed filings by Verve before any
applicable filings are submitted to any relevant patent office or Governmental Authority and (ii) reflecting any reasonable comments offered by Beam in any final filings submitted by Verve to any relevant patent office or Governmental
Authority. If Verve elects not to file a patent application included in the Product-Specific Patent Rights in a country in the Territory or elects to cease the prosecution or maintenance of any Product-Specific Patent Right, Verve will provide Beam
with written notice immediately, but not less than [**] before any action is required, upon the decision to not file or continue the prosecution of such patent application or maintenance of such patent. In such event, Verve will permit Beam to file
or continue prosecution or maintenance of any such Product-Specific Patent Right in such country. 

  

	 	13.2.3	 As between the Parties, Verve shall have the exclusive right to file, prosecute and maintain the Patent
Rights in the Verve Delivery Technology and any other Patent Rights that Verve has licensed to Beam under Section 2.1.2. Subject to Verve’s obligations under Third Party Agreements, Verve shall give Beam the
opportunity to provide comments on and make requests of Verve concerning the prosecution and maintenance of such Patent Rights and Verve shall consider such comments and requests in good faith; however, final decision-making authority with respect
to the prosecution and maintenance of such Patent Rights shall vest in Verve. 

  

	 	13.2.4	 With respect to any Joint Collaboration Patent Right, the Party responsible for the filing, prosecution
and maintenance of such Joint Collaboration Patent Right shall be decided between the Parties in good faith, such decision to take into account the subject matter of the patent right and to which Party such subject matter is most relevant.

  
 62 

	13.3	 Enforcement and Defense of Beam Patent Rights. 

 

	 	13.3.1	 Each Party shall give to the other Party notice of (i) any infringement of Beam Base Editor Patent
Rights, Beam C2C1 Patent Rights, Beam Collaboration Patent Rights, Joint Collaboration Patent Rights to the extent related to Base Editors or the use of C2C1 in a base editor or nuclease product and Patent Rights within the Beam Delivery Technology
but only, in each case, if such Patent Right is not a Product-Specific Patent Right, or (ii) any misappropriation or misuse of Beam Base Editor Know-How, Beam C2C1
Know-How, Beam Collaboration Know-How, Joint Collaboration Know-How to the extent related to Base Editors or the use of C2C1 in a
base editor or nuclease product or Know-How within the Beam Delivery Technology but only, in each case, if such Know-How is not Product-Specific Know-How, that may come to such Party’s attention which infringement or misappropriation is by a Third Party that is developing or commercializing a product that is competitive with a Licensed Product or a
Delivery Technology Product that uses Beam Delivery Technology (a “Beam IP Competitive Infringement”). Beam shall have the sole right to initiate and prosecute such legal action at its own expense and in the name of Beam and, if
requested by Beam in the name of Verve, or to control the defense of any declaratory judgment action relating to Beam Base Editor Technology, Beam Collaboration Technology and Beam Delivery Technology. 

 

	 	13.3.2	 For any action to terminate any Beam IP Competitive Infringement, in the event that Beam is unable to
initiate or prosecute such action solely in its own name, Verve will join such action voluntarily and will execute and cause its Affiliates to execute all documents necessary for Beam to initiate litigation to prosecute and maintain such action.
Each Party shall have the right to be represented by counsel of its own choice, at its own expense in any such action. In connection with any action related to a Beam IP Competitive Infringement, Verve and Beam will cooperate fully and will provide
each other with any information or assistance that either may reasonably request. Beam shall keep Verve informed of developments in any action or proceeding related to a Beam IP Competitive Infringement, including, to the extent permissible by
Applicable Law, consultation on and approval of any settlement, the status of any settlement negotiations and the terms of any offer related thereto. 

  

	 	13.3.3	 Any recovery applicable to Licensed Products or Delivery Technology Products obtained by Beam in
connection with or as a result of any action related to a Beam IP Competitive Infringement contemplated by this Section 13.3, whether by settlement or otherwise, shall be shared in order as follows: 

 

	 	(a)	 Beam shall recoup all of its costs and expenses incurred in connection with the action, including any payments
owed by Beam to a Third Party under any Third Party Agreement as a result of such action or recovery; 

  

	 	(b)	 Verve shall then, to the extent possible, recover its costs and expenses incurred in connection with the
action, including any payments owed by Verve to a Third Party under any Third Party Agreement as a result of such action or recovery; 

  

	 	(c)	 [**]. 

  
 63 

	13.4	 Enforcement and Defense of Verve Patent Rights, Product-Specific Patent Rights or Joint Collaboration
Patent Rights. 

  

	 	13.4.1	 Each Party shall give the other Party notice of (i) any infringement of Patent Rights within the
Verve Delivery Technology, Product-Specific Patent Rights, any Patent Rights licensed by Verve or its Affiliates to Beam under this Agreement or Joint Collaboration Patent Rights to the extent (in the case of Joint Collaboration Patent Rights) not
related to Base Editors or the use of C2C1 in a base editor or nuclease product, or (ii) any misappropriation or misuse of Know-How within the Verve Delivery Technology, Product-Specific Know-How, any Know-How licensed by Verve or its Affiliates to Beam under this Agreement or Joint Collaboration Know-How to the extent
(in the case of Joint Collaboration Know-How) not related to Base Editors or the use of C2C1 in a base editor or nuclease product, that may come to such Party’s attention, which infringement or
misappropriation is by a Third Party that is developing or commercializing a product that is competitive with a Licensed Product or a Delivery Technology Product that uses Verve Delivery Technology (an “Verve IP Competitive
Infringement”). Verve shall have the sole right to initiate and prosecute such legal action at its own expense and in the name of Verve and if requested by Verve in the name of Beam, or to control the defense of any declaratory judgment
action relating to such Patent Rights or Know-How. Each Party shall have the right to be represented by counsel of its own choice at its own expense. 

 

	 	13.4.2	 For any action to terminate any Verve IP Competitive Infringement, in the event that Verve is unable to
initiate or prosecute such action solely in its own name, Beam will join such action voluntarily and will execute and cause its Affiliates to execute all documents necessary for Verve to initiate litigation to prosecute and maintain such action. In
connection with any action related to a Verve IP Competitive Infringement, Verve and Beam will cooperate fully and will provide each other with any information or assistance that either may reasonably request. Verve shall keep Beam informed of
developments in any action or proceeding related to a Verve IP Competitive Infringement, including, to the extent permissible by Applicable Law, consultation on and approval of any settlement, the status of any settlement negotiations and the terms
of any offer related thereto. 

  

	 	13.4.3	 Any recovery obtained by Verve in connection with or as a result of any action contemplated by this
Section 13.4, whether by settlement or otherwise, shall be shared in order as follows: 

  

	 	(a)	 Verve shall recoup all of its costs and expenses incurred in connection with the action, including any payments
owed by Verve to a Third Party under any Third Party Agreement as a result of such action or recovery; 

  

	 	(b)	 Beam shall, to the extent possible, recover its costs and expenses incurred in connection with the action,
including any payments owed by Beam to a Third Party under any Third Party Agreement as a result of such action or recovery; and 

  

	 	(c)	 [**]. 

  
 64 

	13.5	 Patent Term Restoration. The Parties agree to cooperate and to take reasonable actions to
maximize the protections available under the safe harbor provisions of 35 U.S.C. 103(c) for US patents and patent applications. The Parties shall cooperate with each other, including without limitation to provide necessary information and assistance
as the other Party may reasonably request, in obtaining patent term restoration or supplemental protection certificates or their equivalents in any country in the Territory where applicable to Beam Base Editor Patent Rights, Beam C2C1 Patent Rights,
Patent Rights within the Beam Delivery Technology, Patent Rights within the Verve Delivery Technology, other Patent Rights licensed by Verve or its Affiliate under this Agreement or Joint Collaboration Patent Rights. 

 

	13.6	 Trademarks and Corporate Logos. 

 

	 	13.6.1	 In the Collaboration Territory. 

 

	 	(a)	 Verve shall be responsible for developing a list of potential trademarks to be used to identify the
Collaboration Products in the Collaboration Territory. From Verve’s initial list, the JSC shall ultimately be responsible for the selection of the actual trademarks used to identify the Collaboration Products in the Collaboration Territory, and
all trademarks, logos, taglines, trade dress, domain names or indicia of origin for use in connection with the sale or marketing of Collaboration Products in the Collaboration Territory (the “Collaboration Marks”). Verve shall be
responsible for any associated creation, searching, clearance, filing, registration, and maintenance of the Collaboration Marks, and all expenses associated therewith shall be treated as Shared Commercialization Costs to the extent included in the
Commercialization Budget for the applicable Collaboration Product. Verve shall keep Beam reasonably advised of the status of the actual and prospective trademarks filings and, upon Beam’s request, shall provide advance copies of any substantive
papers related to the filing, prosecution and maintenance of such filings. All uses of the proposed major promotional activities using Collaboration Marks and, upon request of the JSC, other representative samples of proposed use of the
Collaboration Marks, shall be reviewed by the JSC prior to first public display and shall comply with all Applicable Laws (including, without limitation, those Applicable Laws and regulations particularly applying to the proper use and designation
of trademarks in the applicable countries of the Collaboration Territory). Verve shall own all Collaboration Marks (including associated goodwill) and copyrights created in connection with the marketing of the Products in the Collaboration
Territory. 

  
 65 

	 	(b)	 With respect to those Collaboration Products for which Beam exercises its right to Co-Promote in the Collaboration Territory as set forth in Article 5, each Party shall provide to the other notice of any infringement or challenge to the Collaboration Marks. Verve and Beam shall
thereafter consult and cooperate fully to determine a course of action, including but not limited to the commencement of legal action by either or both Verve and Beam. However, Verve, upon notice to Beam, shall have the first right to initiate and
prosecute such legal action at its own expense and in the name of Verve and, if requested by Verve, in the name of Beam or to control the defense of any challenge relating to the Collaboration Marks. Verve shall promptly inform Beam if it elects not
to exercise such first right and Beam shall, at its own expense, thereafter have the right to either initiate and prosecute such action or defend such action in the name of Beam and if requested by Beam in the name of Verve. Any recovery obtained by
either or both Verve and Beam in connection with or as a result of any action contemplated by this Section 13.6, whether by settlement or otherwise, shall be shared in order as follows: (i) the Party which initiated
and prosecuted the action shall recoup all of its costs and expenses incurred in connection with the action; (ii) the other Party shall then, to the extent possible, recover its costs and expenses incurred in connection with the action; and
(iii) the amount of any recovery remaining shall then be allocated equally between the Parties. In connection with any action, Verve and Beam will cooperate fully and will provide each other with any information or assistance that either may
reasonably request. Each Party shall keep the other informed of developments in any action or proceeding, including, to the extent permissible by Applicable Law, consultation on and approval of any settlement, the status of any settlement
negotiations and the terms of any offer related thereto. Each Party shall have the right to be represented by counsel of its own choice, at its expense. 

  

	 	13.6.2	 Use of Trademarks of the Other Party. Neither Party shall, without the other Party’s prior written
consent, use any trademarks or house marks of the other Party (including the other Party’s corporate name, and, in the case of Beam, any Collaboration Marks), or marks confusingly similar thereto, in connection with such Party’s marketing
or promotion of Products under this Agreement, except as expressly permitted pursuant to Section 2.3 or as may be expressly agreed to by the Parties and except to the extent required to comply with Applicable Laws.

 Article 14 INDEMNIFICATION 
  

	14.1	 General Indemnification by Beam. Beam shall indemnify and hold harmless Verve, its Affiliates and
their respective directors, officers, employees and agents (collectively, the “Verve Indemnified Parties”), from, against and in respect of any and all liabilities, losses, costs (including costs of investigation and defense),
damages, fines, penalties, government orders, taxes, expenses or amounts paid in settlement (in each case, including reasonable attorneys’ and experts fees and expenses), in each case to the extent resulting from any Action brought by a Third
Party (collectively, “Losses”), to the extent such Losses are incurred or suffered by the Verve Indemnified Parties or any of them as a result of, arising out of or directly or indirectly relating to: [**]. 

  
 66 

	14.2	 General Indemnification by Verve. Verve shall indemnify and hold harmless Beam, its
Affiliates and their respective directors, officers, employees and agents (collectively, the “Beam Indemnified Parties”), from, against and in respect of any and all Losses to the extent such Losses are incurred or suffered by the
Beam Indemnified Parties or any of them as a result of, arising out of or directly or indirectly relating to: [**]. 

  

	14.3	 Products Liability Claims. Notwithstanding anything express or implied to the contrary
herein, including Sections 14.1 and 14.2 hereof, in the event that there is a Third Party products liability claim for death, bodily injury or property damage suffered by such Third Party from or in connection with any Collaboration
Product, then the liability, claims, damage, loss, or expense (including reasonable attorneys’ fees) related to such claim against either Party shall be shared by the Parties in the following allocation: Verve shall bear [**] percent ([**]%)
and Beam shall bear [**] percent ([**]%) of such related liability, claims, damage, loss and expense; provided that in the event such death, bodily injury or property damage giving rise to a Third Party product liability claim is proximately caused
by the negligence or willful misconduct, violation of Applicable Law or breach of the terms and conditions of this Agreement by a Party, its Affiliates or their respective directors, officers, employees or agents, this
Section 14.3 shall not apply and Sections 14.1 and 14.2 will apply to the extent relevant. The Parties shall follow the procedures set forth in Section 14.4 and,
solely for purposes of determining the procedure for the defense of such claim, Verve shall be deemed to be the Indemnifying Party under Section 14.4. 

 

	14.4	 Claims for Indemnification. 

 

	 	14.4.1	 A Person entitled to indemnification under this Article 14 (an “Indemnified
Party”) shall give prompt written notification to the Party from whom indemnification is sought (the “Indemnifying Party”) of the commencement of any Third Party Action for which indemnification may be sought or, if
earlier, upon the assertion of any such Action by a Third Party (it being understood and agreed, however, that the failure by an Indemnified Party to give notice of a Third Party Action as provided in this Section 14.4.1
shall not relieve the Indemnifying Party of its indemnification obligation under this Agreement except and only to the extent that such Indemnifying Party is actually prejudiced as a result of such failure to give notice). 

 

	 	14.4.2	 Within [**] after delivery of such notification, the Indemnifying Party may, upon written notice thereof
to the Indemnified Party, assume control of the defense of such Action using counsel reasonably satisfactory to the Indemnified Party. If the Indemnifying Party does not assume control of such defense, the Indemnified Party shall control such
defense. 

  
 67 

	 	14.4.3	 The Party not controlling such defense may participate therein at its own expense; provided that
if the Indemnifying Party assumes control of such defense and the Indemnified Party reasonably concludes, based on advice from counsel, that the Indemnifying Party and the Indemnified Party have conflicting interests with respect to such action,
suit, proceeding or claim, the Indemnifying Party shall be responsible for the reasonable fees and expenses of counsel to the Indemnified Party solely in connection therewith; provided further, however, that in no event shall
the Indemnifying Party be responsible for the fees and expenses of more than one counsel in any one jurisdiction for all Indemnified Parties. 

  

	 	14.4.4	 The Party controlling such defense shall keep the other Party advised of the status of such action,
suit, proceeding or claim and the defense thereof and shall consider recommendations made by the other Party with respect thereto. 

  

	 	14.4.5	 The Indemnified Party shall not agree to any settlement of such action, suit, proceeding or claim
without the prior written consent of the Indemnifying Party, which shall not be unreasonably withheld. The Indemnifying Party shall not agree to any settlement of such action, suit, proceeding or claim or consent to any judgment in respect thereof
that does not include a complete and unconditional release of the Indemnified Party from all liability with respect thereto or that imposes any liability or obligation on the Indemnified Party without the prior written consent of the Indemnified
Party. 

  

	14.5	 Disclaimer of Liability. IN NO EVENT SHALL ANY PARTY OR ANY OF ITS RESPECTIVE AFFILIATES
BE LIABLE UNDER THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES SUFFERED BY BEAM, VERVE OR ANY OF THEIR RESPECTIVE AFFILIATES IN CONNECTION WITH THIS AGREEMENT WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT
LIABILITY OR OTHERWISE, INCLUDING LOSS OF PROFITS OR REVENUE; PROVIDED THAT THIS SECTION SHALL NOT RELIEVE EITHER PARTY FROM ITS INDEMNIFICATION OBLIGATIONS UNDER THIS AGREEMENT OR FROM ITS LIABILITY FOR ANY DAMAGES BASED UPON SUCH
PARTY’S BREACH OF ITS OBLIGATIONS UNDER ARTICLE 11, GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. 

 Article 15 TERM AND
TERMINATION 
  

	15.1	 Term. The term of this Agreement (the “Term”) will commence on the
Effective Date and extend, unless this Agreement is terminated earlier in accordance with this Article 15, until the last to expire of any Royalty Term for any Product or Delivery Technology Product in the Territory. Following
expiration of the Royalty Term for any Product or Delivery Technology Product in a given country, no further royalties will be payable in respect of sales of such Product or Delivery Technology Product, as applicable, in such country and, thereafter
the license granted to Beam under Section 2.1.3 or to Verve under Section 2.1.1 or 2.1.4 as applicable, with respect to such Product or Delivery Technology Product in such country will
automatically become fully paid-up, perpetual, irrevocable and royalty-free. 

  
 68 

	15.2	 At-Will Termination by Verve. Notwithstanding anything
contained herein to the contrary, Verve may terminate this Agreement as to any Licensed Product or Nuclease Product by ninety (90) days’ prior written notice to Beam at its sole discretion; provided that (a) with respect to a
Licensed Product or Nuclease Product, Verve may not submit a notice of termination under this Section 15.2 unless and until Beam has either (i) submitted a written notice to Verve under this Agreement that it does not
wish to exercise any Beam Opt-In Option with respect to such Product or (ii) not exercised the Beam Opt-In Option with respect to such Product in the relevant [**]
period set forth in Section 5.1 and no longer has the right to so exercise under this Agreement, and (b) Verve may not terminate this Agreement pursuant to this Section 15.2 with respect to
any Collaboration Product. 

  

	15.3	 Termination for Cause. This Agreement may be terminated at any time during the Term:

  

	 	15.3.1	 upon written notice by either Party if the other Party is in breach of its material obligations under
this Agreement and has not cured such breach within [**] after notice requesting cure of the breach; provided, however, in the event of a good faith dispute with respect to the existence of a material breach, the [**] cure period shall
be tolled until such time as the dispute is resolved pursuant to Section 16.7; provided that in the event such breached material obligation does not relate to the Delivery Technology or a Delivery Technology Product,
this Agreement will not be terminated under this Section 15.3.1 with respect to any rights or obligations related to Delivery Technology or a Delivery Technology Product; or 

 

	 	15.3.2	 by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or
receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; provided, however, that in the case of any involuntary bankruptcy proceeding such right to terminate shall only
become effective if the Party consents to the involuntary bankruptcy or such proceeding is not dismissed within [**] after the filing thereof. 

  

	15.4	 Termination for Patent Challenge. If the applicable Licensee or any of its Affiliates or
sublicensees directly or indirectly brings, assumes or participates in, or knowingly, willfully or recklessly assists in bringing a Patent Challenge, then the following shall apply: (a) in the case of Beam as the Licensor, Beam may terminate
this Agreement in its entirety immediately upon written notice to Verve; or (b) in the case of Verve as the Licensor, Verve may terminate the license granted to Beam pursuant to Section 2.1.3 immediately upon written
notice to Beam. For the avoidance of doubt, any participation by the Licensee, any of its Affiliates or sublicensees or its or their employees in any claim, challenge or proceeding that the Licensee, such Affiliates or sublicensees or such employees
are required to participate in pursuant to a subpoena or court order or participates in a proceeding that is initiated by a patent office and not at the instigation of the Licensee, such Affiliates or sublicensees or such employees shall not
constitute a Patent Challenge under this Section 15.4 and shall not give rise to Licensor’s right to terminate any license hereunder. Notwithstanding anything to the contrary in this Agreement but only to the extent
permitted by and consistent with the relevant Third Party Agreement (if any) under 

  
 69 

	 	
which the Challenged Patent Right is sublicensed to the Licensee, the Licensor shall not be entitled to exercise its termination rights pursuant to this Section 15.4
based upon any Patent Challenge by a sublicensee of the Licensee, if such Patent Challenge has been withdrawn or the Licensee has terminated such sublicense within [**] of the date on which the Licensor notifies the Licensee of its intent to
exercise its termination rights pursuant to this Section 15.4. 

  

	15.5	 Effects of Termination. 

 

	 	15.5.1	 General. As of the effective date of termination of this Agreement with respect to
a Product(s) or all Products in the case of termination of this Agreement in its entirety (each such Product, the “Terminated Product”), (a) all rights and licenses granted to Verve by Beam or its Affiliates under Article
2 will terminate with respect to the Terminated Product, (b) no later than [**] after the effective date of such termination, each Party shall return or cause to be returned to the other Party all Confidential Information in tangible
form received from the other Party and all copies thereof; provided, however, that each Party may retain one copy of Confidential Information received from the other Party in its confidential files for record purposes and, unless this
Agreement has been terminated by Verve under Section 15.3, Beam shall be permitted to maintain Confidential Information of Verve necessary or useful to exploit the Terminated Product(s) in accordance with its ongoing rights
and subject to the confidentiality and non-use obligations under this Agreement, and (c) except for the surviving provisions set forth in Section 15.6, the rights and obligations
of the Parties hereunder shall terminate as of the effective date of termination. 

  

	 	15.5.2	 Other Effects of Termination. Except for termination of this Agreement by Verve under
Section 15.3, 

  

	 	(a)	 Where permitted by Applicable Law, upon written request, Verve shall assign to Beam all of its right, title and
interest in and to, and transfer possession to Beam of, all Regulatory Documentation (including, for clarity, regulatory approvals) then in its name applicable to any Terminated Product other than (i) an Independent Product that is not a
Collaboration Product or (ii) a former Collaboration Product for which Beam exercised the Beam Opt-Out Option if Verve has terminated this Agreement within [**] following Beam’s exercise of such Beam
Opt-Out Option (such Terminated Product, other than as described in the foregoing clauses (i) and (ii), a “Terminated Reversion Product”), in the same form in which Verve maintains such
Regulatory Documentation, and upon request execute and deliver such additional documents or instruments reasonably necessary to effect such transfer, in each case at Beam’s cost and expense; 

 

	 	(b)	 Upon written request, Verve shall grant and hereby grants, and shall cause its Affiliates to grant, to Beam an
exclusive (even as to Verve and its Affiliates), perpetual, irrevocable, royalty-bearing (as set forth in and 

  
 70 

	 	
subject to this Section 15.5.2(b)) license under the Patent Rights and Know-How Controlled by Verve or its Affiliates as of the
effective date of termination that either (i) claim or cover the composition, use or manufacture of the applicable Terminated Reversion Product(s) or (ii) were otherwise used or practiced in the Development, Manufacture, Commercialization
or exploitation of the Terminated Reversion Product(s) on or prior to the effective date of termination (collectively, “Post-Termination Licensed Technology”), solely to Develop, Manufacture, Commercialize or otherwise exploit such
Terminated Reversion Product(s) in the Field in the Territory, provided, however, that in the case of any such Patent Right or Know-How that requires payment to a Third Party pursuant to an
applicable license or other agreement, such Patent Right or Know-How shall be [**] to such Third Party as a result of Beam’s exercise of such license. Unless Beam terminates this Agreement for
Verve’s material breach of this Agreement under Section 15.3.1 (in which case no royalties are owed), Beam will pay Verve royalties equal to [**] percent ([**]%) of the annual aggregate Net Sales resulting from the
sale of each such Terminated Reversion Product in the Field in the Territory and such royalties will be due to Verve, on a Product-by-Product and country-by-country basis for the duration of the Royalty Term for the applicable Terminated Reversion Product in the applicable country as if this Agreement had stayed in
effect. [**]. 

  

	 	(c)	 Unless expressly prohibited by any Regulatory Authority, upon written request of Beam, Verve shall transfer
control to Beam conduct of any Clinical Trials of such Terminated Reversion Product(s) being conducted as of the effective date of termination and continue to conduct such Clinical Trial(s) in accordance with a budget and plan agreed upon by the
Parties, at Beam’s cost and expense, for up to [**] to enable such transfer to be completed without interruption of such Clinical Trial(s); provided that Beam shall not have any obligation to continue any Clinical Trial unless required
by Applicable Law; 

  

	 	(d)	 To the extent that, as of the effective date of termination of this Agreement, Verve has existing and ongoing
contracts with Third Parties related to the Development, Manufacture or Commercialization of the Terminated Reversion Product(s), at the written request of Beam, Verve will use good faith commercially reasonable efforts to transfer such contracts
and arrangements to Beam, including using good faith commercially reasonable efforts to assign contracts and arrangements to Beam in part or facilitate separate arrangements with Beam if such contracts and arrangements relate to more than solely the
Terminated Reversion Product(s); 

  
 71 

	 	(e)	 At Beam’s written request, Verve shall deliver such quantities of the applicable Terminated Reversion
Product(s) that Verve or its Affiliates has in its respective inventory or control (including inventory in its control on the premises of a Third Party subcontractor) as of the date of Beam’s request; provided that Beam shall reimburse
Verve for the Cost of Goods Manufactured and the costs of shipping and handling with respect to such quantities; provided further that, with respect to a Collaboration Product, Beam shall only be obligated to reimburse Verve for any
portion of the costs thereof not previously reimbursed pursuant to this Agreement. 

  

	 	(f)	 If Beam does not manufacture the applicable Terminated Reversion Product(s) either itself or on its behalf,
Verve shall supply to Beam such reasonable quantities of such Terminated Reversion Product(s) as Beam indicates in written forecasts and orders from time to time, until the earlier of (i) such time as Beam has established an alternative,
validated source of supply for such Terminated Reversion Product(s) and (ii) the [**] of the effective date of termination of this Agreement. The costs to Beam for supply of such Terminated Reversion Product(s) from Verve shall be equal to
Verve’s Cost of Goods Manufactured for such Terminated Reversion Product(s) [**]. Notwithstanding anything to the contrary in this Agreement, if any such Terminated Reversion Product is manufactured for Verve by a Third Party contract
manufacturer pursuant to a written contract, then Verve may satisfy its obligations pursuant to this Section 15.5.2(f) with respect to such Terminated Reversion Product by assigning its rights and obligations under such
contract (or the portion of such contract pertaining to such Terminated Reversion Product) to Beam. 

  

	 	(g)	 Verve shall, at the written request and expense of Beam, provide Beam with such assistance as is reasonably
necessary to effectuate a smooth and orderly transition to Beam or its designee of any Development, Manufacture and Commercialization activities relating to the applicable Terminated Reversion Product(s) so as to minimize the disruption of such
activities, provided, however, that Verve shall not be obligated to initiate any new substantive activity, distinct from any previously ongoing substantive activity, that would itself create any new obligations on the part of Verve that would
continue following such termination. Further, upon Beam’s written request, Verve shall make its personnel reasonably available to provide such technical assistance, at no cost to Beam (except for reimbursement of Verve’s direct out of
pocket costs therefor), as may reasonably be requested to transfer all Manufacturing technology Controlled by Verve or its Affiliates that is or had been used by or on behalf of Verve and its Affiliates in connection with the Manufacture of any
Terminated Reversion Product. 

  

	 	15.5.3	 Termination for Bankruptcy. If this Agreement is terminated by either Party pursuant to
Section 15.3.2, all licenses and rights to licenses granted under or pursuant to this Agreement by the non-terminating Party to the terminating Party are, and shall otherwise be
deemed to be, for purposes of Section 365(n) of the 

  
 72 

	 	
United States Bankruptcy Code (the “Code”), licenses of rights to “intellectual property” as defined under Section 101(35A) of the Code. The Parties agree that the
terminating Party, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Code, and that upon commencement of a bankruptcy proceeding by or against the non-terminating Party under the Code, the terminating party shall be entitled to a complete duplicate of or complete access to, any such intellectual property and all embodiments of such intellectual property. Such
intellectual property and all embodiments thereof shall be promptly delivered to the terminating Party (i) upon any such commencement of a bankruptcy proceeding upon written request therefor by the terminating Party, unless the non-terminating Party elects to continue to perform all of its obligations under this Agreement or (ii) if not delivered under (i) above, upon the rejection of this Agreement by or on behalf of the non-terminating Party upon written request therefor by the terminating Party. The foregoing provisions of Section 15.5.3 are without prejudice to any rights that either Party may have
arising under the Code or other Applicable Law. 

  

	15.6	 Effect of Termination; Survival. Termination of this Agreement shall not relieve the Parties of
any obligation accruing upon or prior to such termination. Any termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement upon or prior to termination, including
without limitation (a) obligations to pay any license fees or milestones that accrue under this Agreement upon or prior to termination and (b) the obligation to share Shared Costs incurred prior to such termination in accordance with this
Agreement, and to share the Collaboration Territory Revenue from Products sold prior to such termination, in the case of both clause (a) and (b) above, in accordance with the provisions of Article 10. The provisions of
Article 11 shall survive the termination of this Agreement and shall continue in effect for [**] following such termination. In addition, the provisions of Section 2.2.4,
Section 2.2.5(c), Section 2.6.3 (Unauthorized Use of Party Materials), Section 2.6.4 (Title to Party Materials; Return), Section 10.6 (Currency
Exchange) (solely with respect to Terminated Reversion Products), Section 10.7 (Record-Keeping and Audit), Section 10.8 (Income Tax Withholding) (solely with respect to Terminated Reversion
Products and payment obligations accrued under this Agreement upon or prior to termination), Section 10.9 (Late Payments) (solely with respect to Terminated Reversion Products and payment obligations accrued under this
Agreement upon or prior to termination), Section 13.1 (Ownership of Intellectual Property), Section 13.2.4, Section 13.3 (Enforcement and Defense of Beam Patent Rights)
(solely with respect to Joint Collaboration Patent Rights), Section 13.4 (Enforcement and Defense of Verve Patent Rights, Product-Specific Patent Rights or Joint Collaboration Patent Rights) (solely with respect to Joint
Collaboration Patent Rights), Article 14 (Indemnification), Section 15.5 (Effects of Termination), this Section 15.6 (Effect of Termination; Survival), and
Article 16 (Miscellaneous) shall each survive termination of this Agreement in its entirety and all definitions relating to the foregoing, shall survive any termination of this Agreement. 

  
 73 

 Article 16 MISCELLANEOUS 
  

	16.1	 Use of Affiliates. Either Party shall have the right to exercise its rights and perform its
obligations under this Agreement either itself or through any of its Affiliates. In addition, in each case where a Party’s Affiliate has an obligation pursuant to this Agreement or performs an obligation pursuant to this Agreement,
(a) such Party shall cause and compel such Affiliate to perform such obligation and comply with the terms of this Agreement and (b) any breach of the terms or conditions of this Agreement by such Affiliate shall be deemed a breach by such
Party of such terms or conditions, for which such Party is liable. 

  

	16.2	 Interpretation. Except where the context expressly requires otherwise, (a) the use of any
gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b) the words “include”, “includes” and
“including” shall be deemed to be followed by the phrase “without limitation”, (c) the word “will” shall be construed to have the same meaning and effect as the word “shall”, (d) any definition of or
reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such
amendments, supplements or modifications set forth herein), (e) any reference herein to any person shall be construed to include the person’s successors and assigns, (f) the words “herein”, “hereof” and
“hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections or Schedules shall be construed to refer to
Sections or Schedules of this Agreement, and references to this Agreement include all Schedules hereto, (h) the word “notice” means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals
and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder “agree,” “consent” or “approve” or the like shall require that
such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (j) references to any specific
law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, and (k) the term “or” shall be
interpreted in the inclusive sense commonly associated with the term “and/or.” 

  

	16.3	 Force Majeure. Neither Party shall be held liable to the other Party nor be deemed to have
defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party or any of
its Affiliates, potentially including, but not limited to, embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other
acts of God, or acts, omissions or delays in acting by any Governmental Authority or the other Party. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake
all reasonable efforts necessary to resume performance. 

  
 74 

	16.4	 Assignment. Except as provided in this Section 16.4 and
Section 2.2.3, this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the consent of the other Party; provided,
however, that (a) Verve or Beam may, without such consent, assign this Agreement and its rights and obligations hereunder to an Affiliate, in whole or in part and (b) any Party may assign this Agreement and its rights and
obligations hereunder, in whole or in part, in connection with the transfer or sale of all or substantially all of its assets related to the subject matter of this Agreement, or in the event of its merger or consolidation or change in control or
similar transaction. Any attempted assignment not in accordance with this Section 16.4 shall be void and unenforceable. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement.

  

	16.5	 Severability. If any one or more of the provisions contained in this Agreement is held invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely
affects the substantive rights of the Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical,
implement the purposes of this Agreement. 

  

	16.6	 Notices. All notices which are required or permitted pursuant to this Agreement shall be in
writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified
mail, postage prepaid, return receipt requested, addressed as follows: 

  

			
	If to Beam:	  	 Beam Therapeutics Inc.
 26 Landsdowne Street

Cambridge, MA 02139
 Email: [**]

Attn: CEO

		
	With a copy to:	  	 Ropes & Gray LLP
 Prudential Tower

800 Boylston Street
 Boston, MA 02199

Telephone: [**]
 Facsimile: [**]

E-mail: [**]
 Attn: Marc
A. Rubenstein

		
	If to Verve:	  	 Verve Therapeutics, Inc.
 26 Landsdowne
Street
 Cambridge, MA 02139

E-mail: [**]
 Attn:
President

  
 75 

			
		
	With a copy to:	  	 Wilson Sonsini Goodrich & Rosati
 650
Page Mill Road
 Palo Alto, CA 94304
 Telephone: [**]

Facsimile: [**]
 E-mail:
[**]
 Attn: Lowell A. Segal

 or to such other address(es) as the Party to whom notice is to be given may have furnished to the other
Party in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered if personally delivered or sent by facsimile on a Business Day (or if delivered or sent on a
non-Business Day, then on the next Business Day); (b) on the Business Day after dispatch if sent by nationally-recognized overnight courier; or (c) on the fifth (5th) Business Day following the date of
mailing, if sent by mail. 
  

	16.7	 Dispute Resolution. If any dispute between the Parties arises out of or relates to this
Agreement, other than a dispute within the JSC to be resolved as set forth in Section 3.3.3, (a “Dispute”), either Party by written notice to the other Party may have such issue referred for resolution to
the Senior Officers. The Senior Officers shall meet promptly to discuss the matter submitted and to determine a resolution. If the Senior Officers are unable to resolve the Dispute within [**] after it is referred to them, then the Parties may
pursue all other rights and remedies available to them under this Agreement, including the right to terminate this Agreement, and the matter shall, upon written notice of either Party to the other Party, be resolved by final, binding arbitration in
accordance with Section 16.8. 

  

	16.8	 Governing Law and Arbitration. This Agreement will be governed by, and construed in
accordance with, the substantive laws of the Commonwealth of Massachusetts and the patent laws of the United States, in each case without giving effect to any choice or conflict of law provision. Any arbitration of a Dispute shall be conducted by
the American Arbitration Association (“AAA”) under its rules of arbitration then in effect, except as modified in this Agreement. The arbitration shall be conducted in the English language, by a single arbitrator. If the Parties are
unable to agree on an arbitrator, the arbitrator shall be selected in accordance with the AAA rules, or if the AAA rules do not provide for such selection, by the chief executive of AAA. At either Party’s election, the arbitrator shall engage
an independent expert with experience in the subject matter of the Dispute to advise the arbitrator, but final decision making authority shall remain in the arbitrator. The arbitrator shall determine what discovery will be permitted, consistent with
the goal of reasonably controlling the cost and time that the Parties must expend for discovery, provided that the arbitrator shall permit such discovery as he or she deems necessary to permit an equitable resolution of the Dispute. The Parties and
the arbitrator shall use reasonable efforts to complete any such arbitration within [**]. The Parties agree that the decision of the arbitrator shall be the binding remedy between them regarding the Dispute presented to the arbitrator, and judgment
upon the award rendered by the arbitrator may be entered in any court of competent jurisdiction. Unless otherwise agreed by the Parties, the arbitration proceedings shall be conducted in Boston, Massachusetts. The Parties shall

  
 76 

	 	
share equally the cost of the arbitration filing and hearing fees, the cost of an independent expert retained by the arbitrator and the cost of the arbitrator and administrative fees of AAA. Each
Party shall bear its own costs and attorneys’ and witnesses’ fees and associated costs and expenses. Each Party agrees not to commence any legal proceedings based upon or arising out of this Agreement in a court of law, except that a Party
may seek a temporary restraining order or a preliminary injunction from any court of competent jurisdiction in order to prevent immediate and irreparable injury, loss or damage on a provisional basis, pending the selection of the arbitrator or
pending the arbitrator’s determination of the merits of any Dispute pursuant to this Section 16.8. 

  

	16.9	 Entire Agreement; Amendments. This Agreement, together with the Schedules hereto, contains the
entire understanding of the Parties with respect to the subject matter hereof. Any other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, in respect to the subject matter hereof are
superseded by the terms of this Agreement, including (a) the Existing Confidentiality Agreement; provided that nothing in this Section 16.9 shall affect a Party’s ability to enforce the terms of the
Existing Confidentiality Agreement with respect to the subject matter hereof for actions or omissions taking place prior to the Effective Date, and (b) the Material Transfer Agreement. The Schedules to this Agreement are incorporated herein by
reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of each of the Parties. 

 

	16.10	 Headings. The captions to the several Articles, Sections and subsections hereof are not a part of
this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof. 

  

	16.11	 Independent Contractors. It is expressly agreed that Beam and Verve shall be independent
contractors and that the relationship between the Parties shall not constitute a partnership, joint venture or agency, provided, in the event Beam exercises any Beam Opt-In Option, the Parties shall confer and
determine by mutual written agreement whether the Parties have entered into a partnership solely for U.S. income tax purposes. Neither Beam nor Verve shall have the authority to make any statements, representations or commitments of any kind, or to
take any action, which shall be binding on the other Party, without the prior written consent of the other Party. 

  

	16.12	 Waiver. The waiver by either Party of any right hereunder, or of any failure of the other Party
to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party whether of a similar nature or otherwise. 

 

	16.13	 Cumulative Remedies. Except as expressly set forth in this Agreement, no remedy referred to in
this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under Applicable Law. 

  
 77 

	16.14	 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in
connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

 

	16.15	 Business Day Requirements. In the event that any notice or other action or omission is required
to be taken by a Party under this Agreement on a day that is not a Business Day then such notice or other action or omission shall be deemed to be required to be taken on the next occurring Business Day. 

 

	16.16	 Counterparts. This Agreement may be signed in any number of counterparts (facsimile and
electronic transmission included), each of which shall be deemed an original, but all of which shall constitute one and the same instrument. After facsimile or electronic transmission, the parties agree to execute and exchange documents with
original signatures upon written request by either Party. Counterpart signatures delivered via facsimile or e-mail in PDF or similar electronic format shall have the same binding effect as original signatures.

 [Signature page follows] 

  
 78 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date. 

 

									
	VERVE THERAPEUTICS, INC.	 		 	BEAM THERAPEUTICS INC.
					
	BY:	 	/s/ Andrew Ashe	 		 	BY:	 	/s/ John Evans
	NAME:	 	Andrew Ashe	 		 	NAME:	 	John Evans
	TITLE:	 	President and Chief Operating Officer	 		 	TITLE:	 	Chief Executive Officer

 [Signature Page to Collaboration and License Agreement]EX-10.11

 Exhibit 10.11 

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of
information that the registrant treats as private or confidential. Double asterisks denote omissions. 
 AMENDED AND RESTATED 

Development and Option Agreement 

by and between 

ACUITAS THERAPEUTICS, INC. 

and 

VERVE THERAPEUTICS, INC. 

dated 
 October 6,
2020 
  

 Table of Contents 

 

							
	 	  	Page	 
	ARTICLE 1 DEFINITIONS	  	 	1	 
		
	ARTICLE 2 GOVERNANCE	  	 	9	 
			
	 2.1
	 	Management	  	 	9	 
			
	 2.2
	 	Joint Development Committee	  	 	9	 
		
	ARTICLE 3 THE PROGRAM	  	 	10	 
			
	 3.1
	 	Program Generally	  	 	10	 
			
	 3.2
	 	FTEs	  	 	14	 
			
	 3.3
	 	Program Records, Reports and Materials	  	 	14	 
			
	 3.4
	 	Permitted Subcontracting	  	 	16	 
			
	 3.5
	 	Program Licenses	  	 	16	 
		
	 ARTICLE 4 RESERVED TARGETS
	  	 	16	 
			
	 4.1
	 	Generally	  	 	16	 
			
	 4.2
	 	Reserved Target List, Restricted Target List and Target Notices	  	 	17	 
			
	 4.3
	 	Expiration of Pre-Existing Restrictions.	  	 	18	 
			
	 4.4
	 	Fees	  	 	19	 
		
	ARTICLE 5 VERVE LICENSE OPTIONS	  	 	19	 
			
	 5.1
	 	Option	  	 	19	 
			
	 5.2
	 	Verve’s Exercise of Option	  	 	20	 
		
	ARTICLE 6 OWNERSHIP OF PROGRAM TECHNOLOGY	  	 	21	 
			
	 6.1
	 	Disclosure of LNP Know-How	  	 	21	 
			
	 6.2
	 	Ownership	  	 	21	 
			
	 6.3
	 	Assignment	  	 	21	 
			
	 6.4
	 	Prosecution and Maintenance	  	 	22	 
			
	 6.5
	 	Patent Enforcement and Defense	  	 	22	 
		
	ARTICLE 7 CONFIDENTIALITY	  	 	22	 
			
	 7.1
	 	Confidential Information	  	 	22	 
			
	 7.2
	 	Restrictions	  	 	23	 
			
	 7.3
	 	Exceptions	  	 	23	 
			
	 7.4
	 	Permitted Disclosures	  	 	23	 

  
 i 

 Table of Contents 

 

							
	 	  	Page	 
	 7.5
	 	Return of Confidential Information	  	 	24	 
			
	 7.6
	 	Publications	  	 	24	 
			
	 7.7
	 	Patents	  	 	25	 
			
	 7.8
	 	Terms of this Agreement; Publicity	  	 	25	 
		
	ARTICLE 8 WARRANTIES; COVENANTS; LIMITATIONS OF LIABILITY; INDEMNIFICATION	  	 	25	 
			
	 8.1
	 	Representations and Warranties	  	 	25	 
			
	 8.2
	 	Additional Representations and Warranties of Acuitas	  	 	26	 
			
	 8.3
	 	Disclaimers	  	 	27	 
			
	 8.4
	 	No Consequential Damages	  	 	27	 
			
	 8.5
	 	Performance by Others	  	 	27	 
			
	 8.6
	 	Indemnification	  	 	27	 
			
	 8.7
	 	Insurance	  	 	30	 
		
	ARTICLE 9 TERM AND TERMINATION	  	 	30	 
			
	 9.1
	 	Term	  	 	30	 
			
	 9.2
	 	Termination by Verve	  	 	30	 
			
	 9.3
	 	Termination by Acuitas	  	 	31	 
			
	 9.4
	 	Termination Upon Bankruptcy	  	 	31	 
			
	 9.5
	 	Effects of Termination	  	 	32	 
			
	 9.6
	 	Survival	  	 	32	 
		
	ARTICLE 10 MISCELLANEOUS	  	 	33	 
			
	 10.1
	 	Dispute Resolution	  	 	33	 
			
	 10.2
	 	Invoices and Payments	  	 	33	 
			
	 10.3
	 	Relationship of Parties	  	 	34	 
			
	 10.4
	 	Compliance with Law	  	 	34	 
			
	 10.5
	 	Governing Law	  	 	34	 
			
	 10.6
	 	Counterparts; Facsimiles	  	 	34	 
			
	 10.7
	 	Headings	  	 	34	 
			
	 10.8
	 	Further Assurances	  	 	34	 
			
	 10.9
	 	Binding Effect	  	 	35	 

  
 ii 

 Table of Contents 

 

							
	 	  	Page	 
	 10.10
	 	Assignment	  	 	35	 
			
	 10.11
	 	Notices	  	 	35	 
			
	 10.12
	 	Amendment and Waiver	  	 	36	 
			
	 10.13
	 	Severability	  	 	36	 
			
	 10.14
	 	Entire Agreement	  	 	36	 
			
	 10.15
	 	Force Majeure	  	 	36	 

 List of Exhibits 
  

			
		
	Exhibit 1.1	  	Patents in the Acuitas Background Technology
		
	Exhibit 1.48	  	Form of Non-Exclusive License Agreement
		
	Exhibit 3.1(a)	  	Initial Workplan
		
	Exhibit 4.2	  	Form of Target Notice
		
	Appendix 1.15	  	Pre-approved Contract Manufacturing Organizations (CMOs)

  
 iii 

 Amended and Restated Development and Option Agreement 

This Amended and Restated Development and Option Agreement (this “Agreement”), dated as of October 5, 2020 (the
“Amendment Effective Date”), is made by and between Verve Therapeutics, Inc. a Delaware corporation (“Verve”) and Acuitas Therapeutics Inc., a British Columbia corporation (“Acuitas”). Each of Verve
and Acuitas may be referred to herein as a “Party” or together as the “Parties.” 
 WHEREAS,
Acuitas has expertise and intellectual property relating to the development of LNP Technologies (as defined below); 
 WHEREAS, Verve
has expertise and intellectual property relating to gene editing therapeutics, including mRNA Constructs (as defined below) and Genome Editing Constructs (as defined below); and 

WHEREAS, the Parties believe that certain proprietary Acuitas LNP Technology (as defined below) could be useful for the formulation and
delivery of Verve’s proprietary Genome Editing Constructs; and 
 WHEREAS, Verve and Acuitas previously entered into a
Development and Option Agreement (the “Original Agreement”), dated effective as of December 11, 2019 (the “Effective Date”), under which the Parties began a collaboration to evaluate the development of products incorporating
Acuitas LNP Technology and Verve Technology (as defined below); and 
 WHEREAS, Verve and Acuitas wish to amend and restate the
Original Agreement as set forth herein. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other
good and valuable consideration, the amount and sufficiency of which are hereby acknowledged, the Parties hereby agree that, from and after the Amendment Effective Date hereof, the Original Agreement is hereby amended and restated as follows: 

ARTICLE 1 

Definitions 
 The following terms
and their correlatives will have the following meanings: 
 1.1 “Acuitas Background Technology” means any and
all proprietary LNP Technology that is owned or Controlled by Acuitas (a) as of the Effective Date, or (b) developed by Acuitas outside of the scope of this Agreement, and in each case necessary or useful for the conduct of the Workplan
and/or the research, development, manufacturing and commercialization of Licensed Products. The Patents in the Acuitas Background Technology as of the Effective Date are listed in Exhibit 1.1 attached hereto. 

1.2 “Acuitas Indemnitees” has the meaning set forth in Section 8.6(b). 

  
 1 

 1.3 “Acuitas LNP Technology” means the Acuitas Background Technology
and the Acuitas Sole Technology. For the avoidance of doubt, any LNP or component thereof that is proprietary to Acuitas and provided by or on behalf of Acuitas to Verve shall be Acuitas Background Technology and, therefore, Acuitas LNP Technology
under this Agreement. 
 1.4 “Acuitas Sole Technology” means, without regard to inventorship, all Technology (other
than Workplan Data) that arises from the Workplan that is solely an Improvement of Acuitas Background Technology and does not incorporate or consist of an Improvement to the Verve Background Technology. For clarity, any Technology arising out of the
Workplan that (a) is an Improvement of Acuitas Background Technology and (b) specifically relates to any mRNA Construct or Guide RNA provided or used by Verve under the Workplan is Joint IP and not Acuitas Sole Technology. 

1.5 “Acuitas Workplan Leader” has the meaning set forth in Section 2.1. 

1.6 “Affiliate” of a person or entity means any other person or entity which (directly or indirectly) is controlled by,
controls or is under common control with such person or entity. For the purposes of this definition, the term “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”)
as used with respect to an entity will mean (a) in the case of a corporate entity, direct or indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors or (b) in the
case of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%) of the equity interests with the power to direct the management and policies of such entity, provided
that if local Law restricts foreign ownership, control will be established by direct or indirect ownership of the maximum ownership percentage that may, under such local Law, be owned by foreign interests. 

1.7 “Agreement” has the meaning set forth in the Preamble. 

1.8 “Amendment Effective Date” has the meaning set forth in the Preamble. 

1.9 “Calendar Quarter” means the respective periods of three (3) consecutive calendar months ending on
March 31, June 30, September 30 and December 31. 
 1.10 “Collaboration Partner” means with respect to
any Third Party to whom Verve wishes to disclose Acuitas Confidential Information or transfer Acuitas LNP Technology or Materials provided by Acuitas to Verve, any Third-Party licensee or assignee of Verve Technology subject to requirements of
Section 3.1(h). 
 1.11 “Concurrent Reserved List Limits” has the meaning set forth in Section 4.2(e). 

1.12 “Confidential Information” has the meaning set forth in Section 7.1. 

1.13 “Contract Research Organization” means an entity in the business of providing specialized research, development
and manufacturing services on a fee for service basis pursuant to agreements that include terms that provide that all data, materials and intellectual property generated in performing such services be owned by the contracting party in accordance
with Section 3.1(i), excluding improvements to such entity’s Technology that is used to perform such services. 

  
 2 

 1.14 “Contract Year” will refer to the twelve (12)-month period
beginning on the Effective Date and on each anniversary thereafter during the Term. 
 1.15 “Control” or
“Controlled” means, with respect to a particular Technology, Acuitas owns or has a license to use and practice such Technology and has the right to grant a license or sublicense to such Technology without violating the terms of any
agreement with any Third Party and without owing any milestone, royalty or other monetary obligations to a Third Party under the terms of any agreement with such Third Party. 

1.16 “Deficiency” means the existence of any of the following factors, to the extent supported by reasonable and
verifiable documentation or other supporting evidence: (i) a significant failure to adhere to internationally accepted standards of quality and safety in the manufacture of pharmaceutical or biologic products as documented by a regulatory
authority with jurisdiction over pharmaceutical manufacturing, as the same are relevant to the stage of development and certification of the products to be manufactured; (ii) less than [**] of experience in manufacturing pharmaceutical or
biological products; or (iii) a significant history of violating confidentiality or intellectual property rights or (iv) a party who is a direct competitor of Acuitas in the field of LNP Technology. For clarity, no factor that is not
listed in (i), (ii), (iii) or (iv) above will be considered in determining the existence of a Deficiency. A listing of pre-approved CMOs (definition of CMO as in Section 3.1(f)) is provided in
Appendix 1.15. 
 1.17 “Diligent Efforts” means, with respect to the efforts to be expended by each Party with
respect to any activity set forth in the Workplan, active and sustained efforts to conduct the applicable activity, or to attempt to achieve the applicable requirement or goal, in a prompt and expeditious manner, as is reasonably practicable under
the circumstances consistent with the Workplan (including the level of FTE funding and budget for out-of-pocket and Third Party contractors set forth therein) and the
terms of this Agreement. 
 1.18 “Disclosing Party” has the meaning set forth in Section 7.1. 

1.19 “Effective Date” has the meaning set forth in the Preamble. 

1.20 “Escrow Agent” means the Third-Party escrow agent designated by Acuitas and reasonably acceptable to Verve, which
escrow agent shall initially be [**]. 
 1.21 “Executive Officers” has the meaning set forth in Section 2.2(d).

 1.22 “Field of Use” means Genome Editing for all human therapeutic or prophylactic uses of Licensed Products. 

1.23 “Formulated Product” means product produced by Acuitas in accordance with the Workplan that incorporates Verve
Genome Editing Constructs formulated with Acuitas LNP Technology. 
 1.24 “Formulated Product Fee” means the fees to
be charged by Acuitas for supply of Formulated Product to Verve under this Agreement, which fees are set forth in the Workplan and will include FTE Costs and Third-Party costs for materials used in the Formulated Product or its manufacture. 

  
 3 

 1.25 “FTE” means the work of a full-time person for one year, or
more than one person working the equivalent of a full-time person for one year, where “full-time” is determined by the standard practices in the biopharmaceutical industry in the geographic area in which such personnel are working, but
means [**] hours per year, in the performance of the Works and Services, including scientific management oversight as reasonably required. 

1.26 “FTE Costs” mean the actual FTEs employed by Acuitas in the conduct of the Works and Services multiplied by an
annual rate per FTE equal to [**] Dollars (US$[**]). Such FTE Costs represent reimbursement for all costs of FTEs in providing the Works and Services (including salaries, benefits, lab supplies, reagents, equipment and overhead, as well as
other G&A costs). 
 1.27 “Genome Edit(ing)” means to correct, modify, insert, delete, inactivate or repair the
expression of a Human Genome Target for human therapeutic or prophylactic applications. 
 1.28 “Genome Editing
Construct” means a construct consisting of [**] mRNA Constructs that each encode a [**] to Genome Edit up to [**] Human Genome Targets. For the avoidance of doubt, each Genome Editing Construct (i) may, but shall not be required to,
contain Guide RNAs (whether or not formulated with Acuitas LNP Technology) in any combination or combinations and (ii) will be defined by the specific combination of [**] and each different combination of the foregoing will be a different
Genome Editing Construct (provided that each Genome Editing Construct may contain [**]. 
 1.29 “Genome Editing Protein
Target” means a Protein Target that is intended to Genome Edit a Human Genome Target. 
 1.30 “GMP”
means current good manufacture practices as defined under regulations promulgated by the U.S. Food and Drug Administration. 
 1.31
“Guide RNA” means one or more synthetic, short ribonucleic acid sequences composed of a scaffold sequence that binds to the Genome Editing Protein Target and a sequence complementary to the site on the Human Genome at which the
Genome Editing Protein Target is intended to Genome Edit. 
 1.32 “Human Genome Target” means (a) a naturally
occurring human gene, including all coding, non-coding and regulatory regions thereof, as identified by the applicable transcript identifier (i.e., NCBI Refseq transcript ID), gene identifier (i.e., NCBI
Refseq Gene ID), gene name and synonyms and nucleotide sequence coordinates, gene transcript and nucleotide sequence; (b) any naturally occurring non-coding region of the human genome including, but not
limited to, transcriptional regulatory elements, non-protein coding RNA and intergenic regions; and with respect to a gene covered by (a) or (b) above, any variants of such gene, including the wild
type and naturally occurring mutant and allelic variants, provided, however, that any such variant (i) encodes a protein [**] to the protein product of the original (reference) gene and has a coding region with greater than [**]
percent ([**]%) sequence identity to the coding region of the original (reference) gene. For clarity, a nucleotide sequence may be considered to encode a protein regardless of whether such sequence contains a start codon. 

  
 4 

 1.33 “Improvement” means, with respect to the Acuitas Background
Technology or the Verve Background Technology, as applicable, any improvement, enhancement, change, modification, variation or derivative of such Technology. 

1.34 “Indemnification Claim Notice” has the meaning set forth in Section 8.6(c). 

1.35 “Indemnified Party” has the meaning set forth in Section 8.6(c). 

1.36 “Insolvency Legislation” has the meaning set forth in Section 10.1(a). 

1.37 “JDC” has the meaning set forth in Section 2.2(a). 

1.38 “JDC Deadlock” has the meaning set forth in Section 2.2(d). 

1.39 “Joint IP” means, without regard to inventorship, each of the following: (a) Technology that arises out of
the Workplan that relates to, constitutes an Improvement to and/or incorporates both the Acuitas Background Technology and the Verve Background Technology, (b) any other Technology that arises out of the Workplan that in each case does not
constitute either Acuitas Sole Technology or Verve Sole Technology and (c) the Workplan Data. 
 1.40 “Know-How” means all Materials and all confidential and proprietary information including commercial, technical, scientific and other know-how and information, trade
secrets, knowledge, technology, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, specifications, data and
results (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, preclinical, clinical, safety, manufacturing and quality control data and know-how, including
study designs and protocols, in all cases, provided such information is confidential and proprietary, and regardless of whether patentable, in written, electronic or any other form now known or hereafter developed. 

1.41 “Law” or “Laws” means all laws, statutes, rules, regulations, orders, judgments or ordinances
having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision. 
 1.42
“Licensed Product” means any product that (a) consists of up to [**] Genome Editing Constructs that encode [**] specified Genome Editing Protein Targets including up to [**] Guide RNAs intended to Genome Edit up to [**]
Human Genome Targets and (b) is derived from, incorporates, or utilizes, any LNP Technology that is Controlled by Acuitas or its Affiliates as of the Effective Date or at any time during the Term. For clarity, each Licensed Product will consist
of a specific combination of Genome Editing Constructs ([**]) that target either [**] Human Genome Target or [**] Human Genome Targets. 

1.43 “Licensed Technology” means LNP Technology Controlled by Acuitas or its Affiliates, as of the Effective Date or
generated or obtained during the Term (including the Acuitas Background Technology, Acuitas Sole Technology and Acuitas’ interest in any Joint IP) necessary or useful for the research, development, manufacture, use or sale of a Licensed
Product. 
 1.44 “LNP” means lipid nanoparticles. 

  
 5 

 1.45 “LNP Technology” means any Technology that claims, embodies or
incorporates delivery systems (and components thereof) based on or incorporating LNPs. 
 1.46 “Losses” has the
meaning set forth in Section 8.6(a). 
 1.47 “Materials” means any tangible chemical or biological material,
including any compounds, LNP, DNA, RNA (including mRNA), clones, cells, and any expression product, progeny, derivative or other improvement thereto, along with any tangible chemical or biological material embodying any Know-How. 
 1.48 “mRNA Construct” means any mRNA that encodes a Genome Editing
Protein Target and any associated non-coding sequences, including any cap sequence, 5’ UTR, 3’UTR, and any polyadenylation sequences. The term “mRNA Construct” also includes the chemistry
of natural and non-natural nucleic acids, and other chemical modifications associated with such mRNA and associated non-coding sequences. 

1.49 “Non-Exclusive License Agreement” means a
non-exclusive license agreement in the form attached hereto as Exhibit 1.48. 

1.50 “Option” has the meaning set forth in Section 5.1. 

1.51 “Option Exercise Fee” means Two Million Dollars (US$2,000,000). 

1.52 “Option Limit” has the meaning set forth in Section 5.1(c). 

1.53 “Option Notice” has the meaning set forth in Section 5.2(a). 

1.54 “Party” and “Parties” have the meaning set forth in the Preamble. 

1.55 “Patent(s)” means an (a) issued patent, a patent application and a future patent issued from any such patent
application, (b) a future patent issued from a patent application filed in any country worldwide which claims priority from a patent or patent application included in (a), (c) any additions, divisions, continuations, continuations-in-part, invention certificates, substitutions, reissues, reexaminations, extensions, registrations, utility models, supplementary protection certificates and
renewals based on any patent or patent application under (a) or (b), but not including any rights that give rise to regulatory exclusivity periods (other than supplementary protection certificates, which will be treated as “Patents”
hereunder), and (d) any counterpart of any patent or patent application under (a), (b) or (c) filed in any country worldwide. 

1.56 “Pre-Existing Restrictions” means, with respect to a particular Target as
of the date of the applicable Target Notice, that (a) Acuitas or its Affiliates are precluded from granting Verve a non-exclusive license under the Acuitas LNP Technology (as set forth in this Agreement)
due to a conflicting grant of rights (or an outstanding option to obtain such a grant of rights) or covenant to a Third Party with respect to such Target pursuant to a bona fide written agreement that is executed in good faith in the ordinary
course of business prior to the date of the Target Notice for such Target that is still in effect on such date or (b) such Target has been internally reserved by Acuitas. 

  
 6 

 1.57 “Program” means the program of activities using Acuitas LNP
Technology and Verve Genome Editing Technology for the development of Licensed Products incorporating Verve’s Genome Editing Constructs that the Parties engage in under this Agreement pursuant to the Workplan. 

1.58 “Protein Target” means either (a) any naturally occurring protein encoded by a specific gene locus, as
identified by the applicable transcript identifier (i.e., NCBI Refseq transcript ID), gene identifier (i.e., NCBI Refseq Gene ID), gene name and synonyms and DNA sequence coordinates and the applicable amino acid sequence, together with all variants
of such protein, including the wild type, naturally occurring variants, engineered variants wherein modifications to the native amino acid sequence have been introduced (for example, mutated versions, derivatives or fragments), and species homologs
and orthologs thereof, provided however that any such naturally occurring variant, engineered variant, or species homolog or ortholog possesses substantially similar mechanism of action and biological activity to the naturally
occurring human protein (for example immunogenicity in case of antigens); or (b) any protein that is not covered by subclause (a) above (together with any variants, mutated versions, derivatives or fragments of such protein,
provided that any such variant, mutated version, derivative or fragment possesses substantially similar mechanism of action and biological activity as such protein) and has greater than [**] percent ([**]%) sequence identity to a reference
amino acid sequence provided by Verve to the Escrow Agent pursuant to this subclause (b). For clarity, in the case of a Genome Editing Protein Target, substantially similar mechanism of action and biological activity means that any variants, mutated
versions, derivatives or fragments of such protein Genome Edit the same Human Genome Target at the same site. 
 1.59
“Receiving Party” has the meaning set forth in Section 7.1. 
 1.60 “Records” has the
meaning set forth in Section 3.3(a). 
 1.61 “Reserved Target” means a Target with respect to which Verve shall
have delivered to the Escrow Agent a Target Notice and that is deemed to be added to the Reserved Target List in accordance with Section 4.2(d)(ii). A Target that is removed from or replaced on the Reserved Target List pursuant to
Section 4.2 will no longer be deemed a Reserved Target. For avoidance of doubt, the term Reserved Target includes all variants of such Target set forth within the definition of Target. 

1.62 “Reserved Target List” means collectively, the list of all Reserved Targets. 

1.63 “Restricted Target List” has the meaning set forth in Section 4.2(b). 

1.64 “Target” means, collectively, a Genome Editing Protein Target, a Guide RNA, and a Human Genome Target, as the case
may be, each, as identified in the appropriate nomination form. 
 1.65 “Target Notice” has the meaning set forth in
Section 4.2(c). 
 1.66 “Target Reservation and Maintenance Fees” means the annual fees set forth in
Section 4.4(a). 

  
 7 

 1.67 “Target Acceptance Notice” has the meaning set forth in
Section 4.2(d)(ii). 
 1.68 “Target Rejection Notice” has the meaning set forth in Section 4.2(d)(i). 

1.69 “Target Response Notice” has the meaning set forth in Section 4.2(d). 

1.70 “Technology” means collectively Patents and Know-How. 

1.71 “Technology Access Fee” has the meaning set forth in Section 3.4(d). 

1.72 “Technology Maintenance Fee” has the meaning set forth in Section 3.4(d). 

1.73 “Term” has the meaning set forth in Section 9.1. 

1.74 “Territory” means worldwide. 

1.75 “Third Party” means any person or entity other than Verve, Acuitas and their respective Affiliates. 

1.76 “Third Party Claims” has the meaning set forth in Section 8.6(a). 

1.77 “Verve Background Technology” means any and all proprietary Verve Genome Editing Technology provided or made
available to Acuitas by Verve to conduct activities as a part of the Workplan. 
 1.78 “Verve Indemnitees” has the
meaning set forth in Section 8.6(a). 
 1.79 “Verve Genome Editing Technology” means all
Technology that is owned or controlled by Verve as of the Effective Date or during the term of this Agreement and in each case relates to Genome Editing Constructs including mRNA Constructs. 

1.80 “Verve Sole Technology” means without regard to inventorship, (a) all Technology (other than Workplan Data)
that arises out of the Workplan and is solely an Improvement to the Verve Background Technology and that does not incorporate or consist of an Improvement to the Acuitas Background Technology. 

1.81 “Verve Technology” means Verve Background Technology and Verve Sole Technology. For the avoidance of doubt, any
Genome Editing Construct or component thereof that is proprietary to Verve and provided by or on behalf of Verve to Acuitas shall be Verve Background Technology and, therefore, Verve Technology under this Agreement. 

1.82 “Verve Workplan Leader” has the meaning set forth in Section 2.1. 

1.83 “Workplan” has the meaning set forth in Section 3.1(a). 

1.84 “Workplan Data” means the results of studies using Formulated Product conducted in accordance with the Workplan.
For avoidance of doubt, the results of LNP formulation studies conducted by Acuitas and Genome Editing Construct studies conducted by Verve which, in each case support the Formulated Product studies, will not be Workplan Data. 

  
 8 

 1.85 “Workplan Leaders” has the meaning set forth in
Section 2.1. 
 1.86 “Works and Services” means the activities to be performed by Acuitas or Verve, as
applicable, pursuant to the Workplan. 
 ARTICLE 2 

Governance 

2.1 Management. Management of the Program activities will be under the responsibility of [**], for
Acuitas (the “Acuitas Workplan Leader”), and [**] for Verve (the “Verve Workplan Leader,” and together with the Acuitas Workplan Leader, the “Workplan Leaders”). Each Workplan Leader will be the
primary point of contact for the other Party on all matters relating to the Program activities. 
 2.2 Joint Development Committee.

 (a) Development Committee. As soon as practicable, the Parties will establish a joint development committee,
comprised of up to [**] representatives of Verve and up to [**] representatives of Acuitas (the “JDC”). One such representative from each Party will be such Party’s Workplan Leader. Each Party may replace its Workplan Leader
and other JDC representatives at any time upon written notice to the other Party, provided, however, that each Party shall use reasonable efforts to ensure continuity on the JDC. With the consent of the other Party (which will not be
unreasonably withheld, conditioned or delayed), each Party may invite non-voting employees and consultants to attend JDC meetings, subject to their agreement to be bound to the same extent as a permitted
subcontractor under Section 3.1(i). 
 (b) Meetings. During the Term, the JDC shall meet each [**] by
teleconference, videoconference or in person unless agreed otherwise by the JDC representatives. The JDC will have a quorum if at least one (1) representative of each Party is present or participating. Each Party will be responsible for all of
its own expenses of participating in the JDC meetings. The Parties will endeavor to schedule meetings of the JDC at least [**] in advance. The Parties will alternate in preparing the meeting agenda, and the Party that was responsible for preparing
the meeting agenda will prepare and circulate for review and approval by the other Party written minutes of such meeting within [**] after such meeting. The Parties will agree on the minutes of each meeting promptly, but in no event later than [**]
after such meeting. 
 (c) Responsibilities. The JDC will oversee and supervise the overall performance of the Workplan
and within such scope will: 
 (i) review the efforts of the Parties in the performance of the Workplan and allocate those
resources for the Workplan committed by Acuitas (FTE Costs and external costs) hereunder; 
 (ii) revise and approve any
revisions to the Workplan, or confirm that no revisions are necessary, on a regular basis and in any event before the start of each [**] during the Term; 

  
 9 

 (iii) form such other committees as the JDC may deem appropriate,
provided that such committees may make recommendations to the JDC but may not be delegated JDC decision-making authority; 

(iv) address such other matters (A) relating to the activities of the Parties under the Workplan as either Party may bring
before the JDC, (B) that are delegated to the JDC under this Agreement, or (C) as may be mutually agreed by the Parties from time to time; and 

(v) attempt to resolve any disputes within the scope of the JDC’s authority on an informal basis. 

(d) Decision-making. The JDC will make decisions only by consensus with each Party having collectively one (1) vote.
In the event the JDC is unable to reach agreement as to a matter within the JDC’s jurisdiction within [**] after it has first met and attempted to reach agreement (such event, a “JDC Deadlock”), upon the written request of a
Party, such matter will be referred to a senior executive of each Party that is not on the JDC (the “Executive Officers”) (or their designees, provided that such designee is not on the JDC and has decision-making authority on
behalf of such Party), who will attempt in good faith to resolve such JDC Deadlock by negotiation and consultation for a [**] period following receipt of such written notice. If, despite such efforts, agreement on a particular matter cannot be
reached by the Executive Officers within such [**] period, then Verve shall have the final decision-making authority with respect to such JDC Deadlock, subject to Section 3.1(c). 

(e) Limits on JDC Authority. Each Party will retain the rights, powers and discretion granted to it under this
Agreement and no such rights, powers, or discretion will be delegated to or vested in the JDC unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing. The JDC will not have
the power to amend, modify or waive compliance with this Agreement (other than as expressly permitted hereunder). 
 ARTICLE 3 

The Program 

3.1 Program Generally. The Parties will jointly conduct the Program. It is intended that Acuitas will be responsible for
the lipid chemistry and LNP formulation and characterization work, Verve will be responsible for Genome Editing Construct development and Acuitas and Verve will each undertake preclinical studies as set forth in the Workplan. 

(a) Workplan Preparation. The development activities to be undertaken by the Parties with respect to each Reserved
Target will be described in a detailed written development plan (the “Workplan”). The initial Workplan will be finalized within [**] of the Effective Date and will cover the initial [**] of the Program and will be attached
hereto as Exhibit 3.1(a) once finalized.  

  
 10 

 (b) Workplan Contents. The goal of the Workplan and the Program
will be to evaluate and produce LNP formulations that are safe and efficacious for delivery of Verve’s Genome Editing Constructs and to advance the development of such RNA-LNP formulations as therapeutic
drug candidates. All activities using Acuitas LNP Technology will be limited to Reserved Targets and will be only as set forth in the Workplan. The Workplan will include (i) all activities to be undertaken by each Party with respect to the
Program, including Acuitas’ manufacture and supply of Formulated Product at scales and quality sufficient for preclinical non-human primate testing and pilot scale manufacturing, (ii) a detailed
budget of the FTE activities, FTE Costs and out-of-pocket costs to be incurred by Acuitas for which Verve will reimburse Acuitas in connection with the performance of
the Works and Services, (iii) the Materials to be provided by one Party to the other Party, (iv) the specifications, quantity and delivery date for the Formulated Product to be manufactured and supplied by Acuitas, and (v) the
projected timelines for completion of all activities set forth therein. The Workplan will be comprehensive and include all activities using the Acuitas LNP Technology by both Parties commencing after the Effective Date, including any preclinical or
other activities outsourced to Third Parties, to be undertaken prior to Verve exercising an Option for a Non-Exclusive License Agreement. No Acuitas LNP Technology or Formulated Product will be used by Verve
outside of the Workplan prior to Verve exercising an Option for a Non-Exclusive License Agreement and then only to the extent permitted under the Non-Exclusive License
Agreement. 
 (c) Amendments to the Workplan. The Workplan will be reviewed as necessary at each
meeting of the JDC, and at any other time upon the reasonable request of either Party, and will be modified in a manner that is consistent with the requirements for the Workplan set forth in Section 3.1(b) and otherwise at the direction of the
JDC to reflect material scientific (and other) developments. Each [**], the JDC will update the Workplan to cover at least the subsequent [**] of the Program in detail or confirm that no updates are necessary. In all events, the Workplan will be
consistent and not conflict with the terms of this Agreement, and in the event of any conflict between the Workplan and this Agreement, the terms of this Agreement will control. The Workplan may be amended by the JDC to accelerate, decelerate, add
or remove activities thereunder, including reducing or eliminating Acuitas’ responsibilities for an activity thereunder; provided, that Acuitas’ written consent is required in order to make (i) a material change to the Workplan
that significantly accelerates or decelerates the planned Acuitas activities and requires allocation by Acuitas of FTEs significantly greater than or less than (i.e., change of more than [**] percent ([**]%)) those provided for in the Workplan
or (ii) make a material change to the Formulated Product Fees, Formulated Product requirements, delivery dates or specifications. Acuitas shall use commercially reasonable efforts and cooperate with Verve to comply with Verve’s requests.
Verve may not exercise its final decision-making authority to amend the Workplan to include any activities that conflict with Pre-Existing Restrictions. 

(d) Obligations Under the Workplan. During the Term, each Party will perform the Works and Services in a professional
manner and in accordance with the Workplan and all applicable Laws, and each Party will use Diligent Efforts to meet the objectives and timelines set forth therein. Neither Party shall knowingly employ (or use a subcontractor that employs) any
individual or entity debarred by the FDA or its successor agency (or subject to a similar sanction of any other regulatory authority), or any individual or entity which is the subject of an FDA debarment investigation or proceeding (or similar
proceeding of any other regulatory authority), in the performance of the Works and Services. It is understood that the activities and goals of the Workplan are experimental and that successful results cannot be guaranteed. The Parties will otherwise
conduct the Program on the terms and conditions set forth in this Agreement 

  
 11 

 
and in accordance with the Workplan. Each Party will cooperate with and provide reasonably requested non-financial support to the other Party in such other
Party’s performance of its responsibilities under the Workplan. In addition to the reporting obligations set forth in Section 3.3(b), each Party will keep the other Party reasonably informed of such Party’s activities under the
Workplan through the JDC or as otherwise reasonably requested by the other Party. 
 (e) Supply of Formulated
Product. Acuitas will use Diligent Efforts to manufacture and supply Verve with Formulated Product as set forth in the Workplan and Verve will pay to Acuitas the Formulated Product Fee for such Formulated Product. Verve will use the
Formulated Product solely for research purposes in laboratory animals and/or in vitro studies as set forth in the Workplan and will not use Formulated Product in humans. The Formulated Product will be manufactured and supplied
by Acuitas (i) in accordance with the specifications set forth in the Workplan, (ii) in compliance with applicable Laws, and (iii) by the delivery date set forth in the Workplan. No Formulated Product will be used outside of the
Workplan. Verve will not perform any chemical analysis or testing of Formulated Product except as set forth in the Workplan and specifically will not attempt to determine the lipid composition or lipid structures or in any way seek to
reverse-engineer any Formulated Product. Further Verve will not provide any Formulated Product to a Third Party unless previously approved by Acuitas in writing. 

(f) Additional Development Studies for a Licensed Product. Following exercise of a license by Verve, Verve may choose to
include additional development studies for the Licensed Product as part of the Workplan (“Additional Development Studies for a Licensed Product”). As part of such Additional Development Studies for a Licensed Product Acuitas will disclose
to Verve the structure of the cationic lipid component of the LNP compositions actually included in non-human primate studies with Verve for the Licensed Product. Ownership of Technology generated during
Additional Development Studies for Licensed Product will be determined on the same basis as for all other studies conducted under the Workplan in accordance with Section 6.2. 

(g) Technology Transfer to Contract Manufacturing Organization. Prior to Verve’s exercise of an Option for a Licensed
Product, Acuitas will be responsible for the RNA-LNP formulation, including analytical testing and documentation for all Licensed Products directed to Reserved Targets. Following the execution of a Non-Exclusive License Agreement, Acuitas will transfer all Know-How relating to the then-current formulation process for the manufacture of such Licensed Product to Verve or
to a single contract manufacturing organization (a “CMO”) which will be determined by Verve (and reasonably acceptable to Acuitas). In the event the transfer of such Know-How is to a CMO the
information will also be copied to Verve. For clarity, to be reasonably acceptable to Acuitas such proposed CMO must not be subject to a Deficiency. Acuitas will provide reasonable assistance to enable Verve or such CMO to manufacture such Licensed
Product. Initiation of such technology transfer will be determined by Verve and will be for the then current formulation of the Licensed Product. Specifically, in the event that Additional Development Studies for a Licensed Product are undertaken,
Verve will notify Acuitas once a formulation is selected for technology transfer. Acuitas will be reimbursed for such activities by Verve on an FTE basis and Verve will also be responsible for all external costs incurred by Acuitas relating to
transfer of the Licensed Product formulation to Verve or a GMP manufacturer provided such costs have been approved by Verve in advance. Once the Licensed Product formulation is transferred to Verve or the CMO, Verve will assume responsibilities for
future manufacturing of Licensed Product. Acuitas will provide ongoing technical support if requested by Verve with such support reimbursed on a time, materials and FTE basis. 

  
 12 

 (h) Payment for External Expenses. On a Calendar Quarter-by-Calendar Quarter basis, Verve will reimburse Acuitas for any reasonable external costs that are incurred by Acuitas in connection with performing the Works and
Services in accordance with the Workplan and Workplan budget, provided that such external costs have been specified in the Workplan or, if agreed by the JDC, are promptly added to the Workplan. Acuitas will send a reasonably detailed invoice
to Verve no later than [**] after the end of each Calendar Quarter, which invoice shall include a detailed summary of and reasonable documentation for all such external costs. Verve agrees to pay undisputed amounts in each such invoice within [**]
of Verve’s receipt thereof. Except for such reimbursement of external costs and Verve’s payments to Acuitas with respect to FTE Costs as set forth in Section 3.2, each Party will bear its own costs of performing the Workplan. For
clarity, Verve shall not be responsible for reimbursing Acuitas for external costs to the extent that such costs exceed the budgeted amount for such costs in the Workplan for the applicable time period. 

(i) Collaboration Partners. Verve may conduct parts of the Program together with a Third Party other than as set forth in
subsection (i) below (Permitted Subcontracting); provided that such Third Party is a sublicensee of Verve Technology being used in the Program and Verve has obtained the prior written consent of Acuitas (not to be unreasonably withheld,
conditioned or delayed), and the Third Party, upon Verve’s receipt of such written consent, shall be deemed to be a Collaboration Partner hereunder. Acuitas will refuse to consent to a Third Party that Verve wishes to use as a Collaboration
Partner if such Third Party is actively developing and/or commercializing LNP Technology and Acuitas reasonably determines that such Third Party is a competitor of Acuitas and such refusal will be deemed reasonable. Verve shall provide written
notice to Acuitas of its execution of each agreement with a Collaboration Partner. Verve will ensure that each Collaboration Partner is subject to terms and conditions consistent with the terms and conditions in this Agreement (i) protecting
and limiting use and disclosure of Confidential Information and Materials and Know-How, and (ii) requiring such Collaboration Partner and its personnel to assign to Verve all right, title and interest in
and to any Patents and Know-How created, conceived, developed or reduced to practice in connection with the performance of activities in accordance with this Agreement in order to give effect to the provisions
of Article 6. For avoidance of doubt, breach of any of the terms or conditions of this Agreement by a Collaboration Partner shall be a breach by Verve. 

(j) Permitted Subcontracting. Each Party may subcontract activities to be performed under the Workplan to any of
its Affiliates, subject to the Affiliate’s compliance with the terms and condition of this Agreement including Article 6 and Article 7 below. In addition, each Party may subcontract its activities to be performed under the Workplan to a
Contract Research Organization. Any such Contract Research Organization will have entered into a written agreement with the subcontracting Party that includes terms and conditions protecting and limiting use and disclosure of Confidential
Information and Materials and Know-How at least to the same extent as under this Agreement, and requiring such Contract Research Organization and its personnel to assign to the subcontracting Party all right,
title and interest in and to any Patents and Know-How and Materials created, conceived, developed or reduced to practice in connection with the performance of subcontracted activities in accordance with this
Agreement in order to give effect to the provisions of Article 6 and Article 7. Any such subcontracting activities will be described in the reports for the Program required by Section 3.3(b). 

  
 13 

 3.2 FTEs. 

(a) Generally. Acuitas will perform the Works and Services under the Workplan and as part of the Program. The actual
number of Acuitas FTEs committed to work on the Program at any particular point in time will be set forth in the Workplan. The Parties will prepare the Workplan, which will determine the number of Acuitas FTEs to be funded each year. Notwithstanding
anything to the contrary set forth herein, in no event will (i) Acuitas be required to devote any FTEs to the conduct of the Program other than those funded by Verve or (ii) Verve be required to fund more than the actual number of FTEs
devoted by Acuitas to the Workplan. 
 (b) FTEs. Acuitas shall ensure that those individuals selected by Acuitas to
perform the Works and Services and otherwise support the activities to be undertaken by Acuitas pursuant to the Workplan will have sufficient scientific expertise, skill, training and competency to perform the proposed work and have similar skills,
training and competency as those FTEs employed by Acuitas to perform work on Acuitas’ internal programs and for Third Parties. In the event that Verve has concerns regarding the selection of an individual to perform the Works and Services or
other activities under this Agreement, the Parties will discuss such concerns in good faith through the JDC. 
 (c) FTE
Costs. Verve will fund Acuitas FTEs based on the number of hours actually worked by such FTEs and otherwise as set forth in the Workplan. Verve will reimburse Acuitas for FTE Costs on a Calendar Quarter-by-Calendar Quarter basis. Acuitas will send a reasonably detailed invoice to Verve no later than [**] after the end of each Calendar Quarter, which invoice shall include a summary of all activities
by the name of each individual, number of hours devoted by each such individual, and Works and Services type/activity performed by each such individual during such Calendar Quarter. Verve agrees to pay undisputed amounts in each such invoice within
[**] of Verve’s receipt thereof. 
 3.3 Program Records, Reports and Materials. 

(a) Records. Each Party will maintain, or cause to be maintained, records of its activities under the Program in sufficient
detail and in good scientific manner appropriate for scientific, Patent and regulatory purposes, which will properly reflect all work included in the Program (“Records”) for a period of at least [**] after the creation of such
Records or such longer period required by applicable Laws. Verve will have the right to request and receive a copy of any such Records maintained by Acuitas; and Acuitas will have the right to request and receive a copy of any such Records
maintained by Verve to the extent such Records are required by Acuitas to exercise its rights under this Agreement. 
 (b) Data
and Program Reports. Acuitas and Verve will share with one another through the JDC the Workplan Data. The Parties will not share with each other Confidential Information or Know-How relating to
their Background Technologies or the Acuitas Sole Technology or Verve Sole Technology, respectively, including, in the case of Acuitas, LNP 

  
 14 

 
formulation information, except as provided in Section 3.1(f) and 3.1(g). Verve will share with Acuitas Workplan Data regarding the Genome Editing Constructs only as and if needed by Acuitas
to evaluate performance of the LNP Technology in order to conduct the Program. Acuitas shall not disclose any Workplan Data to any Third Party except in connection with the filing of patent applications for Acuitas Sole Technology (so long as no
Verve Confidential Information is disclosed) and may use any Workplan Data only for internal research and development purposes. Verve may only use Workplan Data for research and development activities (which, for clarity, shall not include
commercial exploitation of a product) and may disclose Workplan Data to Third Parties so long as no Acuitas Confidential Information is disclosed; provided that following Verve’s exercise of an Option, Verve may also use such Workplan
Data as set forth in the Non-Exclusive License Agreement. Acuitas may only use Workplan Data for research and development activities (which, for clarity, shall not include commercial exploitation of a product)
and may disclose Workplan Data to Third Parties so long as no Verve Confidential Information is disclosed. During the Term, each Party will furnish to the JDC a summary written report within [**] after the end of each Calendar Quarter describing its
progress under the Workplan and evaluating such work in relation to the goals of the Workplan as well as provide such other information as reasonably requested by the JDC. Within [**] following expiration or earlier termination of this
Agreement, each Party will furnish to the JDC a final summary written report. 
 (c) Materials. 

(i) Each Party will, during the Term, furnish to each other samples of Materials which comprise, embody or incorporate Verve
Technology or Acuitas LNP Technology only as expressly set forth in the Workplan. Acuitas will furnish to Verve the quantities of Formulated Product as set forth in the Workplan and will use commercially reasonable efforts to provide any additional
quantities which will be required in performance of the Program. In addition, each Party will, upon the other Party’s reasonable written request, furnish to such other Party other samples of Materials which comprise, embody or incorporate Verve
Technology or Acuitas LNP Technology that are in such Party’s Control and are reasonable (both in quantity and identity) and useful for the other Party to carry out its responsibilities under the Workplan, provided (A) such
Materials are reasonably and readily available in excess of the providing Party’s own requirements, and (B) supply of such Materials will not, in the providing Party’s reasonable judgment, (1) conflict with the providing
Party’s internal or Third Party research programs, (2) conflict with the providing Party’s internal policies regarding such Materials, or (3) violate any agreement to which the providing Party is a party. Upon termination or
expiration of this Agreement and unless such Material is necessary and useful for the exercise of a Party’s rights or obligations under a Non-Exclusive License Agreement, Materials will, at the providing
Party’s option and request to be made (if at all) within [**] after such termination or expiration or the effective date of termination, be returned to the providing Party or destroyed. The provision of Materials hereunder by either Party will
not constitute any grant, option or license under any Patents or Know-How, except as expressly set forth herein. 

  
 15 

 (ii) Each Party will use such Materials only in accordance with the Workplan
and otherwise in accordance with the terms and conditions of this Agreement. Except as otherwise specified in the Workplan or except with the prior written consent of the supplying Party, the Party receiving any Materials will not distribute or
otherwise allow the release of Materials to any Third Party, except, with respect to either Party, to any permitted subcontractors under Section 3.1(i) and, with respect to Verve, to any Collaboration Partners. All Materials delivered to the
receiving Party will remain the sole property of the providing Party and will be used in compliance with all applicable Laws and only to perform activities set forth in the Workplan. The Materials supplied under this Agreement will be used with
prudence and appropriate caution in any experimental work because not all of their characteristics may be known. 
 3.4 Program
Licenses. 
 (a) By Acuitas. Subject to the terms and conditions of this Agreement, Acuitas hereby grants to
Verve (and to its Affiliates) a worldwide, non-exclusive, royalty-free license under the Acuitas LNP Technology, solely to the extent necessary to enable Verve (and its Affiliates) to perform its activities
set forth in the Workplan and for no other purpose. The foregoing license shall not include the right to grant sublicenses, except to permitted Collaboration Partners and Contract Research Organizations in accordance with Sections 3.1(i) and
3.1(h). 
 (b) By Verve. Subject to the terms and conditions of this Agreement, Verve hereby grants to Acuitas a
worldwide, non-exclusive, royalty-free license under the (i) Verve Technology, solely to the extent needed to enable Acuitas to perform its activities set forth in the Workplan and for no other purpose.
The foregoing license shall not include the right to grant sublicenses, except to permitted Contract Research Organizations in accordance with Section 3.1(i). 

(c) No Other Licenses. No license or right is or will be created or granted hereunder by implication, estoppel or
otherwise. All licenses and rights are or will be granted only as expressly provided in this Agreement. 
 (d) Technology Access
Fee. Within [**] following the Effective Date, Verve will pay to Acuitas a technology access fee equal to Five Hundred Thousand Dollars (US$500,000) (“Technology Access Fee”).    On each anniversary
of the Effective Date during the Term, Verve will pay to Acuitas a maintenance fee of Two Hundred Fifty Thousand Dollars (US$250,000) (“Technology Maintenance Fee”) for each of the maximum of two (2) Options that has not
been exercised as a Non-Exclusive License Agreement prior to the Anniversary Date. Technology Access Fees are not reimbursable and will not be pro-rated. 

ARTICLE 4 
 Reserved
Targets 
 4.1 Generally. Verve shall have the right, but not the obligation, to
non-exclusively reserve Targets for potential use in the Workplan, in accordance with this Article 4. Verve will select the Targets that will be the subject of the work performed as part of the Program from
the Reserved Targets specified in accordance with this Article 4. Additionally, Verve shall have the right, but not the obligation, to exercise Options in accordance with this Article 4 and Article 5. 

  
 16 

 4.2 Reserved Target List, Restricted Target List and Target Notices. 

(a) Escrow Agent. The Escrow Agent shall maintain in confidence the Restricted Target List and respond to Verve’s
Target Notices and Option Notices on behalf of Acuitas.    The Escrow Agent shall not inform Acuitas of any Verve potential Reserved Targets without Verve’s prior written consent, which shall be deemed given with respect to
a Human Genome Target (but not any other Reserved Target, including if such Reserved Target is set forth on the same Target Acceptance Notice as such Human Genome Target) upon Verve’s receipt of a Target Acceptance Notice for such Human Genome
Target in accordance with Section 4.2(d)(ii). For the avoidance of doubt, the Escrow Agent shall not notify Acuitas if a potential Reserved Target has been rejected from the Reserved Target List under this Section 4.2. All costs and
expenses incurred through the Escrow Agent will be borne by Acuitas. 
 (b) Pre-Existing Restrictions. Acuitas shall maintain,
at the Escrow Agent, a current and up-to-date list of Targets that are subject to Pre-Existing Restrictions (the
“Restricted Target List”). Such list will also identify the scope of the Pre-Existing Restrictions. Acuitas represents, warrants and covenants to Verve that (i) the Restricted
Target List is and will at all times be accurate and (ii) neither Acuitas nor any of its Affiliates will grant any licenses, options or other rights in or to the Acuitas LNP Technology that would preclude Acuitas from granting to Verve a non-exclusive license for each Reserved Target as set forth herein. The decision of the Escrow Agent with respect to the Targets subject to Pre-Existing Restrictions
will be conclusive unless there is fraud on the part of Acuitas in which case Verve reserves all rights against Acuitas but absent fraud on the part of the Escrow Agent, Verve shall have no recourse against the Escrow Agent. 

(c) Target Notices. If (i) Verve desires to add or remove a Target from the Reserved Target List, or
(ii) Verve desires to exercise an Option for a Licensed Product, Verve will notify the Escrow Agent in writing of the same. Such notice will identify as applicable, in addition to the information relating to such proposed Targets set forth on
the form of Target Notice attached hereto as Exhibit 4.2 (I) in the case of clause (i) above, whether Verve wishes to non-exclusively reserve such Target or remove such
Target from the Reserved Target List, (II) in the case of clause (ii) above, if Verve wishes to exercise an Option, and if so, the information required under Section 5.2(a) (each such notice, a “Target Notice”). Each
Target Notice in the case of clause (I) above will specify each Target and each Target Notice in the case of clause (II) above will specify the Human Genome Target(s) and each Genome Editing Protein Target and Guide RNAs associated with
each Genome Editing Construct to Genome Edit such Human Genome Target(s).  

  
 17 

 (d) Target Response Notices. The Escrow Agent, on behalf of
Acuitas, will review each Target Notice provided by Verve and, within [**] of the Escrow Agent’s receipt of a Target Notice, the Escrow Agent will provide Verve with written notice that includes the following information (each such notice, a
“Target Response Notice”): 
 (i) If, as of the date of Verve’s Target Notice for a Target, such Target
is on the Restricted Target List and is listed as being subject to Pre-Existing Restrictions that restrict Acuitas from taking the action requested by Verve in the Target Notice, or if the action requested by
Verve would exceed the applicable Concurrent Reserved List Limit or the Option Limit, then the Target Response Notice issued for such Target will so certify to Verve and will specify whether such applicable Target is subject to a Pre-Existing Restriction (such notice, a “Target Rejection Notice”). For clarity, the Target Rejection Notice will specify which Target (Human Genome Target or Genome Editing Protein Target) is
subject to a Pre-Existing Restriction. 
 (ii) If, as of the date of Verve’s
Target Notice for a Target, such Target is not subject to any Pre-Existing Restrictions that would prevent the action requested by Verve in the Target Notice, and the action requested by Verve would not exceed
the applicable Concurrent Reserved List Limit or the Option Limit, then such Target shall, consistent with the Target Notice, automatically be as of the date of the Target Notice (A) added or removed from the Reserved Target List on a non-exclusive basis, and (B) subject to the payment of the Option Exercise Fee, deemed to be subject to an Option exercised by Verve on a non-exclusive basis, and
the Target Response Notice issued for the Targets included in the Licensed Product will certify the same to Verve (such notice, an “Target Acceptance Notice”). So long as a Human Genome Target is on the Reserved Target List, Acuitas
and its Affiliates shall be prohibited from granting any Third Party an exclusive license (or an option to obtain such a grant of rights) under the Acuitas LNP Technology with respect to such Human Genome Target. This Section 4.2(d)(ii) shall
survive the termination or expiration of this Agreement solely in the event that the Parties enter into a Non-Exclusive License Agreement prior to such termination or expiration. 

(e) Concurrent Reserved List Limits. During the Term, Verve will have the right to select up to [**] Human
Genome Targets and up to [**] Genome Editing Protein Targets and up to [**] Guide RNAs associated with each Human Genome Target at any one time to be placed on the Reserved Target List (the “Concurrent Reserved List Limit”). Genome
Editing Protein Targets and Guide RNAs can be removed from the Reserved List, added to the Reserved List and/or replaced on the Reserved List at any time subject to the limitations on the total numbers of each Target to be associated with the Human
Genome Targets. The Concurrent Reserved List Limit for Human Genome Targets will be reduced by one for each Option exercised such that number of Reserved Human Genome Targets plus the number of Options exercised shall not exceed four (4). 

(f) Minimum Target Reservation Requirement. Verve will elect and maintain at least one (1) Target consisting of a
Human Genome Target to be placed on the Reserved Target List at all times (“Minimum Target Reservation Requirement”). 

4.3 Expiration of Pre-Existing Restrictions. If any Pre-Existing Restrictions identified in a Target Rejection Notice that precluded Acuitas from taking the action requested by Verve in a Target Notice later expire or otherwise are modified or terminate such that
Acuitas is no longer precluded from taking the action requested by Verve in a Target Notice, the Escrow Agent will notify Verve of such event and Verve will have an option, for a period of [**] following delivery of such notice to Verve, to
(a) add such Target to the Reserved Target List, or (b) exercise 

  
 18 

 
an Option with respect to such a Licensed Product including such Human Genome Target or Genome Editing Protein Target, as the case may be, in each case ((a) and (b)), subject to the Concurrent
Reserved List Limits and the Option Limit. For clarity, Verve will at all times thereafter have the right to provide a Target Notice for such Target to the Escrow Agent pursuant to Section 4.2(c) but such Target Notice will be subject to any
intervening Pre-Existing Restrictions. 
 4.4 Fees. 

(a) Target Reservation and Maintenance Fees. Verve will pay to Acuitas (i) One Hundred Thousand
Dollars (US$100,000) per Contract Year prorated on a monthly basis for each Human Genome Target until such Target is removed from the Reserved Target List or Verve exercises an Option with respect to such Target. Human Genome Target(s) removed
from the Reserved Target List shall be available to Third Parties and the related payments will not be credited against any Option Exercise Fees, unless the same Target is re-nominated to the Reserved Target
List. 
 (b) Credit. The Target Reservation and Maintenance Fee for a Human Genome Target will be creditable up
to Two Hundred Fifty Thousand Dollars (US$250,000) against the Option Exercise Fee payable if Verve exercises its Option for a Non-exclusive License for a Licensed Product directed to such Human Genome
Target. 
 ARTICLE 5 

Verve License Options 

5.1 Option. From the period commencing on the Effective Date and ending on the expiration of the Term, Acuitas hereby
grants to Verve the options (each, an “Option”) set forth below. Verve’s Option is non-exclusive with respect to each combination of Reserved Targets included in a Licensed Product. 

(a) Non-Exclusive License. On a Licensed Product by Licensed Product basis, an
Option shall include the right to enter into a non-exclusive, worldwide, license, with a right to sub-license through multiple tiers, under the Licensed Technology to
research, develop, make, have made, keep, use, sell, offer to sell, have sold, import, export and/or otherwise commercialize and exploit Licensed Products in the Field of Use in the Territory. The Option to obtain a
non-exclusive license will be limited to Targets that are on the Reserved Target List at the time of exercise of the Option. 

(b) Option Limit. Verve shall have the right to exercise Options with respect to a maximum of [**] (the “Option
Limit”). For avoidance of doubt, Verve may exercise [**]. 
 (c) Form of
Non-Exclusive License Agreement. The Non-Exclusive License Agreement shall be used for all licenses granted upon the exercise of an Option hereunder. Each Non-Exclusive License Agreement will grant rights for a Licensed Product that include the Reserved Targets specified in the Option Notice. 

  
 19 

 (d) Combination Product. In the event that Verve has exercised both
options under the Development and Option Agreement and has taken two non-exclusive licenses each directed against a single Human Genome Target and wishes to combine the rights under both licenses into a single
combination product (“Combination Product”) the Parties will negotiate in good faith the terms of an amendment to both licenses to allow such Combination Product. Such amendment will provide that any Milestone Events not yet
achieved for either product will be combined into a single new milestone (which will be the sum of the individual Milestone Payments) and will be due on achievement of the Milestone Event for the Combination Product. The Royalty Rate for the
Combination Product will be [**]% with a Minimum Royalty of [**]%. Other provisions of Section 4.3 of the Non-Exclusive License Agreement will remain unchanged. This Section 5.1 (d) will survive the Term of this Agreement.

 5.2 Verve’s Exercise of Option. Verve may exercise each such Option by delivering to Acuitas an
Option Notice and paying to Acuitas the Option Exercise Fee in accordance with this Section 5.2. If not exercised prior to the expiration of the Term, the Options granted to Verve under this Article 5 with respect to all Reserved Targets will
terminate in full and will no longer be exercisable. 
 (a) Option Notice. Verve has the right to deliver to the Escrow
Agent, prior to the expiration of the Term, a Target Notice including the information set forth in Exhibit 4.2(c), as applicable, with respect to up to [**] Human Genome Target(s), the Genome Editing Protein Targets and Guide RNAs included in the
Licensed Products for which Verve wishes to exercise an Option (each such Target Notice, an “Option Notice”). Each Option Notice will specify up to [**] Genome Editing Constructs (including the Genome Editing Protein Targets and
Guide RNAs included therein) and up to [**] Human Genome Targets. Verve will submit one (1) Option Notice for each Licensed Product for which Verve wishes to exercise the Option and each Licensed Product will be defined by the Genome Editing
Constructs and Human Genome Target(s) set forth in the Option Notice. 
 (b)
Non-Exclusive License Agreement. Within [**] of the Escrow Agent’s receipt of an Option Notice, Verve and Acuitas will enter into a Non-Exclusive
License Agreement using the form specified in Appendix 1.48 for the Licensed Products specified in the relevant Option Notice. 
 (c)
Option Exercise Fee. Within [**] after entry into a Non-Exclusive License Agreement, Acuitas will issue an invoice to Verve for the Option Exercise Fee less any amounts creditable against
such Option Exercise Fee for such Non-Exclusive License Agreement pursuant to Section 4.4(b). Each such payment will be due within [**] after Verve’s receipt of such invoice from Acuitas. A separate
Option Exercise Fee will be required for each Non-Exclusive License Agreement executed by the Parties in accordance with this Article 5. 

  
 20 

 ARTICLE 6 

Ownership of Program Technology 

6.1 Disclosure of LNP Know-How. Notwithstanding anything to the contrary in this
Agreement, Acuitas shall not disclose to Verve any Know-How within the Acuitas LNP Technology without Verve’s prior written consent other than pursuant to a
Non-Exclusive License Agreement following Verve’s exercise of an Option. 
 6.2
Ownership. 
 (a) Verve Owned Technology. As between the Parties, Verve will own all right, title and
interest in and to the Verve Technology. 
 (b) Acuitas Owned Technology. As between the Parties, Acuitas will own all
right, title and interest in and to the Acuitas LNP Technology. 
 (c) Joint Technology. The Parties will jointly
own any and all Joint IP. Each Party will have an undivided one-half interest in and to such Joint IP. Subject to the terms of this Agreement and any Non-Exclusive
License Agreement, each Party will exercise its ownership rights in and to such Joint IP, including the right to license and sublicense or otherwise to exploit, transfer or encumber its ownership interest, without an accounting or obligation to, or
consent required from, the other Party, but subject to the licenses hereunder and the other terms and conditions of this Agreement. At the reasonable written request of a Party, the other Party will in writing grant such consents and confirm that no
such accounting is required to effect the foregoing regarding Joint IP. 
 (d) Assignment of Technology. Each Party, for
itself and on behalf of its Affiliates, hereby assigns (and to the extent such assignment can only be made in the future, hereby agrees to assign), to the other Party (i) any Technology that is solely owned by such other Party under this
Section 6.2, and (ii) a joint and undivided interest in and to all Joint IP. The Parties will reasonably cooperate to more fully document the rights of each Party as defined in this Section 6.2, including by executing all lawful
papers and instruments, obtaining and executing necessary powers of attorney and assignments by the named inventors, making all rightful oaths and declarations and providing consultation and assistance as may be necessary. 

6.3 Assignment. Each Party shall require, to the extent legally possible under relevant national or local Laws, all of its
employees, Affiliates or any Third Parties working pursuant to this Agreement on its behalf, to assign or otherwise convey rights to such Party its right, title and interest in any invention or Patent conceived, reduced to practice, created or
otherwise made in order to accomplish the ownership provisions set forth in this Article 6. Each Party shall be responsible for any compensation payable by such Party to its employees, Affiliates or any Third Parties working pursuant to this
Agreement on its behalf. 

  
 21 

 6.4 Prosecution and Maintenance. 

(a) General. As between the Parties and subject to any Non-Exclusive License
Agreement, Verve will have the sole right but not the obligation, at its expense, to prosecute and maintain Patents within the Verve Technology and Acuitas will have the sole right but not the obligation, at its expense, to prosecute and maintain
Patents within the Acuitas LNP Technology. Upon request by either Party, the Parties will promptly enter into a joint prosecution and maintenance agreement with respect to the Joint IP that, unless otherwise agreed by the Parties, shall provide at a
minimum that the Party with the responsibility to prosecute and maintain the Patents within the Joint IP will (i) keep the other Party reasonably informed of its prosecution and maintenance activities, (ii) provide the other Party
with a reasonable opportunity to review and comment on any material submissions or correspondence with a patent office and incorporate in good faith any comments from the other Party, and (iii) provide to the other Party copies of all
correspondence sent to or received from a patent office with respect to such Patents. 
 (b) Cooperation.
Each Party will reasonably cooperate with the other Party in the prosecution and maintenance of the Patents within the Joint IP. Such cooperation includes promptly executing all documents, or requiring inventors, subcontractors, employees
and consultants to execute all documents, as reasonable and appropriate so as to enable the prosecution and maintenance of any such Patents in any country. 

6.5 Patent Enforcement and Defense. 

(a) Notice. To the extent not in breach of an obligation of confidentiality, each Party will promptly notify, in writing,
the other Party upon learning of any actual or suspected infringement of any Patents comprised in the Acuitas LNP Technology by a Third Party, or of any claim of invalidity, unenforceability, or
non-infringement of any Patents comprised in the Acuitas LNP Technology, and will, along with such notice, supply the other Party with any evidence in its possession pertaining thereto. 

(b) Enforcement. As between the Parties and subject to any Non-Exclusive License
Agreement, Acuitas will have the sole right, but not the obligation, to seek to abate any infringement of the Patents comprised in the Acuitas LNP Technology by a Third Party, or to file suit against any such Third Party for such infringement. 

(c) Defense. As between the Parties and subject to any Non-Exclusive
License Agreement, Acuitas will have the sole right, but not the obligation, to defend against a declaratory judgment action or other action challenging any Patents comprised in the Acuitas LNP Technology. 

ARTICLE 7 

Confidentiality 

7.1 Confidential Information. Each Party (“Disclosing Party”) may disclose to the other Party
(“Receiving Party”), and the Receiving Party may acquire during the course and conduct of activities under the Agreement, certain proprietary or confidential information of the Disclosing Party in connection with this Agreement. The
term “Confidential Information” means all information of any kind, whether in written, oral, graphical, machine-readable or other form, whether or not marked as confidential or proprietary, that is disclosed or made available by or
on behalf of the Disclosing Party to or on behalf of the Receiving Party in connection with this 

  
 22 

 
Agreement; provided, that (a) the Acuitas Sole Technology will be considered the Confidential Information of Acuitas and the Verve Sole Technology will be considered the Confidential
Information of Verve, (b) the Joint IP will be considered Confidential Information of both Parties, and either Party may use and disclose Joint IP in connection with such Party’s permitted exploitation of such Technology, provided
that the recipient is bound by confidentiality and non-use obligations corresponding to the obligations under this Agreement, and (c) the data and results generated from the Workplan shall be subject to
Section 3.3(b), which shall supersede any other provisions of this Agreement to the contrary. 
 7.2
Restrictions. During the Term and for [**] thereafter, or with respect to any trade secret included in the Confidential Information for so long as such trade secret is protected under applicable Laws (provided, that
Receiving Party has not publicly disclosed such trade secret in breach of its obligations under this Article 8), the Receiving Party will keep all Disclosing Party’s Confidential Information in confidence with the same degree of care with which
Receiving Party holds its own confidential information, but in no event less than reasonable care. Receiving Party will not use Disclosing Party’s Confidential Information except for in connection with the performance of its obligations and
exercise of its rights under this Agreement or any Non-Exclusive License Agreement. Receiving Party has the right to disclose Disclosing Party’s Confidential Information without Disclosing Party’s
prior written consent to (a) Receiving Party’s Affiliates, and (b) each of Receiving Party’s employees, permitted subcontractors (subject to Section 3.1(i)) and Collaboration Partners, consultants or agents who have a need
to know such Confidential Information in order to perform its obligations and exercise its rights under this Agreement and who are under written obligations to comply with the restrictions on use and disclosure that are no less restrictive than
those set forth in this Section 7.2. Receiving Party assumes responsibility for such persons maintaining Disclosing Party’s Confidential Information in confidence and using same only for the purposes described herein. 

7.3 Exceptions. Receiving Party’s obligation of nondisclosure and the limitations upon the right to use the
Disclosing Party’s Confidential Information will not apply to a specific portion of the Disclosing Party’s Confidential Information to the extent that Receiving Party can demonstrate that such portion: (a) was known to Receiving Party
or any of its Affiliates prior to the time of disclosure by the Disclosing Party without obligation of confidentiality; (b) is or becomes public knowledge through no fault or omission of Receiving Party or any of its Affiliates; (c) is
obtained on a non-confidential basis by Receiving Party or any of its Affiliates from a Third Party who to Receiving Party’s knowledge is lawfully in possession thereof and under no obligation of
confidentiality to Disclosing Party; or (d) has been independently developed by or on behalf of Receiving Party or any of its Affiliates without the aid, application or use of Disclosing Party’s Confidential Information. 

7.4 Permitted Disclosures. Receiving Party may disclose Disclosing Party’s Confidential Information to the
extent (and only to the extent) such disclosure is permitted under Section 7.2 or is reasonably necessary in the following instances: 

(a) in order and to the extent required to comply with applicable Laws (including any securities Laws or the regulations or rules of a
securities exchange applicable to Receiving Party) or with a legal or administrative proceeding; 

  
 23 

 (b) in connection with prosecuting or defending litigation; 

(c) in connection with filing, prosecuting and enforcing Patents in connection with Receiving Party’s rights and obligations
pursuant to this Agreement; 
 (d) to acquirers or permitted assignees, investment bankers, investors and lenders, including potential
acquirers, assignees, investment bankers, investors and lenders; and 
 (e) in the case of Verve, to Collaboration Partners, but in
case the Collaboration Partner is only a potential licensee, partner or assignee, only such information that is reasonably necessary or useful for the potential licensee, partner or assignee to evaluate the Technology of interest, including design
of experiments conducted under the Workplan, data and results generated under the Workplan and LNP/Licensed Product manufacturing processes, but if a Non-Exclusive License Agreement has not been executed
excluding the particular chemical structure and formulation of any lipid nanoparticles (which excluded information may be disclosed to such potential licensee, partner or assignee upon Acuitas’ prior written consent); 

provided, that (1) where reasonably possible, Receiving Party will notify Disclosing Party of Receiving Party’s intent to make any disclosure
pursuant to subsections (a) and (b) sufficiently prior to making such disclosure so as to allow Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed,
and (2) with respect to subsections (d) and (e), each of those entities are required to comply with the restrictions on use and disclosure in Section 7.2 (other than investment bankers, investors and lenders, which must be bound prior
to disclosure by commercially reasonable obligations of confidentiality). 
 7.5 Return of Confidential Information.
Upon expiry or earlier termination of the Agreement, upon written request of a Party (such request, if made, to be made within [**] of such expiry or termination) the other Party will destroy or return (as shall be specified in such request) to the
requesting Party all copies of the Confidential Information of the requesting Party; provided, that a Party may retain: (a) one copy of such Confidential Information for record-keeping purposes, for the sole purpose of ensuring
compliance with this Agreement; (b) any copies of such Confidential Information as is required to be retained under applicable Laws; (c) any copies of such Confidential Information as is necessary or useful for such Party to exercise a
right or fulfill an obligation under this Agreement; and (d) any copies of any computer records and files containing Confidential Information that have been created by such Party’s routine archiving/backup procedures, in each case provided
that such copies are maintained in accordance with this Article 7. 
 7.6 Publications. Notwithstanding
anything in this Agreement to the contrary, each Party shall be permitted to publish the results of the Program including Workplan Data that constitute the other Party’s or joint Confidential Information only with the prior written consent of
the other Party, subject to Verve’s right to publish the results of its development under the applicable Non-Exclusive License Agreement in accordance with Section 8.6 thereof. Acuitas shall submit
any proposed publication of the results of the Program to Verve. Following receipt of the proposed publication by Verve, Verve will use commercially reasonable efforts to review and provide any objection to disclosure of Verve or Joint Confidential
Information. Verve shall 

  
 24 

 
submit any proposed publication of the results of the Program to Acuitas. Following receipt of the proposed publication by Acuitas, Acuitas will use commercially reasonable efforts to review and
provide any objection to disclosure of Acuitas or Joint Confidential Information. Expedited reviews for abstracts or poster presentations, or for other publications that may relate to potential patent applications, may be arranged only with the
prior written consent of both Parties. Verve and Acuitas will each comply with standard academic practice regarding authorship of scientific publications and recognition of the contributions of other parties in any publications relating to studies
conducted under the Workplan. 
 7.7 Patents. Except as expressly permitted under this Agreement, neither Party
will file a patent application that includes or discloses the Confidential Information of the other Party or Joint Confidential Information, without the consent of such other Party. 

7.8 Terms of this Agreement; Publicity. The Parties agree that the material terms of this Agreement will be treated as
Confidential Information of both Parties, and thus may be disclosed only as permitted by Sections 7.2 and 7.4. Except as required by applicable Laws (including any securities Laws or the regulations or rules of a securities exchange) or
otherwise agreed by the Parties in writing, each Party agrees not to issue any press release or public statement disclosing information relating to the existence of this Agreement or the transactions contemplated hereby or the terms hereof without
the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed. 
 ARTICLE 8 

Warranties; Covenants; Limitations of Liability; Indemnification 

8.1 Representations and Warranties. Each Party represents and warrants to the other as of the Effective Date that
(a) it is a corporation duly organized, validly existing, and in good standing under the Laws of the jurisdiction in which it is incorporated, (b) it has the legal right and power to enter into this Agreement, to extend the rights,
licenses and options granted or to be granted to the other in this Agreement, and to fully perform its obligations hereunder, (c) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this
Agreement and the performance of its obligations hereunder, (d) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in
accordance with its terms, (e) the execution, delivery and performance of this Agreement by such Party does not violate any Law of any court, governmental body or administrative or other agency having jurisdiction over such Party, and
(f) no government authorization, consent, approval, license, exemptions of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable Laws
currently in effect, is necessary for the transactions contemplated by this Agreement or for the performance of its obligations under this Agreement. 

  
 25 

 8.2 Additional Representations and Warranties of Acuitas. Acuitas
hereby represents and warrants to Verve as of the Effective Date as follows: 
 (a) Impairment. Neither
Acuitas nor any of its Affiliates has entered into any agreement or otherwise licensed, granted, assigned, transferred, conveyed or otherwise encumbered or disposed of any right, title or interest in or to any of its assets, including any
Technology, that would in any way conflict with or impair the scope of any rights, licenses or options granted to Verve hereunder or that would be granted to Verve under any Non-Exclusive License Agreement.

 (b) Patents and Know-How. Exhibit 1.1 sets forth a
complete and accurate list of all Patents included in the Acuitas Background Technology. Acuitas Controls the Acuitas Background Technology. All Acuitas inventors of the Acuitas Background Technology have validly assigned their rights to the Acuitas
Background Technology to Acuitas. Acuitas is and will remain entitled to grant to Verve the licenses specified herein or under a Non-Exclusive License Agreement during the Term, to the Patents and the Know-How within the Acuitas LNP Technology. To Acuitas’ knowledge, the Patents listed on Exhibit 1.1 have been diligently prosecuted and maintained in accordance with applicable Law.
None of the Patents included in the Acuitas Background Technology listed on Exhibit 1.1 are or have been involved in any opposition, cancellation, interference, reissue or reexamination proceeding, and to Acuitas’
knowledge as of the Effective Date, no Acuitas Background Technology is the subject of any judicial, administrative or arbitral order, award, decree, injunction, lawsuit, proceeding or stipulation. As of the Effective Date, neither Acuitas nor any
of its Affiliates has received any notice alleging that the Patents in the Acuitas Background Technology listed on Exhibit 1.1 are invalid or unenforceable, or challenging Acuitas’ ownership of or right to use the
Acuitas Background Technology. 
 (c) Entire LNP Technology. The Acuitas LNP Technology licensed to Verve under this
Agreement or any Non-Exclusive License Agreement comprises all LNP Technology owned or Controlled by Acuitas. As of the Effective Date, the License Agreement dated [**] between Acuitas and [**] is the only LNP
Technology owned or controlled by Acuitas that is not Acuitas LNP Technology. 
 (d) Encumbrances. Acuitas and its
Affiliates are not subject to any payment obligations to Third Parties as a result of the execution or performance of this Agreement. As of the Effective Date, neither Acuitas nor any of its Affiliates has granted any liens or security interests on
the Acuitas Background Technology, and the Acuitas Background Technology is free and clear of any mortgage, pledge, claim, security interest, covenant, easement, encumbrance, lien or charge of any kind. 

(e) Defaults. The execution, delivery and performance by Acuitas of this Agreement and the consummation of the
transactions contemplated hereby will not result in any violation of, conflict with, result in a breach of or constitute a default under any understanding, contract or agreement to which Acuitas is a party or by which it is bound, including each of
the agreements which Acuitas has identified to Verve prior to the Effective Date, in each case as would reasonably be expected to have a material adverse effect on the rights granted to Verve hereunder or under any
Non-Exclusive License Agreement. 
 (f) Litigation. There is no action, suit,
proceeding or investigation pending or, to the knowledge of Acuitas, currently threatened in writing against or affecting Acuitas that questions the validity of this Agreement, the right of Acuitas to enter into this Agreement or consummate the
transactions contemplated hereby or that relates to the Acuitas LNP Technology. 

  
 26 

 (g) Infringement. Neither Acuitas nor any of its Affiliates has
received any notice of any claim, nor does Acuitas or its Affiliates have any knowledge of any basis for any claim, that any Patent, Know-How or other intellectual property owned or controlled by a Third Party
would be infringed or misappropriated by the practice of any Acuitas LNP Technology in connection with the performance of the Workplan or the use of Acuitas LNP Technology in connection with the production, use, research, development, manufacture or
commercialization of any product as contemplated by a Non-Exclusive License Agreement. 
 (h)
Third Party Infringement. To Acuitas’ knowledge, no Third Party is infringing or has infringed any Patent within the Acuitas LNP Technology or is misappropriating or has misappropriated any Know-how within the Acuitas LNP Technology. 
 8.3 Disclaimers. Without
limiting the respective rights and obligations of the Parties expressly set forth herein, each Party specifically disclaims any guarantee that the Program will be successful, in whole or in part. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS
AGREEMENT, THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED. 
 8.4 No
Consequential Damages. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR OTHERWISE, NEITHER PARTY WILL BE LIABLE TO THE OTHER OR ANY THIRD PARTY WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT FOR ANY INDIRECT, PUNITIVE, SPECIAL,
INCIDENTAL OR CONSEQUENTIAL DAMAGES; PROVIDED THAT THIS SECTION 8.4 WILL NOT APPLY TO BREACHES OF ARTICLES 6 OR 7 OR THE PARTIES’ INDEMNIFICATION RIGHTS AND OBLIGATIONS UNDER ARTICLE 8. 

8.5 Performance by Others. The Parties recognize that each Party may perform some or all of its obligations under
this Agreement through Affiliates, and/or permitted subcontractors in accordance with Section 3.1(i); provided, however, that each Party will remain responsible and liable for the performance by its Affiliates and/or permitted
subcontractors and will cause its Affiliates and permitted subcontractors to comply with the provisions of this Agreement in connection therewith. 

8.6 Indemnification. 

(a) Indemnification by Acuitas. Acuitas will indemnify Verve, its Affiliates and their respective directors, officers,
employees, Third Party licensors, licensees, permitted subcontractors, Collaboration Partners and agents, and their respective successors, heirs and assigns (collectively, “Verve Indemnitees”), and defend and hold each of them
harmless, from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) (collectively, “Losses”) in connection with any and all suits, investigations, claims
or demands of Third Parties (collectively, “Third Party Claims”) against the Verve Indemnitees to the extent arising from or occurring as a result of: (i) the breach by Acuitas of any provision of this Agreement; or
(ii) any negligence or willful misconduct on the part of any Acuitas Indemnitee in the conduct of the Workplan; or (iii) any alleged infringement or misappropriation of Patents or other intellectual property rights by Verve in the conduct
of the Workplan based solely on Verve’s use of Acuitas LNP Technology as permitted hereunder in the performance of the Program (excluding for clarity infringement of Patents, Know-How or Materials
covering Verve Technology used by Verve in the performance of the Workplan) except in each case (i)-(iii) to the extent Verve is obligated to indemnify an Acuitas Indemnitee in accordance with Section 8.6(b). 

  
 27 

 (b) Indemnification by Verve. Verve will indemnify Acuitas, its
Affiliates and their respective directors, officers, employees and agents, and their respective successors, heirs and assigns (collectively, “Acuitas Indemnitees”), and defend and hold each of them harmless, from and against any and
all Losses in connection with any and all Third Party Claims against Acuitas Indemnitees to the extent arising from or occurring as a result of: (i) the breach by Verve of any provision of this Agreement; or (ii) any negligence or willful
misconduct on the part of any Verve Indemnitee in the conduct of the Workplan; or (iii) any alleged infringement or misappropriation of Patents or other intellectual property rights by Acuitas in the conduct of the Workplan based solely on
Acuitas’ use of Verve Technology as permitted hereunder in the performance of the Program (excluding, for clarity, infringement of Acuitas LNP Technology used by Acuitas in the performance of the Workplan), except in each case (i)-(iii) to the
extent Acuitas is obligated to indemnify Verve in accordance with Section 8.6(a). 
 (c) Notice of Claim.
All indemnification claims provided for in subsections (a) and (b) above will be made solely by such Party to this Agreement (the “Indemnified Party”). The Indemnified Party will promptly notify the indemnifying Party (the
“Indemnifying Party”) in writing of any Losses or the discovery of any fact upon which the Indemnified Party intends to base a request for indemnification under subsections (a) or (b) above (each such notice, an
“Indemnification Claim Notice”), provided that the failure to promptly provide such notice and details shall not relieve the Indemnifying Party of any of its indemnification obligations hereunder, except to the extent that
the Indemnifying Party’s defense of the relevant Third Party Claim is prejudiced by such failure. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature
and amount of such Loss is known at such time). The Indemnified Party will furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any Losses and Third-Party Claims. 

(d) Defense, Settlement, Cooperation and Expenses. 

(i) Control of Defense. At its option, the Indemnifying Party may assume the defense of any Third-Party Claim by giving
written notice to the Indemnified Party within [**] after the Indemnifying Party’s receipt of an Indemnification Claim Notice. Upon assuming the defense of a Third-Party Claim, the Indemnifying Party may appoint as lead counsel in the defense
of the Third Party Claim any legal counsel selected by the Indemnifying Party (the Indemnifying Party will consult with the Indemnified Party with respect to such legal counsel and a possible conflict of interest of such counsel retained by the
Indemnifying Party). In the event the Indemnifying Party assumes the defense of a Third-Party Claim, the Indemnified Party will immediately deliver to the Indemnifying Party all original notices and documents (including court papers) received by the
Indemnified Party in connection with the Third-Party Claim. 

  
 28 

 (ii) Right to Participate in Defense. Without limiting subsection
(i) above, any Indemnified Party will be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment will be at
the Indemnified Party’s own cost and expense unless (A) the Indemnifying Party has failed to assume the defense and employ counsel in accordance with subsection (i) above (in which case the Indemnified Party will control the defense)
or (B) the interests of the Indemnified Party and the Indemnifying Party with respect to such Third Party Claim are sufficiently adverse to prohibit the representation by the same counsel of both Parties under applicable Law, ethical rules or
equitable principles, in which case the Indemnifying Party will assume [**] percent ([**]%) of any such reasonable costs and expenses of counsel for the Indemnified Party. 

(iii) Settlement. With respect to any Third Party Claims that relate solely to the payment of money damages in
connection with a Third Party Claim and that will not (A) result in the Indemnified Party’s becoming subject to injunctive or other relief, (B) include any admission or concession of liability or wrongdoing on the part of the
Indemnified Party, or (C) otherwise adversely affect the business or Patents of the Indemnified Party in any manner, and as to which the Indemnifying Party will have acknowledged in writing the obligation to indemnify the Indemnified Party
hereunder, the Indemnifying Party will have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its sole discretion, will deem appropriate.
With respect to all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of the Third Party Claim in accordance with subsection (i) above, the Indemnifying Party will have authority to consent
to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss provided it obtains the prior written consent of the Indemnified Party (which consent will not be unreasonably withheld, conditioned or delayed). Where the
Indemnifying Party has assumed the defense of the Third-Party Claim in accordance with subsection (i) above, the Indemnifying Party will not be liable for any settlement or other disposition of a Loss by an Indemnified Party that is reached
without the written consent of the Indemnifying Party. Regardless of whether the Indemnifying Party chooses to defend or prosecute any Third-Party Claim, no Indemnified Party will admit any liability with respect to or settle, compromise or
discharge, any Third-Party Claim without the prior written consent of the Indemnifying Party, such consent not to be unreasonably withheld, conditioned or delayed. 

(iv) Cooperation. Regardless of whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the
Indemnified Party will, and will cause each other Indemnified Party to, cooperate in the defense or prosecution thereof and will furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery
proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith at the Indemnifying Party’s expense. Such cooperation will include access during normal business hours afforded to the Indemnifying Party to, and
reasonable 

  
 29 

 
retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making indemnified parties and other employees and agents available on a
mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party will reimburse the Indemnified Party for all its reasonable out-of-pocket costs and expenses in connection therewith. 
 (v) Costs and
Expenses. Except as provided above in this Section 8.6, the costs and expenses, including reasonable attorneys’ fees and expenses, incurred by the Indemnified Party in connection with any claim will be reimbursed on a Calendar Quarter
basis by the Indemnifying Party, without prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to prompt refund in the event the Indemnifying Party is ultimately held not to be
obligated to indemnify the Indemnified Party. 
 8.7 Insurance. Each Party will maintain at its sole cost and
expense, an adequate liability insurance or self-insurance program to protect against potential liabilities and risk arising out of activities to be performed under this Agreement and upon such terms (including coverages, deductible limits and
self-insured retentions) as are customary in the respective industry of such Party for the activities to be conducted by such Party under this Agreement. The coverage limits set forth herein will not create any limitation on a Party’s liability
to the other under this Agreement. Upon the request of a Party, the other Party will provide evidence of the insurance coverage required by this Section 8.7. 

ARTICLE 9 
 Term and
Termination 
 9.1 Term. This Agreement will commence as of the Effective Date and, unless sooner
terminated in accordance with the terms this Article 9 or by mutual written consent, will terminate on the third (3rd) anniversary of the Effective Date; provided, Verve will have
one (1) option to extend the initial three (3) year term for an additional two (2) year period by providing written notice thereof to Acuitas at least six (6) months prior to the third (3rd) anniversary of the Effective Date (the “Term”). 
 9.2 Termination
by Verve. 
 (a) Breach. Verve will have the right to terminate this Agreement or the Program in full
upon delivery of written notice to Acuitas in the event of a material breach by Acuitas of its obligations under this Agreement, provided that such breach has not been cured within [**] after written notice thereof is given by Verve to
Acuitas specifying the nature of the alleged breach. In the event of a termination of the Program for Acuitas’ uncured material breach, the JDC will be disbanded, Acuitas will receive no further reimbursement for FTE Costs or external expenses
and Acuitas will conduct a technology transfer and provide necessary licenses to Verve or its Third Party designee each as reasonably necessary for Verve or such Third Party designee to complete the conduct of the Program. For avoidance of doubt,
termination of the Program pursuant to this Section 9.3(a) will not terminate Verve’s reservation of Reserved Targets or the Options, subject to the payment of the fees associated therewith. Any Option that is in effect as of the effective
date of termination pursuant to this Section 9.2(a) will continue in effect until the expiration of the Term, as the Term may be extended by Verve. 

  
 30 

 (b) Discretionary Termination. Verve will have the
right to terminate this Agreement in full at any time without cause by giving thirty (30) days’ prior written notice to Acuitas. Upon termination by Verve pursuant to this subsection, Verve will pay to Acuitas all accrued, then-unpaid
Target Reservation and Maintenance Fees, and any amounts payable to Acuitas for any Works and Services performed pursuant to the Workplan up through the date of such termination and provided however, that if Verve terminates the
Agreement within the first year after the Effective Date, payment of any outstanding amount of the FTE Costs that would have due under the Workplan for the first year (to the extent that such FTE Costs have been specified in the Workplan). 

9.3 Termination by Acuitas. Acuitas will have the right to terminate this Agreement in full upon delivery of
written notice to Verve in the event of a material breach by Verve of its obligations under this Agreement, provided that such breach has not been cured within [**] after written notice thereof is given by Acuitas to Verve specifying
the nature of the alleged breach. Verve hereby agrees that Acuitas is entitled to receive payment of any amounts payable to Acuitas for any Works and Services performed pursuant to the Workplan up through the date of such termination. If Acuitas
terminates this Agreement pursuant to this Section 9.3, then Acuitas will have the right, but not the obligation, to terminate any then-existing Non-Exclusive License Agreement. 

9.4 Termination Upon Bankruptcy. If either Party makes an assignment for the benefit of creditors, appoints or
suffers appointment of a receiver or trustee over all or substantially all of its property, files a petition under any bankruptcy or insolvency act in any state or country or has any such petition filed against it which is not discharged within [**]
of the filing thereof, then the other Party may thereafter terminate this Agreement effective immediately upon written notice to such Party. All rights and licenses granted under or pursuant to this Agreement by Acuitas are, and will otherwise be
deemed to be, for purposes of Section 65.11(7) of the Bankruptcy and Insolvency Act, R.S.C. 1985, c. B-3 and Section 32(6) of the Companies’ Creditors Arrangement Act, R.S.C. 1985, c. C-36 (the “Insolvency Legislation”), a grant of “right to use intellectual property” as used in the Insolvency Legislation. The Parties agree that Verve and its Affiliates, as licensees of
such rights under this Agreement, will retain and may fully exercise all of their rights and elections under the Insolvency Legislation subject to the payment of amounts provided for herein. Without limiting Verve’s rights under the Insolvency
Legislation, if Acuitas becomes insolvent or makes an assignment for the benefit of its creditors or there is filed by or against the Acuitas any bankruptcy, receivership, reorganization or similar proceeding pursuant to or under the Insolvency
Legislation or otherwise, Verve shall be entitled to a copy of any and all such intellectual property and all embodiments of such intellectual property, and the same, if not in the possession of Acuitas, shall be promptly delivered to it
(a) before this Agreement is rejected by or on behalf of Acuitas, within [**] after Verve’s written request, unless Acuitas, or its trustee or receiver, elects within [**] to continue to perform all of its obligations under this Agreement,
or (b) after any rejection of this Agreement by or on behalf of Acuitas, if not 

  
 31 

 
previously delivered as provided under clause (a) above. All rights of the Parties under this Section 9.4 and under Section 65.11(7) of the Bankruptcy and Insolvency Act, R.S.C.
1985, c. B-3 and Section 32(6) of the Companies’ Creditors Arrangement Act are in addition to and not in substitution of any and all other rights, powers, and remedies that each Party may have under
this Agreement, the Insolvency Legislation, and any other applicable Laws. 
 9.5 Effects of Termination. 

(a) In the event of a dispute as to whether Verve has materially breached its payment obligations or Acuitas has materially breached its
obligations under the Workplan, Verve shall make payment of the disputed amounts to a Third-Party trustee selected by Verve and reasonably acceptable to Acuitas. The Third-Party trustee shall confirm to Acuitas that it holds such payment and will
forward the monies to Acuitas or return the monies to Verve once the dispute has been finally resolved and depending on the outcome of the resolved dispute. Upon the request of Verve, the following shall apply to any dispute described in the first
sentence of this Section 9.5(a): the informal dispute resolution process in Section 10.1(a) shall not apply; the negotiation period for the Executive Officers in Section 10.1(a) shall be limited to [**]. 

(b) Upon termination by either Party under Sections 9.2, 9.3 or 9.4, (a) Acuitas will terminate all Works and Services in
progress in an orderly manner as soon as practical and in accordance with a schedule agreed to by Verve, (b) Acuitas will use commercially reasonable efforts to terminate or limit any outstanding commitments and costs associated with the
Workplan, (c) Acuitas will deliver to Verve any Verve Materials in its possession or control and all deliverables developed through termination or expiration, and (d) Acuitas will promptly issue a final invoice to Verve and Verve will pay
Acuitas any monies due and owing Acuitas, up to the time of termination or expiration, for Works and Services actually performed and all authorized expenses actually incurred (as specified in the Workplan). 

9.6 Survival. In addition to the termination consequences set forth in Section 9.5, the following provisions
will survive termination or expiration of this Agreement, as well as any other provision which by its terms or by the context thereof, is intended to survive such termination: Article 1 (to the extent applicable to any other surviving provisions),
Article 6, Article 7 and Article 10 and Section 3.1(f) (with respect to Acuitas’ obligation to complete a technology transfer, as applicable), Section 3.3(a), Section 3.3(b) (with respect to the Parties’ permitted use of
Workplan Data), Section 3.3(c)(i) (with respect to the Parties’ obligation to return or destroy Materials after expiration or termination of this Agreement), Section 5.1 (d), Section 5.2 (to the extent that Verve exercises an
Option, as applicable), Section 8.3, Section 8.4, Section 8.6, Section 9.5 and this Section 9.6. Termination or expiration of this Agreement will not relieve the Parties of any liability or obligation which accrued hereunder
prior to the effective date of such termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at Law or in equity with respect to any breach of this Agreement nor prejudice either Party’s
right to obtain performance of any obligation. All other rights and obligations will terminate upon expiration of this Agreement. 

  
 32 

 ARTICLE 10 

Miscellaneous 

10.1 Dispute Resolution. 

(a) Disputes. Disputes arising under or in connection with this Agreement will be resolved pursuant to this
Section 10.1; provided, however, that in the event a dispute cannot be resolved without an adjudication of the rights or obligations of a Third Party (other than any Verve Indemnitees or Acuitas Indemnitees identified in
Section 8.6), the dispute procedures set forth Sections 10.1(b) and 10.1(c) will be inapplicable as to such dispute. 
 (b)
Dispute Escalation. In the event of a dispute between the Parties, the Parties will first attempt in good faith to resolve such dispute by negotiation and consultation between themselves or the Workplan Leaders. In the event
that such dispute is not resolved on an informal basis within [**], any Party may, by written notice to the other, have such dispute referred to each Party’s Chief Executive Officer or his or her designee (who will be a senior executive), who
will attempt in good faith to resolve such dispute by negotiation and consultation for a [**] period following receipt of such written notice. 

(c) Dispute Resolution. In the event the Chief Executive Officers of the Parties are not able to resolve such dispute as
set forth above, the Chief Executive Officers will together elect whether to submit the dispute to mediation, litigation or arbitration. In the absence of such an agreement, either Party may elect to initiate litigation. 

(d) Injunctive Relief. Notwithstanding the dispute resolution procedures set forth in this Section 10.1, in
the event of an actual or threatened breach hereunder, the aggrieved Party may seek equitable relief (including restraining orders, specific performance or other injunctive relief) in any court or other forum, without first submitting to any dispute
resolution procedures hereunder. 
 (e) Tolling. The Parties agree that all applicable statutes of limitation and
time-based defenses (such as estoppel and laches) will be tolled while the dispute resolution procedures set forth in this Section 10.1 are pending, and the Parties will cooperate in taking all actions reasonably necessary to achieve such a
result. 
 (f) Prevailing Party. The prevailing Party in any suit related to this Agreement will be entitled to recover
from the losing Party all out-of-pocket fees, costs and expenses (including those of attorneys, professionals and accountants and all those arising from appeals and
investigations) incurred by the prevailing Party in connection with such arbitration or suit. 
 10.2 Invoices and
Payments. All invoices to be delivered to Verve hereunder shall be delivered in accordance with Section 10.11 or in such other manner specified by Verve from time to time. All amounts specified in, and all payments to be made by Verve
hereunder will be in, U.S. dollars and will be paid by wire transfer to such bank account as Acuitas may designate at least [**] before such payment is due. Verve may withhold from payments due to Acuitas amounts for payment of any withholding tax
that is required by Law to he paid to any taxing authority with respect to such payment. Verve will provide Acuitas all relevant documents and correspondence, 

  
 33 

 
and will also provide to Acuitas any other cooperation or assistance on a reasonable basis as may be necessary to enable Acuitas to claim exemption from such withholding taxes and to receive a
refund of such withholding tax or claim a foreign tax credit. Upon the request of Acuitas, Verve will give proper evidence from time to time as to the payment of any such tax. 

10.3 Relationship of Parties. Nothing in this Agreement is intended or will be deemed to constitute a partnership, agency,
employer-employee or joint venture relationship between the Parties. No Party will incur any debts or make any commitments for the other, except to the extent, if at all, specifically provided therein. There are no express or implied Third-Party
beneficiaries hereunder. 
 10.4 Compliance with Law. Each Party will perform or cause to be performed any and all of
its obligations or the exercise of any and all of its rights hereunder in good scientific manner and in compliance with all applicable Law. 

10.5 Governing Law. This Agreement will be governed by and construed in accordance with the Laws of the state of New York,
United States of America, without respect to its conflict of Laws rules, provided that any dispute relating to the scope, validity, enforceability or infringement of any Patents or Know-How will be governed
by, and construed and enforced in accordance with, the substantive Laws of the jurisdiction in which such Patents or Know-How apply. 

10.6 Counterparts; Facsimiles. This Agreement may be executed in one or more counterparts, each of which will be deemed an
original, and all of which together will be deemed to be one and the same instrument. Facsimile or PDF execution and delivery of this Agreement by either Party will constitute a legal, valid and binding execution and delivery of this Agreement by
such Party 
 10.7 Headings. All headings in this Agreement are for convenience only and will not affect the meaning of
any provision hereof. 
 (a) Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel
in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement will be construed against the drafting Party will not apply. 

(b) Interpretation. Whenever any provision of this Agreement uses the term “including” (or
“includes”), such term will be deemed to mean “including without limitation” (or “includes without limitation”). “Herein,” “hereby,” “hereunder,” “hereof” and other equivalent
words refer to this Agreement as an entirety and not solely to the particular portion of this Agreement in which any such word is used. In this Agreement, the word “or” means “and/or”. All definitions set forth herein will be
deemed applicable whether the words defined are used herein in the singular or the plural. Unless otherwise provided, all references to Sections and Exhibits in this Agreement are to Sections and Exhibits of this Agreement. References to any
Sections include Sections and subsections that are part of the related Section. 
 10.8 Further Assurances. Each Party
shall take all customary and reasonable actions and do all things reasonably necessary or proper, including under applicable law, to make effective and further the intents and purposes of the transactions contemplated by this Agreement, including
executing any further instruments reasonably requested by the other Party. 

  
 34 

 10.9 Binding Effect. This Agreement will inure to the benefit of and be
binding upon the Parties, their Affiliates, and their respective lawful successors and assigns. 
 10.10 Assignment.
This Agreement may not be assigned by either Party, nor may either Party delegate its obligations or otherwise transfer licenses or other rights created by this Agreement, except as expressly permitted hereunder, without the prior written consent of
the other Party, which consent will not be unreasonably withheld, conditioned or delayed; provided, that either Party may assign this Agreement without such consent to an Affiliate or to its successor in connection with the sale of all or
substantially all of its assets or business or that portion of its business pertaining to the subject matter of this Agreement (whether by merger, consolidation or otherwise). 

10.11 Notices. All notices, requests, demands and other communications required or permitted to be given pursuant to this
Agreement will be in writing and will be deemed to have been duly given upon the date of receipt if delivered by hand, email, recognized international overnight courier, or registered or certified mail, return receipt requested, postage prepaid to
the following addresses: 
  

			
	if to Verve:	  	 Verve Therapeutics, Inc.
 500 Technology
Square
 Cambridge, MA 02139
 Email: [**]

Attn: COO

		
	With a copy to:	  	 Wilson Sonsini Goodrich & Rosati
 650
Page Mill Road
 Palo Alto, CA 94304
 Attention: Lowell
Segal
 Email: [**]

		
	If to Acuitas:	  	 Acuitas Therapeutics Inc.
 6190 Agronomy Road,
Suite 405
 Vancouver, B.C.
 Canada V6T 1Z3

Attention: President and CEO
 Email: [**]

		
	With a copy to:	  	 McCarthy Tetrault LLP
 Suite 2400 745 Thurlow
Street
 Vancouver, B.C.
 Canada V6E 0C5

Attention: Miranda Lam, Esq.
 Email: [**]

  
 35 

 Either Party may change its designated address by notice to the other Party in the manner provided in this
Section 10.11. 
 10.12 Amendment and Waiver. This Agreement may be amended, supplemented, or otherwise modified
only by means of a written instrument signed by both Parties; provided that any unilateral undertaking or waiver made by one Party in favor of the other will be enforceable if undertaken in a writing signed by the Party to be charged with the
undertaking or waiver. Any waiver of any rights or failure to act in a specific instance will relate only to such instance and will not be construed as an agreement to waive any rights or fail to act in any other instance, whether or not similar.

 10.13 Severability. In the event that any provision of this Agreement will, for any reason, be held to be invalid or
unenforceable in any respect, such invalidity or unenforceability will not affect any other provision hereof, and the Parties will negotiate in good faith to modify the Agreement to preserve (to the extent possible) their original intent. 

10.14 Entire Agreement. This Agreement together with any Non-Exclusive License
Agreements (including all appendices and exhibits hereto and thereto) entered into during the Term are the sole agreements with respect to their subject matter and supersede all other agreements and understandings between the Parties with respect to
same. 
 10.15 Force Majeure. Neither Acuitas nor Verve will be liable for failure of or delay in performing obligations
set forth in this Agreement (other than any obligation to pay monies when due), and neither will be deemed in breach of such obligations, if such failure or delay is due to natural disasters or any causes reasonably beyond the control of Acuitas or
Verve; provided that the Party affected will promptly notify the other of the force majeure condition and will exert reasonable efforts to eliminate, cure or overcome any such causes and to resume performance of its obligations as soon as
possible. 
 [Signature page to follow] 

  
 36 

 IN WITNESS WHEREOF, the Parties have caused this Development and Option Agreement to
be executed by their respective duly authorized officers as of the Effective Date. 
 ACUITAS THERAPEUTICS,
INC. 
  

			
		
	By:	 	 /s/ T.D. Madden

		 	(Signature)
		
	Name:	 	Thomas Madden
		
	Title:	 	President & CEO
	
	 VERVE THERAPEUTICS,
INC.

		
	By:	 	 /s/ Andrew D. Ashe

		 	(Signature)
		
	Name:	 	Andrew D. Ashe
		
	Title:	 	President & COO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]